Novartis Confidential Page 2
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 8
List of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 14
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
1.1.1 MET and capmatinib (INC280) ............................................................ 19
1.1.2 Spartalizumab (PDR001) ...................................................................... 21
1.1.3
Combination of capmatinib with a checkpoint inhibitor....................... 22
1.2 Purpose .................................................................................................................. 24
2Objectives and endpoints ................................................................................................... 25
3Study  design ................................ ................................ ................................ ...................... 26
4Rationale ............................................................................................................................ 29
4.1 Rationale for stud y design ................................ ................................ ..................... 29
4.2 Rationale for dose/regimen and duration of treatment .......................................... 29
4.2.1
Capmatinib in combination with spartalizumab ................................... 29
4.3
Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 31
4.4
Purpose and timing of interim anal yses/design adaptations .................................. 31
4.5 Risks and benefits .................................................................................................. 31
4.5.1 Capmatinib ............................................................................................ 32
4.5.2 Spartalizumab ........................................................................................ 32
4.5.3 Cap
matinib combined with spartalizumab ............................................ 33
4.5.4 Docetaxel ............................................................................................... 33
4.5.5 Risks of I maging Procedures ................................................................ 34
5Population ................................ ................................ ................................ .......................... 34
5.1 Inclusion criteria .................................................................................................... 34
5.2 Exclusion criteria ................................................................................................... 36
6Treatment ................................ ................................ ................................ ........................... 39
6.1 Study  treatment ...................................................................................................... 39
6.1.1 Investigational and control drugs .......................................................... 40
6.1.2 Additional study  treatments .................................................................. 40
6.1.3 Treatment arms/group ........................................................................... 41
6.1.4 Guidelines for continuation of treatment .............................................. 41

Novartis Confidential Page 4
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
9Study  discontinuation and completion ............................................................................ 114
9.1 Discontinuation .................................................................................................... 114
9.1.1 Discontinuation of study  treatment ..................................................... 114
9.1.2 Withdrawal of informed consent ......................................................... 115
9.1.3 Lost to follow -
up................................................................................. 116
9.1.4 Early study termination by the sponsor ............................................... 116
9.2 Study  completion and post -study  treatment ........................................................ 116
9.2.1 Follow up for saf ety evaluations ......................................................... 117
9.2.2 Follow up for efficacy  evaluations ...................................................... 117
9.2.3
Survival follow up............................................................................... 118
10Safety  monitoring and reporting ...................................................................................... 118
10.1 Definition of adverse events and reporting requirements .................................... 118
10.1.1 Adverse events .................................................................................... 118
10.1.2 Serious adverse events ........................................................................ 121
10.1.3 SAE reporting
...................................................................................... 122
10.1.4 Pregnancy  reporting ............................................................................ 122
10.1.5 Reporting of stud y treatment errors including misuse/abuse .............. 123
10.2 Additional Safety  Moni toring .............................................................................. 123
11Data Collection and Database management .................................................................... 123
11.1 Data c ollection ..................................................................................................... 123
11.2 Database management and quality  control .......................................................... 124
11.3 Site monitoring .................................................................................................... 124
12Data analy sis and statistical methods ................................ ................................ .............. 125
12.1 Analy sis sets ........................................................................................................ 125
12.2
Subject demographics and other baseline characteristics.................................... 126
12.3 Treatments ........................................................................................................... 126
12.4 Analy sis of the primary  endpoint(s) .................................................................... 127
12.4.1 Definition of primary  endpoint(s) ....................................................... 127
12.4.2 Statistical mo del, hy pothesis, and method of anal ysis........................ 127
12.4.3 Handling of missing values/censoring/discontinuations ..................... 128
12.4.4 Sensitivity  and supportive anal yses.................................................... 129
12.5 Analy sis of secondary  endpoints ......................................................................... 129
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................. 129
12.5.2 Safety  endpoints .................................................................................. 129
12.5.3 Pharmacokinetics ................................................................................ 131
133
12.7 Interim anal yses................................................................................................... 135

Novartis Confidential Page 6
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 6-5 Number of prior lines of sy stemic therapy ................................ ............ 49
Table 6-6 Criteria for defining dose limiting toxicities (DL Ts)............................ 51
Table 6-7 Dose reduction steps for capmatinib..................................................... 53
Table 6-8 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Haematological Adverse 
Events .................................................................................................... 55
Table 6
-9 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Creatinine Increases ............ 57
Table 6-10 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for liver laboratory  
alterations .............................................................................................. 57
Table 6
-11 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Am ylase and/or Lipase 
Elevation Related Adverse Events........................................................ 61
Table 6
-12 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Cardiac Related Adverse 
Events ................................ ................................ ................................ ....61
Table 6-13 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Gastrointestinal Adverse 
Events ................................ ................................ ................................ ....63
Table 6-14 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Skin and Subcutaneous 
Tissue Adverse Events ................................ ................................ .......... 66
Table 6-15 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Respiratory , Thoracic and 
Mediastinal Adverse Events ................................ ................................ ..67
Table 6-16 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Endocrine Adverse 
Events ................................ ................................ ................................ ....69
Table 6-17 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for General and 
Administration Site Adverse Events ..................................................... 71
Table 6
-18 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Other Potential I mmune -
Related Adverse Events of Special Interest including C ytokine 
Release S yndrome ................................................................................. 71
Table 6
-19 Criteria for interruption and re- initiation of docetaxel treatment .......... 74
Table 6-20 Dose and treatment schedule................................................................. 79
Table 8-1 Allowable window for subject assessments .......................................... 82
Table 8
-2 Assessment Schedule, Run -in and Arm 1 (capmatinib and 
spartalizumab combination) - length of a cy cle is 28 day s ................... 83

Novartis Confidential Page 8
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 16-11 Prior distributions for the parameters of the MAP model used to 
derive the prior for the single -agent spartalizumab model 
parameters ........................................................................................... 186
Table 16
-12 Historical dose -DLT data from s partalizumab single agent clinical 
studies ................................ ................................ ................................ ..186
Table 16-13 Historical dose -DLT data from capmatinib in combination with 
spartalizumab 300 mg Q3W................................................................ 187
Table 16
-14 Prior distribution for the model parameters ........................................ 187
Table 16
-15 Summary  of prior distribution of DL T rates ................................ .......188
Table 16-16 Hypothetical DLT scenarios ............................................................... 188
List of figures
Figure 3 -
1 Study  Design Part 1: Run-in................................ ................................ .27
Figure 3 -2 Study  Design Part 2: Randomized ........................................................ 28
Figure 6 -
1 Optional Treatment Bey ond Disease Progression ................................. 43
Figure 16 -
1 Safety  follow -up diagram for run -in and arm 1 .................................. 182

Novartis Confidential Page 9
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
List of abbreviations
Ab Antibody
ACTH Adrenocorticotropic hormone
ADA Anti-drug Antibodies
ADL Activity daily living
ADR Adverse drug reaction
AE adverse event
AESI adverse event of special interest
ALK Anaplastic lymphoma kinase
ALP alkaline phosphatase
alpha -FP alpha -fetoprotein
ALT alanine aminotransferase
ANC Absolute neutrophil count
ANP Atrial natriuretic peptide
aPTT Activated Partial Thromboplastin Time
AST aspartate aminotransferase
ATC Anatomical Therapeutic Chemical
ATP Adenosine triphosphate
AUC Area under curve
BAL Bronchoalveolar lavage
BID Twice a day
BIRC blinded independent review committee
BLQ Below the limit of quantification
BLRM Bayesian Logistic Regression Model
BOR Best Overall Response
BSA Body Surface Area
BSC best supportive care
BUN blood urea nitrogen
BVN bivariate normal
C Cycle
CFR Code of Federal Regulation
CI Confidence Interval
CK Creatine kinase
Cmax The maximum (peak) concentration of drug in plasma
CMO&PS Chief Medical Office and Patient Safety
CMV Cytomegalovirus
CNS Central Nervous System
COA Clinical Outcome Assessments
COPD Chronic obstructive pulmonary disease
CPK creatine phosphokinase
CR Complete Response
CRA Clinical research associate
CRF Case Report/Record Form (paper or electronic)
CRS case retrieval strategy
CSF Colony -stimulating factor
CSR Clinical study report

Novartis Confidential Page 10
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
CT Computerized Tomography
CTCAE Common Terminology Criteria for Adverse Events
ctDNA circulating tumor DNA
CV coefficient of variation
D Day
D5W dextrose 5% in water
DBP Diastolic Blood Pressure
DCR Disease control rate
DDE direct data entry
DDI Drug -drug interaction
DDS Dose -determining set
DILI Drug -Induced Liver Injury
DLCO Diffusing capacity of the lungs for carbon monoxide
DLT Dose Limiting Toxicity
DNA deoxyribonucleic acid
DOR Duration of response
DRID Dose reference ID
EBV Epstein –Barr virus
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EDC Electronic Data Capture
EGFR epidermal growth factor receptor
ELISA Enzyme -linked immunosorbent assay
EM electromagnetic
EMA European Medicines Agency
EOT End of treatment
EPR early progression rate
ESA Erythropoiesis agent
EU European Union
EWOC Escalation with overdose control
FAS Full Analysis Set
FDA Food and Drug Administration
FDG -PET Fluorodeoxyglucose positron emission tomography
FISH Fluorescent in situ hybridization
FPFV First patient first visit
FPG Fasting plasma glucose
FSH Follicle -stimulating hormone
GABA Gamma -Aminobutyric acid
GCN Gene copy number
GCP Good Clinical Practice
GGT Gamma -glutamyltransferase
GI Gastrointestinal
h hour
HBcAb Hepatitis B core antibody
HBsAb Hepatitis B surface antibody

Novartis Confidential Page 11
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HBV DNA Hepatitis B virus DNA
HCC Hepatocellular carcinoma
hCG human chorionic gonadotrophin
HCV Hepatitis C virus
HCV RNA Hepatitis C virus RNA
Hgb Hemoglobin
HGF Hepatocyte growth factor
HIV human immunodeficiency virus
HR Hazard ratio
HSV Herpes simplex virus
i.v. intravenous
IB Investigator's brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use
IEC Independent Ethics Committee
IFN Interferon
IG Immunogenicity
IgG4 Immunoglobulin G4
IHC International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
IL-2 Interleukin
ILD Interstitial lung disease
INR International normalized ratio
IO Immuno -oncology
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent to treat

Novartis Confidential Page 13
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PLT Platelet
PPI Proton -pump inhibitor
PR Partial response
PS Performance status
QD Daily
QMS Quality management system
QTcF Fridericia QT correction formula
QxW Every x week(s)
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
RNA Ribonucleic acid
RoW Rest of the World
RP2D Recommended Phase 2 dose regimen
RT-PCR Reverse transcription polymerase chain reaction
SAE serious adverse event
SAP The Statistical Analysis Plan (SAP) is a regulatory document which provides evidence of 
preplanned analyses
SBP Systolic blood pressure
SD standard deviation
SD Stable Disease
SOD Sum of Diameter
SOP Standard operating procedure
SUSARs Suspected unexpected serious adverse reactions
TBIL Total bilirubin
TdP Torsades de Pointes
TFQ Trial feedback questionnaire
TKI Tyrosine kinase inhibitor
TL Target lesion
TNBC Triple negative breast cancer
TP Time point
TSH Thyroid -stimulating hormone
TTF Time to treatment failure
TTP Time to progression
TTR Time to response
UC Unchanged
ULN upper limit of normal
UNK Unknown
US United States , ultrasound
VAS Visual analogue scale
VATS Video -assisted thoracic surgery
WHO World Health Organization
wt wild type

Novartis Confidential Page 14
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cohort A specific group of subjects fulfilling certain criteria
Control drug Any drug (an active drug or an inactive drug, such as a placebo) which is used as a 
comparator to the investigational drug being tested in the trial
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg once a day, 
75 mg twice a day)
Investigational 
drugThe study drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is synonymou s 
with “investigational new drug” or “test substance”
Medication number A unique identifier on the label of each study drug package in studies that dispense 
study drug using an IRT system.
Part A single component of a study which contains different objec tives or populations within 
that single study. Common parts within a study are: a single dose part and a multiple 
dose part, or a part in patients with established disease and in those with newly -
diagnosed disease.
Patient An individual with the condition of interest
Period A minor subdivision of the study timeline; divides phases into smaller functional 
segments such as screening, baseline, titration, washout, etc.
Personal Data Subject information collected by the Investigator that is transferred to Novartis for the 
purpose of the clinical trial. This data includes subject identifier information, study 
information and biological samples.
Withdrawal of study consent: W ithdrawal of consent from the study occurs only when a 
subject does not want to parti cipate in the study any longer, and does not allow any 
further collection of personal data
Randomization 
numberA unique identifier assigned to each randomized subject, corresponding to a specific 
treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
Stage A major subdivision of the study timeline; begins and ends with major study milestones 
such as enrollment, randomization, completion of treatment, etc.
Study completion Point/time at which the subject came in for a final evaluation visit or when study drug was 
discontinued whichever is later.
Study drug 
discontinuationPoint/time when subject permanently stops taking study drug for any reason; may or may 
not also be the point/time of premature subject withd rawal.
Study treatment Any drug administered to the study participants as part of the required study procedures; 
includes investigational drug (s), control(s) or non -investigational medicinal product(s)
Study treatment 
discontinuationWhen the subject permanently stops taking study treatment prior to the defined study 
treatment completion date
Study treatment 
interruption Includes any delay or withholding of study treatment for any reason as well as an 
interruption during an infusion of study treatmen t for any reason
Subject A trial participant (can be a healthy volunteer or a patient)
Subject number A unique number assigned to each subject upon signing the informed consent. This 
number is the definitive, unique identifier for the subject and should be used to identify 
the subject throughout the study for all data collected, sample labels, etc.
Treatment number A unique identifier assigned in non -randomized studies to each dosed subject, 
corresponding to a specific treatment arm 
Variable Informati on used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points
Withdrawal of 
consent ( WoC)Withdrawal of consent from the study is defined as when a subject does not want to 
participat e in the study any longer, anddoes not want any further visits or assessments, 
anddoes not want any further study related contact, anddoes not allow analysis of 
already obtained biologic material

Novartis Confidential Page 15
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Protocol summary
Protocol number CINC280D2201
Full Title A phase II, multicenter, randomized, two -arm study of capmatinib (INC280, an oral 
MET inhibitor) and spartalizumab (PDR001, a PD -1 inhibitor) combination therapy 
versus docetaxel in pretreated adult patients with EGFR wild -type, ALK 
rearrangement neg ative locally advanced/metastatic non -small cell lung cancer.
Brief title Study of efficacy and safety capmatinib (INC280, an oral MET inhibitor) and 
spartalizumab (PDR001, a PD -1 inhibitor) combination therapy versus docetaxel in 
pretreated adult patient s with locally advanced/metastatic non-small cell lung 
cancer
Sponsor and Clinical 
PhaseNovartis, Phase II
Investigation type Drug
Study type Interventional
Purpose and rationale The purpose of this prospective, multicenter, randomized phase II study is to 
evaluate the safety and efficacy of the combination of capmatinib and 
spartalizumab in subjects with EGFR wt (for exon 19 deletions and exon 21 L858R 
substitution mutations), ALK -negative rearrangement, advanced/metastatic (stage 
IIIB (not amenable f or definitive chemo -radiotherapy) or IV) NSCLC, regardless of 
MET and PD -L1 status
The study will enroll subjects with advanced/metastatic NSCLC which are EGFR wt, 
ALK negative, after failure of prior platinum doublet and checkpoint inhibitor 
administered for the treatment of the advanced stage disease. Subjects must be 
docetaxel naive. A Run -in part will be conducted to determine safety, tolerability 
and preliminary efficacy of the capmatinib and spartalizumab combination.A 
Randomized part will be conducte d to assess the overall survival (OS) of the 
combination of capmatinib and spartalizumab in comparison to docetaxel.
Primary Objective(s) Part 1: Run -in 
● To assess the safety and tolerability of the capmatinib and spartalizumab 
combination.
Part 2: Randomized
● To assess the overall survival of the combination of capmatinib and 
spartalizumab in comparison to docetaxel.
Secondary Objectives Part 2 Randomized part: To assess objective response rate (ORR), disease control 
rate (DCR), progression -free s urvival (PFS), duration of response (DOR) and time 
to response (TTR) based on RECIST 1.1 (Response Evaluation Criteria in Solid 
Tumors). To assess the incidence and severity of adverse events (AEs) and 
serious adverse events (SAEs).
Study design This is a two-part prospectively designed, multicenter, open -label, randomized 
phase II study to evaluate the safety and the efficacy of capmatinib in combination 
with spartalizumab in adult subjects with EGFR wild type and ALK rearrangement 
negative advanced stage IIIB or IV NSCLC after failure of platinum doublet 
chemotherapy and checkpoint inhibitor treatment.
Part 1: run -in phase: will confirm the safety and tolerability and assess the efficacy 
of the combination of capmatinib and spartalizumab.
Part 2: randomized phase: will evaluate the efficacy and safety of the combination 
of capmatinib and spartalizumab compared to docetaxel
Population The study population (15 subjects in run -in phase and 90 subjects in randomized 
phase, total of 105 subjects) will include adult subjects with locally advanced stage 
IIIB/IV non -small cell lung cancer. Subjects will be docetaxel naive, and subjects 
with EGFR mutations and ALK rearrangements will be excluded.

Novartis Confidential Page 17
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
1 Introduction
1.1 Background
Lung cancer has been the most common cancer in the world for several decades. In 2012, there 
were an estimated 1.8 million new cases, representing 12.9% of all new cancers worldwide. It 
was also the most common cause of death from cancer, with 1.6 million deaths representing 
19.4% of the total deaths from cancer (Ferlay et al 2015). For 2017, approximately  155,870 
deaths due to lung cancer are expected in the United States (US) (Siege let
al2017) and 275,700 
deaths are predicted in the European Union (Malvezzi et
al2017).
The World Health Organization (WHO) divides lung cancer into 2 major classes based on its 
biology , therapy , and prognosis: non-small cell lung cancer (NSCL C) and small cell lung cancer. 
NSCL C accounts for more than 85% of all lung cancer cases, and it includes 2 major ty pes: (1) 
non-squamous carcinoma (including adenocarcinoma, large -cell carcinoma, other cell types); 
and (2) squamous cell (epidermoid) carcinoma. Adenocarcinoma (40% of lung cancers; 47% in 
NSCL C) is the most common ty pe of lung cancer seen in the United States and is also the most 
frequentl y occurring cell type in nonsmokers (Novello et
al2016). One reason for the high 
mortality  
rate of lung cancer is the advanced stage at diagnosis; only 25 to 30% of new NSCLC 
cases are diagnosed with localized disease that is potentially  curable with surger y 
(Nguyenet al 2012 ). The majority  of subjects are diagnosed with locally  advanced or metastatic 
disease and they  are not candidates for surgery .
Platinum combination therap y is superior to best supportive care in subjects with 
advanced, 
incurable disease , and platinum doublet chemotherap y (i.e., cisplatin or carboplatin in 
combination with other chemotherap y agents, with or without bevacizumab) has been the 
standard initial (i.e., first -line) treatment for subjects with locally  advanced or metastatic (i.e, 
stage IIIB or IV) NSCLC in absence of a druggable molecular driver or PD-L1 (Programmed 
Death -Ligand 1) expression >1% (Novello et
al2016, NCCN 2018 ). Pemetrexed- based 
platinum doublet therapy  has become a standard first -line treatment option for NSCL C subjects 
with non-squamous histology . In a Phase 3, non-inferiority  trial of chemotherapy -naive subjects 
with stage IIIB or IV NSCL C, pemetrexed plus cisplatin (pemetrexed/cisplatin) was shown to 
be non -inferior to (median OS 10.3 versus 10.3 months, respectivel y) and better tolerated than 
gemcitabine/cisplatin (Scagliotti et
al2008). With respect to OS, pemetrexed/cisplatin was 
superior to gemcit abine/cisplatin in the subset of subjects with 
adenocarcinoma (OS 12.6 versus 
10.9 months, respectively ) and large -cell carcinoma (10.4 versus 6.7 months, respectivel y).
Single agent chemotherapy  like pemetrexed (in non-squamous) or docetaxel (in an y histo logy) 
are established treatment options for pretreated NSCLC subjects and have served as the control 
arms of several prospective, randomized trials in second or third setting. In a randomized trial 
comparing both agents in the second -line setting, efficacy was similar with both treatments (the 
response rate of approximately  9-10%, median PFS of 2-3 months, and median OS of 
approximately  7-8 months), although pemetrexed was associated with less toxicit y 
(Hanna et
al2004). Overall, the reported response rates to second- line chemotherap y also with 
other single agent chemotherapeutics have generally  been < 11% with median PFS and OS 
generall y below 4 and 11 months respectively (deMarinis andGrossi 2008, 
Weiss andStinchcombe 2013, Novello et al2016, NCCN 2018). Upon progression after 
second -line chemotherapy , subjects may be candidates for further treatment, although 

Novartis Confidential Page 18
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
randomized evidence is scarce and most data come from phase II trials or retrospective analyses. 
Subjects have often limited response to third line therapy , although it may have a useful 
palliative effect (Shepherd et al 2005, deMarinis andGrossi 2008 , Eccles et al 2011, 
Reck et
al2014, Besse et al 2014 , NCCN 2018 ).
Activating mutations in EGFR and ALK translocations have been the first molecular drivers to 
show strong predictiv e value of improved efficacy  and better tolerance of EGFR and ALK 
Tyrosine Kinase Inhibitors (TKIs) when compared with standard chemotherap y in subjects 
harboring EGFR activating mutations and ALK translocations, becoming the new standard of 
care in both the pretreated setting and in treatment naive setting (Ettinger et al 2010 , 
Sequist et al 2013, Zhou et al2011, Fukuoka et al2011 , Shaw andEngelman 2013, 
Shaw et
al2013, Rosell etal2012 , Solomon et al 2014, NCCN 2018). Importantly , due to the 
high oncogenic addiction to the molecular abnormality  during the course of the disease, the 
efficacy  of these targeted therapies seem to be independent of line of treatment, and high 
response rates are still observed in subjects who received several treatments (generally 
excluding therapies targeting the same pathway ) before receiving the given targeted therapy  
(Camidge et
al2012 ). The success of EGFR and ALK TKIs highlights the importance of 
identify ing specific molecular drivers of NSCLC to appropriately direct targeted agents in 
specific subject populations. Similarly , other TKIs targeting rarer targets like ROS1 
translocation and BRAF mutation are now available in these subject subsets 
(Solomon et al 2014, Hamanishi et al2016 ). The potential for prolonged response by  targeting 
these oncogenic drivers delays the need for chemotherap y or other treatments. The landscape 
of NSCL C treatment is changing and the treatment paradigm of “one size fits all” has 
progressivel y switched to a personalized therap y.
Monoclonal antibody  (mAb) inhibitors of immunological checkpoints, including PD-1 and PD-
L1, have demonstrated significant antitumor activity in subjects with various solid tumors with 
less toxicity  than chemotherap y or broad immune activators, such as IL-2 (interleukin -2) and 
IFN-α (interferon -α). PD-1 is a particularly  important immunological target, with inhibitors 
active across a variet y of solid tumors. Two mAbs targeting PD-
1, pembrolizumab and 
nivolumab, have demonstrated significant single agent activit y in melanoma, NSCL C and other 
solid tumors (Hamanishi et al 2016).
Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for 
metastatic NSCL C lacking sensitizing EGFR 
or ALK mutations. PD-(L)1 inhibitors (nivolumab, 
pembrolizumab, atezoli zumab) are now standard of care in second/third -line NSCL C; 
pembrolizumab is also approved in first-line (PD-L1 ≥◦50%) and in combination with platinum 
chemotherap y (irrespective of PD-L1 status). Results of several studies with 
immunotherapy /platinum chem otherap y and immunotherapy  plus immunotherapy  
(ipilimumab/nivolumab, tremelimumab/durvalumab) are becoming available in 2018/19 which 
might further reshape the treatment landscape in first- line, shifting treatment paradigms in later 
lines of treatment ( Gandhi et al 2018).
Checkpoint inhibitors are currently  being evaluated in additional phase III studies with 
immunotherapy -based treatment in both pretreated and first-line setting, with several regulatory 
approvals expect ed in 2018 and 2019.
Overall, currentl y approved PD -1 (nivolumab and pembrolizumab) and PD -L1 (atezolizumab) 
inhibitors have shown ORR 17-19%, median PFS 2-4 months, and overall survival of 9-14 

Novartis Confidential Page 19
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
months, in subjects who progressed after first line platinum doublet in randomized phase 3 
studies versus docetaxel (Herbst et al 2016, Rittmey eret al2017, Borghaei et al 2015).
With the advancement of im
munotherapy  in the treatment of NSCL C, more and more subjects 
are exposed to checkpoint inhibitors in the course of their disease, either as single agents or in 
combination with other anticancer therapies. As disease progression is inevitable in these 
subjects, the need to develop innovative therapies which are effective in this post-
immunotherapy , second, and third -line setting is currentl y criticall y important. The efficacy  of 
standard therapies, including docetaxel or rechallenging with immunotherapy -based therapies 
after progression on checkpoint inhibitors, is currently  unknown (UNK) with only anecdotal 
reports ( Park andCheung 2017, Schvartsman etal2017 ).
1.1.1 MET and capmatinib (IN C280)
In human malignant disease, the MET pathway  is frequentl y dysregulated, triggering a diverse 
set of signaling cascades (including the RAS -MAPK as well as the PI3K-AKT pathway ), which 
are promoting proliferation, survival, motility  and angiogenesis (Christensen et al 2005). In 
addition, various roles of MET/HGF signaling in immune cells, primarily  of the myeloid lineage, 
have 
been proposed that could lead to MET- dependent immune suppression 
(Molnarfi et al 2015 ). Several mechanisms have been identified by which the MET pathway 
becomes aberrantly  activated in cancer such as gene amplification, receptor overexpression, 
mutations, autocrine or paracrine secretion of its ligand HGF. MET amplification and MET 
mutations are currently  the most studied MET dysregulations in NSCLC, being evaluated as 
predictors of response to MET inhibitors. Overall MET dy sregulation is rare.
MET amplification (with gene copy number [GCN] > 6) is reported in ~3-4% of NSCL C 
(Comprehensive molecular profiling oflung adenocarcinoma, 2014 ) with up to 1% of these 
tumors demonstrating even higher levels of amplification (GCN ≥ 10). Responses to MET 
inhibitors in NSCL C harbori ng high levels of MET amplification have been reported in clinical 
trials ( Schuler et al 2016 , Wolf 2017, Camidge et al 2018).
MET mutations causing skipping of exon 14, thereby  removing the juxtamembrane domain of 
MET, leads to protein stabilization and oncogenic activation (Kong -Beltran et
al2006). Next 
generation sequencing of tumor specime
ns identified many  different variants that can result in 
exon 14 skipping. These variants are primaril y fou nd in lung cancer at a frequenc y of about 3% 
(Frampton et al 2015, Schrock et al2016). Recent clinical observations indicate that such 
mutations are predictors of response to capmatinib and other MET targeting agents 
(Frampton et al 2015, Paik et al 2015, Jenkins et al2015 , Mendenhall andGoldman 2015, 
Waqar et
al2015, Liuet al 2015 , Schuler et al 2016 , Drilon 2016, Cedrés et al 2018).
Numerous effects of MET signaling on immune cells have 
been reported in the preclinical 
literature (Molnarfi et al 2015). For example, activation of MET through HGF was found to 
impact the differentiation of dendritic cells towards a “tolerogenic” (i.e. immunosuppressive) 
phenoty pe (Rutella et
al2006), suggesting that MET inhibition could have a positive 
immunomodulatory  effect on the activation of T cells by  dendritic cells.
Recent studies in multiple mouse models have demonstrated that MET
-positive neutrophils 
suppress immune therap y-induced T cell expansion and effector functions, and that concomitant 
MET inhibition with capmatinib can enhance the efficacy  of cancer immunotherapies in non-

Novartis Confidential Page 20
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
MET driven tumor models (Glodde et al 2017). It has also been reported that MET is expressed 
on a subset of cytotoxic T lymphocy tes suppressing their function when activated by HGF. 
These observations demonstrate an immunomodulatory potential of MET and HGF b y directl y 
acting on immune cells, irrespective of the MET dysregula tion. MET inhibitors also may restore 
immune cell function by preventing/reducing hepatocy te growth factor (HGF) signaling. 
Additional information supporting the role of MET inhibitors like capmatinib as 
immunomodulators can be found i n Section 4.2.1.
MET dysregulation is a negative prognostic factor in patients with NSCLC (Guo et
al2014, 
Landi et
al2017, Awad etal2017), particularl y when both MET amplification and mutation 
occur in the same tumor ( Awad et
al2017 ).
While no selective MET inhibitors or antagonists have been approved for use in cancer patients 
to date, several investigational agents are being currentl y evaluated in clinical trials.
Capmatinib (INC280) is a small adenosine triphosphate (ATP) competitive, orally  bioavailable, 
highl y potent, and selective reversible inhibitor of the MET receptor tyrosine kinase 
(Liuet al 2011) capable of blocking MET activation developed primaril y in MET d ysregulated 
solid tumors. Capmatinib also exhibits preclinical immunomodulatory  activity  in tumor models 
irrespective of MET d ysregulation.
Overall, preclinical and early clinical data indicate that capmatinib has a manageable safet y 
profile. 
As of the cut-off date of 28-Sep-2017, a total of 1109 cancer subjects and 158 non-
cancer subjects have received capmatinib. A total of 622 subjects with solid tumors have been 
treated with capmatinib as a single agent, and 487 subjects have been treated with capmatinib 
in combination therapies. Treatment was with either the capsule formulation or tablets or both. 
Twenty -one clinical studies are currentl y ongoing with capmatinib. A total of 19 subjects have 
experienced 25 Dose Limiting Toxicities (DLTs): 6 subjects in single agent studies and 13 in 
combination studies. For more information, please refer to the current [capmatinib 
Investigator’s Brochure (IB) ].
Overall, the majority  of the reported adverse events (AEs) are mild or moderate in severit y. The 
most frequent AEs suspected to be related to capmatinib of any grade reported in the largest 
single agent trial [CINC280A2201] (220 subjects) were edema peripheral (77 subjects, 
[35.0%]), nausea (69 subjects, [31.4%]), vomiting (40 subjects, [18.2%]), blood creatinine 
increased (39 subjects, [17.7%]), and fatigue (34 subjects, [15.5%]), majority  Grade 1/2. The 
most frequently  occurring Grade 3/4 AEs suspected to be related to capmatinib as a single agent 
included edema peripheral and lipase increased (each in 9 subjects, [4.1%]), fatigue (8 subjects, 
[3.6%]), alanine aminotransferase increased (ALT) (7 subjects, [3.2%]), aspartate 
aminotransferase increased (AST), hypophosphataemia, nausea and vomiting (each in 3 
subjects, [1.4%]).
Caution is recommended when capmatinib is administered in combination with other anticancer 
drugs with a known risk of hepatotoxicity . One case of liver function test (LFT) abnormal 
meeting Hy’s Law criteria for hepatotoxicity  (PHHO2015CN003025) has been reported for a 
subject enrolled in the NSCL C combination study with gefitinib [CI NC280X2202]. The event 
could not be attributed solely  to either drug alone or to the combination. The subject 
permanentl y discontinued both study  drugs. Liver function tests improved after treatment 
discontinuation.

Novartis Confidential Page 21
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
As of the IB cut -off of 28 -Sep-2017, pneumonitis and ILD (interstitial lung disease) have been 
reported from both capmatinib single agent and combination studies with the EGFR TKIs, 
including events with fatal outcomes. Investigators are advised to carefull y monitor subjects for 
signs and symptoms of pneumonitis and implement dose modification and follow -up 
evaluations described in the protocol in all capmatinib studies, both single agent and in 
combination studies.
The maximum tolerated dose (MTD) for capmatinib capsules or tablets as single agent was not 
reached. The RP2D (Recommended Phase 2 dose regimen) for capmatinib as a single agent has 
been determined to be 600 mg BID (twice a day) in capsule formulation and 400 mg BID in 
tablet formulation. For more information, please refer to the current [capmatinib I nvestigator’s 
Brochure].
1.1.2 Spartalizumab (PDR001)
Spartalizumab (PDR001) is a monoclonal antibody (mAb) directed against human Programmed 
Death -
1 (PD-1). PD-1 is a critical immune -checkpoint receptor that is expressed on CD4 and 
CD8 T cells upon activation (Freeman andSehn 2018). Engagement of PD- 1 by itsligands, 
PD-L1 and PD-L2 (Programmed Death -Ligand 2), transduces a signal that inhibits T-cell 
proliferation, cytokine production, and cytolytic function (Riley et al 2009). During 
tumorigenesis, cancer cells from a wide range of tumor types exploit immune checkpoint 
pathway s, such as PD-(L)1, to avoid detection by the adaptive immune system 
(Murph yet
al2011). Monoclonal antibody  (mAb) inhibitors of immunological checkpoints, 
inclu
ding PD -1 and PD -L1 mAb’s, have demonstrated significant antitumor activity in patients 
with various solid tumors.
Spartalizumab is a high-affinit y, ligand -blocking, humanized immunoglobulin G4 (IgG4) 
antibody  directed against PD-1 that blocks the binding of PD-L1 and PD-L2 and enhances 
interleukin -2 production in ex-vivo lymphocy te stimulation assay s. It does not cross react with 
rodent PD-1; therefore, toxicology  studies were performed only in cynomolgus monkey s where 
there was acceptable cross reactivit y with monkey  PD-1. Anti- drug antibodies (ADA) to 
spartalizumab were observed in some spartalizumab treated cynomolgus monkey s. A trend of 
reduced drug exposure was observed in these ADA -positive animals. For further details, please 
refer to the latest [spartalizumab I nvestigator’s Brochure].
As of 19-Jan-2018 (latest IB cut-off date), approximately  1239 subjects across 23 Novartis -
sponsored clinical studies have been treated with spartalizumab. Of these, a total of 517 subjects 
were exposed to spartalizuma b single agent, and 722 subjects were exposed to spartalizumab 
in combination with other agents (LBH589, LCL161, CJM112, EGF816, ACZ885 and TMT212, 
LAG525, MBG453; other combination studies with spartalizumab have not yet gathered 
sufficient PK data to war rant inclusion in the IB).
The available safet y data from these clinical studies indicate that spartalizumab is generall y 
well tolerated. In the dose escalation phase of the first-in-man study  CPDR001X2101 in patients 
with advanced solid tumors, no DLTs were reported. The preliminarily  identified safet y risks 
associated with spartalizumab are consistent with and characteristic of agents that inhibit the 
PD-1 receptor, and an advanced cancer population investigated in the respective trials. Severe 
immune -related adverse events (irAEs) were infrequent and typically  manageable with dose 

Novartis Confidential Page 22
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
interruption and use of immunosuppressive treatment or other supportive therap y as clinically 
indicated; discontinuations due to irAEs were rare.
Based on pooled safety  data from four studies comprising 513 patients treated with single agent 
spartalizumab across different regimen (400 mg Q4W [n=382], 300 mg Q3W [n=59] and 1 -10 
mg/kg Q2W or Q4W [n=76]) and various advanced solid tumors types (i.e. mainly  NSCLC, 
melanoma, triple negative breast cancer (TNBC), anaplastic thyroid carcinoma, neuroendocrine 
tumors and nasophary ngeal carcinoma), the most common AEs (>10%), all grades, regardless 
of relationship with study treatment included: fatigue (23.6%), decreased appetite (19.7%) , 
anemia (19.1%), nausea (19.1%), dyspnea (18.9%), cough (17.2%), pyrexia (16.0%), 
constipation (15.4%), diarrhea (13.8%), vomiting (12.9%), asthenia (11.5%) and abdominal 
pain (11.3%). Most common AEs (>3%), all grades, suspected to be study  drug related included 
fatigue (13.1%), hy pothyroidism (6.4%), nausea (6.2%), decreased appetitive (5.8%), diarrhea 
(5.7%), rash (5.5%), pruritus (4.9%), pyrexia (4.7%), asthenia (4.3%), anemia (3.7%), AST 
increase (3.5%) and ALT increase (3.1%).
Most common SAEs (>1%), all grades, regardless of relationship with study  treatment were 
dyspnea (3.5%), pleural effusion (2.5%), abdominal pain (2.3%), pneumonia (2.3%), pyrexia 
(1.8%), h ypercalcemia (1.6%), anemia (1.4%), sepsis (1.4%) and vomiting (1.2%). There were 
no SAEs s uspected to be study  drug related that occurred in more than 1% of patients.
Adverse events of special interest (AESI) for spartalizumab include endocrinopathies, colitis, 
skin reactions, hepatitis, nephritis, pneumonitis and other irAEs, and infusion reac tions.
Based on the available pharmacokinetics (PK) and safet y data, two RP2Ds for spartalizumab 
have been declared: 400 mg Q4W or 300 mg Q3W, with the choice between these two regimens 
determined b y scheduling convenience, for example in combination setti ngs. The safet y pro file 
was similar across the different dose and disease groups and is consistent with the safet y profile 
of other similar PD- 1 inhibitors.
For further details, please refer to the latest version of the [spartalizumab Investigator’s 
Brochu re], as well as Section 4.5(Risks and Benefits) and Section 6.5.3.1 (Dose Modifications) 
of the protocol.
1.1.3 Combination of capmatinib with a checkpoint inhibitor
1.1.3.1 Combination of capmatinib and nivolumab
The combination of capmatinib and nivolumab has been explored in the study  
[CEGF816X2201C]. This is an ongoing phase II, open -label, study of capmatinib in 
combination with nivolumab in adult subjects with advanced immunotherap y immuno -
oncology  (IO)-naive NSCL C (either with high or low MET expression). As of the data cutoff 
of 10-Aug-2017, 18 subjects have been enrolled and treated with capmatinib 400 mg BID + 
nivolumab 3 mg/kg Q2W.
All 18 subjects (100%) experienced AEs of any grade, regardless of causality . The most 
common AEs (occurring in more than 20% of subjects) of any grade were nausea (77.8%), 
vomiting (61.1%), diarrhea (44.4%), rash (group term that includes rash, macular rash, 
maculopapular rash, and eczema, 44.4%), constipation (33.3%) , peripheral edema (33.3%), 
decreased appetite (27.8%), fatigue (27.8%), pyrexia (27.8%), increased amylase (22.2%), 

Novartis Confidential Page 23
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
arthralgia (22.2%), asthenia (22.2%), back pain (22.2%), and dyspnoea (22.2%); the majorit y 
of AEs were Grade 1/2.
With regard to AEs suspe cted to be related to study  treatment, all 18 subjects (100%) 
experienced AEs of any grade. The most frequent AEs (occurring in more than 10% of subjects) 
of an y grade suspected to be related to stud y treatment were nausea (77.8%), diarrhea (44.4%), 
rash (group term, 44.4%), vomiting (44.4%), peripheral edema (33.3%); decreased appetite 
(27.8%), increased amylase (22.2%), asthenia (22.2%), fatigue (22.2%), arthralgia (22.2%), 
increased blood creatinine (16.7%), hy poalbuminemia (16.7%), lethargy  (16.7%), neu tropenia 
(16.7%), pyrexia (16.7%), constipation (11.1%), dry skin (11.1%), increased lipase (11.1%), 
pruritus (11.1%), and thrombocy topenia (11.1%); the majority  of AEs were Grade 1/2.
Ten subjects (55.6%) experienced at least one SAE regardless of causality . Five subjects 
(27.8%) experienced at least one SAE suspected to be related to study  treatment. These included 
SAEs of lethargy , gastroesophageal reflux disease, somnolence, and temporal arteritis in one 
subject; pyrexia in one subject; pyrexia, maculop apular rash, neutropenia, thrombocy topenia, 
and disseminated intravascular coagulation in one subject; anaph ylactic reaction in one subject; 
macular rash and vomiting in one subject; and colitis, vomiting, and diarrhea in one subject. 
Each of these suspect ed related SAEs were reported as recovered, except for temporal arteritis 
(recovering) and colitis (not recovered).
Overall, the safet y profile of this combination was manageable; however, the data generated in 
this study  are still preliminary , and caution is warranted due to the partial overlapping toxicity  
from both single agents.
This study  has provided initial information regarding the safet y of the combination of a PD-1 
inhibitor and capmatinib; efficacy data generated in this setting of pretreated adv anced NSCL C 
subjects will further support the rationale for combining capmatinib with spartalizumab in 
advanced NSCL C in this CI NC280D2201 study .
1.1.3.2 Combination of capmatinib and spartalizumab
Capmatinib in combination with spartalizumab is currently  being evaluated in the dose 
escalation and expansion study  [CINC280X2108] in subjects with hepatocellular carcinoma 
(HCC).
This is an ongoing phase Ib/II, open -label, multi- center study  of capmatinib in combination 
with spartalizumab or spartalizumab single agent conducted in advanced IO-naive 
hepatocellular carcinoma after sorafenib failure.
As of the data cut-off of 25-Sep-2017 [capmatinib Investigator’s Brochure], 20 subjects were 
enrolled and treated in the dose escalation (phase Ib) part of the stud y, at three dose levels: 200 
mg B ID capmatinib (N=6), 300 mg BID capmatinib (N=8) and 400 mg BID capmatinib (N=6), 
all in combination with 300 mg Q3W spartalizumab.
One DLT was reported for a subject treated with capmatinib 400 mg (BID) in combination with 
spartalizu mab 300 mg (Q3W): Grade 3 diarrhea, suspected to be related to study  treatment. 
Seven subjects (35%) have permanently discontinued study treatment, 1 subject (5%) due to an 
AE, 4 subjects (20%) due to progression of disease, 1 subject (5%) due to subject/g uardian 
decision and 1 subject (5%) due to death (caused by  progression of disease).

Novartis Confidential Page 24
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
AEs, all grades, regardless of relationship to study drug, were reported in 19 subjects (95%) 
overall, with the most frequent AEs being peripheral edema (10 subjects, 50%) , nausea (7 
subjects, 35%), blood creatinine increased, fatigue (each in 6 subjects, 30%), and rash (5 
subjects, 25%).
Of the 20 subjects treated, 9 (45%) experienced Grade 3 or Grade 4 AEs regardless of 
relationship to study  drug. The most frequent Grade 3/4 AEs included nausea, dy spnoea, ALT 
increased, bilirubin increased (each in 2 subjects, 10%). Seven subjects (35%) had Grade 3/4 
AEs suspected to be related to study  treatment: nausea (2 subjects, 10%), peripheral edema, 
ALT increased, diarrhea, stomati tis, hypotension, platelet count decreased, acute myocardial 
infarction, unstable angina, blood bilirubin increased, dehydration and neutropenia (each in 1 
subject, 5%).
Of the 20 subjects treated, 17 (85%) experienced AEs (all grades) suspected to be related to 
study  treatment. The most frequent suspected AEs included peripheral edema (9 subjects, 45%), 
fatigue, rash (each in 5 subjects, 25%), blood creatinine increased, nausea, vomiting (each in 4 
subjects, 20%).
SAEs, all grades, regardless of relationsh ip to study  drug, were reported in 4 subjects (20%). 
50% of the SAEs were Grade 3 or 4 (3 out of 6). SAEs suspected to be related to study  treatment 
included unstable angina pectoris, deh ydration and diarrhea.
Similar to the combination with nivolumab described in Section 1.1.3.1, the safet y profile of 
the combination of capmatinib and spartalizumab was manageable. The RP2D of the 
combination of capmatinib and spartalizumab has been established at a dose of capmatinib 400 
mg BID and spartalizumab 300 mg Q3W. At this dose level the combination was well tolerated 
and there 
was one DLT, Grade 3 diarrhea, as outlined above. While the safety  findings 
generated in this study  might be extrapolated to other disease settings, it should be noted that 
HCC subjects tend to represent a unique subject population, prone to exacerbated toxicity  due 
to their underly ing disease and related comorbidities. Further monitoring and confirmation of 
the safet y of this drug combination in this NSCL C indication will be conducted in this 
CINC280D2201 study , which will use a different schedule for spartalizumab (400 mg Q4W).
1.2 Purpose
The purpose of this prospective, multicenter, randomized phase II study  is to evaluate the safet y 
and efficacy  of the combi nation of capmatinib and spartalizumab in subjects with EGFR wt (for 
exon 19 deletions and exon 21 L858R substitution mutations), ALK -negative rearrangement, 
advanced/metastatic (stage IIIB [not amenable for definitive chemo -radiotherapy ] or IV) 
NSCL C, 
regardless of MET and PD-L1 status. Subjects must have progressed on prior 
treatment with a platinum doublet and a checkpoint inhibitor (either approved or 
investigational), either as single treatments or in combination. A run-in phase will be conducted 
befor e starting the randomized phase to evaluate safet y, tolerability and preliminary efficacy of 
the combination of capmatinib 400 mg BID and spartalizumab 400 mg i.v. Q4W in the selected 
NSCL C setting.
This study  will generate clinical data with the proposed combination doses/schedule for 
capmatinib and spartalizumab in advanced NSCLC. Additionally , this study  will be the first to 
evaluate the activity  of capmatinib in combination with a checkpoint inhibitor in NSCL C in a 

Novartis Confidential Page 25
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
post-checkpoint and post-platinum setting and will also confirm the efficacy of docetaxel in this 
setting.
2 Objectives and endpoints
Objectives and related endpoints are described in Table 2-1below.
Table 2
-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary  objective(s) Endpoint(s) for primary  objective(s)
● Run-in part: To assess safety and tolerability of 
capmatinib and spartalizumab combination● Run-in part: Inc idence and severity of AEs and SAEs, 
including changes in laboratory values, vital signs and 
ECGs, dose interruptions, reductions, and dose 
intensity.
● Randomized part: To assess the overall survival 
of combination of capmatinib and spartalizumab in 
comparison to docetaxel● Randomized part: Overall Survival
Secondary  objective(s) Endpoint(s) for secondary  objective(s)
● To assess the objective response rate (ORR), 
disease control rate (DCR), progression -free 
survival (PFS), duration of response (DO R), and 
time to response (TTR) of the capmatinib and 
spartalizumab combination and that of docetaxel● Objective response rate (ORR), disease control rate 
(DCR), progression -free survival (PFS), duration of 
response (DOR), and time to response (TTR) based on 
RECIST 1.1 
● To assess the safety profile of capmatinib and 
spartalizumab combination therapy● Incidence and severity of AEs and SAEs
● To characterize the pharmacokinetics of 
capmatinib and spartalizumab as a combination 
therapy in this patient population● Pharmacokinetic parameters (e.g. Ctrough, Cmax, 
AUC)
● To evaluate the prevalence and incidence of 
immunogenicity● Antidrug antibodies (ADA) prevalence at baseline and 
ADA incidence on treatment

Novartis Confidential Page 26
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
3 Study  design
This is a two-part prospectively  designed, multicenter, open -label, randomized phase II study 
to evaluate the safet y and efficacy  of capmatinib in combination with spartalizumab in adult 
subjects with EGFR wt (for exon 19 
deletions and exon 21 L858R substitution mutations), ALK 
rearrangement negative in locally  advanced (stage IIIB, not eligible for definitive chemo -
radiation) or metastatic (stage IV) NSCL C after failure of platinum doublet and checkpoint 
inhibitor treatment. The study  will enroll approximately  105 subjects (approximately  15 
subjects in the run-in [part 1] and 90 subjects in the randomized phase [part 2]). Crossover is 
not allowed.
Part 1: Run -in
Prior to the randomiz ed part of the stud y, a run -in to assess the safet y and tolerability as well as 
preliminary  efficacy  of the capmatinib and spartalizumab combination will be conducted. 
Approximately  15 subjects will be enrolled and treated with capmatinib and spartalizumab
combination. A review meeting will take place after all subjects have at least 24 weeks of 
follow -up. The decision to expand the study  to the randomized part will be based on the safet y, 
tolerability , and preliminary  efficacy  of the capmatinib and spartal izumab combination.
Refer to Figure 3-1for an overview of the Part I study  design.

Novartis Confidential Page 27
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Figure 3-1 Study  Design Part 1: Run-in
pts: patients FUP: follow -up
Part 2: Randomized
In the randomized part, approximately  90 subjects will be randomized in a 2:1 ratio to either 
capmatinib plus spartalizumab (n=60) or docetaxel (n=30). Subjects will be stratified based on 
the number of prior lines of ther apy (1 vs. >1). The primary  objective of part 2 is to assess the 
overall survival of the combination of capmatinib with spartalizumab in comparison to 
docetaxel.
Subjects will continue treatment with capmatinib and spartalizumab combination or docetaxel 
until they experience an y of the following: documented disease progression by RECI ST 1.1 (as 
assessed by the investigator), withdrawal of consent, pregnancy , lost to follow -
up, or death 
irrespective of start of new anti- neoplastic therap y (please refer to Section 9).

Novartis Confidential Page 28
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
For all subjects (either in the run-in part or randomized to capmatinib and spartalizumab or 
randomized to docetaxel), the respective treatment (either with capmatinib and spartalizumab 
combination or docetaxel) may b e continued beyond initial disease progression as per RECI ST 
1.1 (as assessed b y the investigator) if, in the judgment of the investigator, there is evidence of 
clinical benefit, and the subject wishes to continue on the study  treatment (for additional det ails 
please refer to Section 6.1.5.1).
After treatment discontinuation, all subjects will be followed for safety  evaluations during the 
safet y follow -
up period, and the subject’s status will be collected every  8 weeks as part of the 
survival follow-up (for additional details please refer to Section 9).
Refer to Figure 3-2for an overview of the Part 2 study  design.
Figure 3
-2 Study  Design Part 2: Randomized

Novartis Confidential Page 29
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
pts: patients FUP: follow -up
4 Rationale
4.1 Rationale for study  design
The rationale for the study  design is described in the table below.
Table 4-1 Rationale for study  design
Study  Design Aspect Rationale
Subject population The study will enroll subjects with advanced/metastatic NSCLC which are EGFR wt, 
ALK negative, after failure of prior platinum doublet and checkpoint inhibitor 
administered for the treatment of the advanced stage. Subjects must be docetaxel 
naive.
Subjects with targetable oncogenic drivers (such as EGFR -sensitizing mutations, or 
ALK translocation) will be excluded given t he preferred approach for these subjects 
is targeted therapy with small -molecules. For more details on subject population, 
please refer to Section 5.
Two-part study (Part 1: 
run-in and Part 2: 
randomized) The randomized part will be preceded by a run-in in order to assess the safety, 
tolerability and preliminary efficacy of the combination of capmatinib and 
spartalizumab.
Comparator treatment Docetaxel was selected as the comparator treatment as it is a globally established 
treatment in this pretreated setting, irrespective of the histology and has been used 
as a comparator in many phase III studies in the post -platinum setting.
Open -label The trial is open -label for the following reasons: 1) double blinding would require 
twosets of i.v. administration for subjects due the difference in dosing schedules 
between the two arms, which would pose an unnecessary burden for the subject; 
and 2) effective blinding would be difficult, given the varying toxicities between the 
study trea tments.
Stratification factors Number of prior lines of therapy was chosen as a stratification factor due the 
expected difference in clinical outcome between subjects based on the number of 
prior lines of therapy received.
Randomization and 2:1 
ratioSubjects will be randomized as the efficacy of standard therapies, including 
docetaxel in this post -platinum doublet/post -checkpoint inhibitors setting is currently 
unknown with only anecdotal reports (Park andCheung 2 017, 
Schvartsman etal2017 ). The randomization 2:1 increases the chances for subjects 
to receive the innovative combination of immunotherapy and a MET inhibitor, which 
exhibits preclinical immunomodulatory properties a nd synergistic effect with 
immunotherapy. Furthermore, a 2:1 randomization ratio will allow for increased 
chance to detect adverse events with the capmatinib and spartalizumab 
combination.
Treatment beyond 
disease progressionThis is to ensure those subje cts (in either arm) who are clinically stable, tolerate the 
treatment, and are deriving clinical benefit can continue to receive treatment. 
Timely follow -up after the initial PD will ensure that subjects with confirmed/rapid 
progression will be discontinue d and can initiate adequate subsequent therapies.
4.2 Rationale for dose/regimen and duration of treatment
4.2.1 Capmatinib in combination with spartalizumab
Inhibition of MET by pharmacological or genetic means can enhance T cell mediated anti-
tumor immunity  in a variet y of treatment regimens and mouse tumor models (including 
melanoma lung, breast, and colon cancer models) ( Glodde et al 2017).

Novartis Confidential Page 30
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Glodde et al. proposed a model in which capmatinib counteracts an HGF -driven negative 
feedback loop in a T cell inflamed tumor microenvironment, activated immune cells and/or 
tumor -associated stroma secrete HGF, which is mirrored b y an increased serum HGF level. As 
a consequence, MET -positive neutrophils are mobilized and invade tumor and a djacent ly mph 
nodes, where they acquire immunosuppressive properties, dampening the T cell response 
(Glodde et al 2017 ).
In order to independently reproduce these results, the combination of anti -PD1 and capmatinib 
was tested in two syngeneic mouse models at Novartis [RD-2017- 00370]. Combination 
treatment led to increased T 
cell infiltration in the short term, and an improved anti-tumor 
immune response with a higher cure rate than either single agent in the long term. Th e in vivo
studies were extended in a second model (cervical carcinoma) that was generated at Novartis 
in a geneticall y engineered mouse strain with error- prone DNA (deoxy ribonucleic acid) 
replication, which also leads to a high mutation burden. Again, addition of capmatinib to anti -
PD1 therapy  led to an increased cure rate, while the MET inhibitor was largel y inactive on its 
own.
Besides these direct functional data in mouse models, the reported immunosuppressive effects 
of HGF/MET on dendritic cells and T cells (Section 1.1.1) further support the rationale for 
combining anti-PD1 and capmatinib, because both agents have the potential to enhance T 
cell 
mediated anti-tumor immunity  through complementary  mechanisms. While inhibi tion of 
HGF/MET signaling is expected to enhance antigen presentation and T cell stimulation by 
dendritic cells and potentially  even increase cytotoxicity  of a subset of T cells, anti-PD1 
antibodies will prevent suppression of T cell function through PD -L1expressed on tumor cells 
or other immune cells.
The feasibility  of the combination of capmatinib with a checkpoint inhibitor has alread y been 
confirmed in two studies ([CINC280X2108] and [CEGF816X2201C]). (For details, please refer 
to Section 1.1.3.1 and Section
1.1.3.2).
The combination of capmatinib with spartalizumab has been evaluated in the study 
[CINC280X2108] (which used a fixed dose of spartalizumab 300 mg with a Q3W schedule) 
conducted in HCC where, based on the BL RM-EWOC (Bay esian Logistic Regression Model -
Escalation With Overdose Control) model, the RP2D was declared at 400 mg BID for 
capmatinib in combination with 300 mg spartalizumab Q3W.
In the current study  [CINC280D2201] , the alternate dosing regimen of spartalizumab 400 mg 
Q4W will be used. 
Pharmacokinetic and safet y data across dose levels in study 
[CPDR001X2101] supported the declaration of two RP2Ds, 300 mg Q3W and 400 mg Q4W 
for spartalizumab as a single agent. Based on the population PK model simulations, both 
regimens are expected to achieve similar exposure range at stead y-state and achieve a mean 
steady -state Ctrough value higher than the ex vivoEC50 for antigen -stimulated IL-2 production, 
a translational biomarker for PD-1 blockade (for additional information, please refer to 
Section 1.1.2). Two RP2Ds were chosen to allow more convenient scheduling of treatments for 
subjects receiving combination therapy  with spartalizumab. I n this study , a Q4W schedule has 
been chosen based on scheduling convenience in this setting of advanced NSCLC. The activit y 
of docetaxel in the context of post-platinum and post-checkpoint inhibitor is unknown with 
anecdotal reports ( Park andCheung 2017Schvartsman et al2017 ).

Novartis Confidential Page 31
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
Docetaxel is an established treatment option for pretreated NSCL C subjects and has served as 
a control arm for several prospective, randomized trials in the second -or third- line setting 
including the most recent phase 3 studies with PD-(L)1 inhibitors (Herbst et al 2016 , 
Rittmey er et al 2017, Borghaei et al2015, Brahmer et al2015 , Hanna etal2004), and it is 
approved for the use in NSCL C irrespective oftumor histology . In the context of the post-
platinum setting, a response rate of approximately  9-13%, median PFS of 3-4 months, and 
median OS of approximately  8-
10 months is expected with docetaxel (Hanna et al 2004, 
Herbst et
al2016, Rittmey eret al2017, Borghaei et al2015, Brahmer et al2015). Overall, the 
reported response rates to second -line chemotherap y (including other single agent 
chemotherapeutics) have generall y been < 11%, with median PFS and OS generally below 4 
and 11 months, respectively  (deMarinis andGrossi 2008, Weiss andStinchcombe 2013, 
NCCN 2018, Novello et al 2016). Upon progression after second -line chemotherap y, subjects 
may be candidates for further tre atment, although randomized evidence is scarce and most data 
come from phase II trials or retrospective analyses. Subjects often have limited response to 
third
-line therap y, although it may have some palliative effect (Shepherd et al 2005, 
deMarinis andGrossi 2008 , Eccles et
al2011, Reck et al 2014, Besse et al 2014, NCCN 2018). 
The activity  of docetaxel in the context of post-platinum and post-checkpoint inhibitor is 
unknown with anecdotal reports ( Park andCheung 2017, Schvartsman etal2017 ).
4.4 Purpose and timing of interim analy ses/design adaptations
Not applicable.
4.5 Risks and benefits
Subjects in this study  have advanced non -small cell lung cancer and have progressed after one 
or two lines of prior approved chemotherap y, radiotherap y and/or immunotherap y. Given the 
clinical and molecular characteristics of their disease they have limited therapeutic options and 
the established standard, single agent chemotherapy  regimens approved for this setting are of 
limited benefit.
Synergistic antitumor effect has been shown preclinically with capmatinib in combination with 
checkpoint inhibitors in non-MET driven tumor models. The safety  profile of capmatinib and 
spartalizumab as monotherapies is well characterized (seeSection 1.1.1 and Section 1.1.2 ). This 
new combination has been proven to be safe at the dose of 400 mg BID capmatinib and 
spartalizumab 300 mg Q3W in HCC subjects treated in study  [CINC280X2 108] (see 
Section 1.1.3.2). The 24 weeks follow - up of this run-in phase is intended not only to allow a 
thorough assessment of the safet y profile of this new schedule but also to assess the preliminary 
efficacy  of this combination before enrolling more subjects into the randomized part.
Appropriate eligibility  criteria and stopping rules are included in this protocol. Recommended 
guidelines for proph ylactic or supportive treatment for expected toxicities, including the 
management of study -drug induced AEs, (e.g. infusion reaction, pneumonitis) are provided in 
Section 6.5. The risk to subjects in this trial may be minimized by compliance with the 
eligibility  criteria and study  procedures, as w ell as by  close clinical monitoring.

Novartis Confidential Page 32
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
As with any  clinical study , there may  be unforeseen risks with the combination studied, which 
could be serious. The specific risks for each compound are discussed below. For more details, 
refer to the toxicity  data provided in the [capmatinib Investigator's Brochure] and in the 
[spartalizumab I nvestigator's Brochure]
4.5.1 Capmatinib
Based upon the clinical experience with capmatinib to date, the overall risk -benefit assessment 
of capmatinib is considered favorable with a manageable safet y profile. Most of the AEs that 
have been reported, irrespective of relationship to study  drug, have been manageable and 
generall y mild or moderate in severit y.
Caution is recommended when capmatinib is administered in combination with other anticancer 
drugs with a known risk of hepatotoxicity . One case of liver function test abnormal meeting 
Hy’s Law criteria for hepatotoxicity  (PHHO2015CN003025) has been reported for a subject 
enrolled in the NSCL C combination study  with gefitinib [CINC280X22 02]. The event could 
not be attributed solely  to either drug alone or to the combination.
As of the IB cut-off of 28-Sep-2017, pneumonitis and ILD have been reported from both 
capmatinib single agent and combination studies with the EGFR TKIs, including events with 
fatal outcomes. Investigators are advised to carefully  monitor subjects for signs and s ymptoms 
of pneumonitis and implement dose modification and follow -
up evaluations described in the 
protocol in all capmatinib studies, both single agent and in combination studies.
For further information on potential toxicities, please refer to Section 1.1.1 and the current 
[capmatinib I nvestigator's Brochure].
4.5.2 Spartalizumab
Spartalizumab is a humanized mAb which belongs to a class of agents known as immune -
checkpoint inhibitors, specificall y anti-PD-1. This class of compounds has demonstrated 
significant improvement in efficacy  combined with a tolerable and manageable safet y profile, 
supporting regulatory  approvals in various indications.
Overall, clinical experience with spartalizumab to date suggests that it can cause 
irAEs. Immune -checkpoint inhibitors of this class may be associated with the occurrence of 
immune -mediated adverse events (irAE). In general, irAE can potentially  involve every  organ 
system but gastrointestinal (GI) (e.g. diarrhea, colitis), dermatologic (e.g. rash, pruritus), hepatic 
(e.g. hepatitis), pulmonary (e.g. pneumonitis), renal (e.g. nephritis) and endocrine toxicities (e.g. 
hypothy roidism, hy perthy roidism, ty pe I diabetes, hy pophy sitis including hy popituitarism and 
adrenal insufficiency ) being typicall y the most frequent. Other immune -mediated AEs may 
rarely include the nervous system (e.g. encephalitis, Guillain- Barre syndrome, myasthenia 
gravis), eye (e.g. uveitis, vision changes), musculo -skeletal system (e.g. myositis, arthritis), 
pancreas (e.g. pancreatitis), cardio -vascular system (e.g. vasculitis, myocarditis) or blood 
system (e.g. anemia, cytopenias), and severe skin reactions such as toxic epidermonecroly sis or 
Steven Johnson syndrome. Furthermore, complications in patients with bone marrow or solid 
organ transplant have been reported (e.g. organ rejection, severe graft -versus- host disease).
These side effects are generall y manageable and reversible with dose interruption and 
administration of corticosteroids and/or other immunosuppressants. However, fatal events have 

Novartis Confidential Page 33
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
been reported in some cases with checkpoint inhibitors; furthermore, some events like 
endocrinopathies may  require life -long hormonal replacement. While most irAEs are expected 
to occur during the treatment with spartalizumab, onset may be delay ed and irAEs may also 
occur after discontinuation of study  treatment (Spain et al 2016, Hofmann et al2016 , 
Champiat et al 2016, Brahmer et al2018, Haanen et al2017 ). In addition, mAb’s can be 
associated with infus ion-related reactions some of which can be severe; these are often 
immediate and usually  occur within minutes of the exposure to the study  drug. Therefore, 
infusions should take place in a facility  with appropriate resuscitation equipment available at 
the bedside and a physician readil y available, and patients monitored for respective signs and 
symptoms. Patients who experience severe or life -threatening irAEs or infusion reactions may 
need to permanently  discontinue spartalizumab (see Section 6.5.3.1 for further guidance).
It is therefore important to be vigilant and carefully  identify  events that may be suggestive of 
potential irAEs, as their appearance may be sub-clinical (for example an asymptomatic 
laboratory  abnormali ty), and early diagnosis is critical for appropriate management and 
possibly  prevent complications. Serological, 
immunological and histological assessments (such 
as biopsy of the affected tissue) should be performed as deemed appropriate by the investigato r 
to verify  the potential immune -mediated nature of the AE and to exclude alternative diagnoses 
or disease progression. Following appropriate and complete evaluation, an empiric trial of 
corticosteroids may  contribute to the identification of irAEs.
It is expected that spartalizumab would have a similar safety  profile as other immune checkpoint 
inhibitors with the above -mentioned side effects possibly  occurring in subjects treated with 
spartalizumab. For further detail on potential adverse events with spart alizumab treatment 
please refer to Section 1.1.2 of this protocol.
4.5.3 Capmatinib combined with spartalizumab
Pharmacokinetic drug-drug interaction (DDI) is anticipated to be low for the combination of 
capmatinib and spartalizumab.
Both capmatinib and spartalizumab are well tolerated as single agents. There is no 
pharmacological or clinical evidence that would anticipate any cumulative, interactive or 
unexpected toxicity  between the compounds if given in combination. T he combination is 
currentl y being evaluated in the dose escalation and expansion study  [CINC280X2108] in 
subjects with hepatocellular carcinoma (HCC). To date, the safety  profile of the combination in 
this disease setting has been manageable.
For further detail on potential adverse events with the combination of capmatinib and 
spartalizumab please refer to Section
1.1.3.2 of this protocol.
4.5.4 Docetaxel
In this patient population, safet y and efficacy  of docetaxel has been well- established since its 
approval in 1996. Docetaxel is licensed as single agent and indicated for the treatment of 
patients with locally  advanced or metastatic non-small cell lung cancer after failure of prior 
platinum chemotherap y. The median survival was 9.0 months with docetaxel versus 4.6 months 
for best 
supportive care (BSC) (P = 0.016 ). Quality -of-life analysis showed significant 
improvement in several disease -related s ymptoms in patients who received docetaxel.

Novartis Confidential Page 34
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
The common adverse reactions to docetaxe l are infections, neutropenia, anemia, febrile 
neutropenia, h ypersensitivity , thrombocytopenia, neuropath y, dysgeusia, dyspnea, constipation, 
anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, 
alopecia, skin r eactions and my algia.
Please refer to the current prescribing guidelines for docetaxel in this disease setting.
4.5.5 Risks of Imaging Procedures 
Tumor assessments required by the trial include Computerized Tomograph y (CT) and Magnetic 
Resonance Imaging (MRI) s canning. There are both benefits and risks associated with the use 
of CT and MRI  for imaging.
Contrast enhancement is a standard tool to evaluate potential metastatic lesions; subjects with 
contrast allergy  are exempted from its use. The ordering phy sician should ensure that subjects 
are well hy drated and precautions taken to avoid renal injury  due to contrast agents.
MRI  is considered a very safe imaging modality ; however, there is an underl ying risk of 
potential injury  to subjects due to the strong electr omagnetic (EM) fields used in MRI  scanning. 
Subjects with known metallic foreign bodies or implanted devices should not have MRI scans.
5 Population
The study  population will include adult subjects with locally  advanced (stage IIIB, not eligible 
for definiti ve chemo -radiation) or metastatic (stage IV) non-small cell lung cancer. Subjects 
must be docetaxel naive, and subjects with EGFR mutations and ALK rearrangement will be 
excluded.
To be eligible, patients must have progressed on prior treatment with a plat inum doublet and a 
PD-L1 checkpoint inhibitor (either approved or investigational), either as single treatments 
(with the checkpoint inhibitor as last treatment) or in combination:
Patients who have progressed after receiving a checkpoint inhibitor in comb ination with a 
platinum doublet, as first- line therap y.
Patients who have progressed on anti
-PD-(L)1 checkpoint inhibitor as second- line therap y, 
after receiving a platinum doublet as first -line therap y.
Finally , patients who have received a checkpoint inh ibitor as maintenance after platinum 
chemo -radiotherap y for stage III NSCL C and progressed to advanced stage within 12 
months since the end of this therap y are also eligible.
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational clinical studies. The investigator or designee must ensure that only  patients who 
meet all the following inclusion and none of the exclusion criteria are offered treatment in the 
study .
5.1 Inclusion criteria
Subjects eligible for inclus ion in this study  must meet allof the following criteria:
1.Written informed consent must be obtained prior to any  screening procedures
2.Adult ≥ 18 y ears old at the time of informed consent 

Novartis Confidential Page 35
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
3.Histologicall y confirmed locally advanced/metastatic (stage IIIB or IV per AJCC/I ASL C 
v. 8) NSCL C
4.Histologicall y or c ytologically  confirmed diagnosis of NSCL C that is both EGFR wt 
status and ALK - negative rearrangement status:
Patients with NSCL C of pure squamous cell histology can enter screening without 
EGFR mutation or ALK rearrangement testing or result; however, patients with pure 
squamous cell histology  who are known to have EGFR mutations in exons 19 or 21 or 
ALK rearrangements will be excluded
5. Patients must have demonstrated progression of locally  advanced/ metasta tic NSCL C 
(stage IIIB, not amenable for definitive chemo -irradiation, or stage IV) following one 
prior platinum doublet and one prior PD -(L)1 checkpoint inhibitor (either alone or in 
combination)
Maintenance therap y given after first -line chemotherap y wil l be considered as part of 
the first -line therap y if given to patients with documented response or stable disease 
before starting the maintenance therap y.
Neo-adjuvant and adjuvant sy stematic therapies will count as one prior line of 
systemic treatment for the advanced stage if relapse occurred within 12 months from 
the end of the neoadjuvant or adjuvant sy stemic therapy .
The most recent line of therap y should include a PD- (L)1 checkpoint inhibitor (either 
alone or in combination)
6.Patients must be candidates for single agent chemotherap y with docetaxel
7.Patients must have recovered from all toxicities related to prior anticancer therapies to 
grade ≤ 1 (CTCAE v5.0). Patients with any  grade of alopecia are allowed to enter the 
study
8.At least one measur able lesion as defined b y RECIST 1.1. A previously  irradiated site 
lesion may  only be counted as a target lesion if there is clear sign of progression since the 
irradiation
9.Patients must have adequate organ function including the following laboratory  value s at 
the screening visit:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support
Platelets ≥ 75 x 109/L
Hemoglobin (Hgb) ≥ 9 g/dL
Calculated creatinine clearance (using Cockcroft -Gault formula) ≥ 45 mL/min
Total bilirubin (TBIL) ≤ 1.5 x ULN (upper limit of normal)
Aspartate transaminase (AST) ≤ 3 x ULN, except for patients with liver metastasis, 
who may  only be included if AST ≤ 5 x UL N
Alanine transaminase (ALT) ≤ 3 x ULN, except for patients with liver metastasis, 
who may  only be incl uded if AL T ≤ 5 x ULN
Alkaline phosphatase (ALP) ≤ 5.0 x UL
Asymptomatic serum amy lase ≤ Grade 2. Patients with Grade 1 or Grade 2 serum 
amylase at the beginning of the study  must be confirmed to have no signs and/or 

Novartis Confidential Page 36
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
symptoms suggesting pancreatitis or pan creatic injury  (e.g. elevated P -amylase, 
abnormal imaging findings of pancreas, etc.)
Serum lipase ≤ ULN
Fasting plasma glucose ≤ 160 mg/dL (≤ 8.9 mmol/L)
10.ECOG performance status (PS) of 0 or 1
11.Willing and able to comply  with scheduled visits, treatment pl an and laboratory  tests
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
1. Prior treatment with a MET inhibitor or HGF- targeting therapy
2.Any untreated central nervous sy stem (CNS) lesion. However, patients are eligible if all 
known CNS lesions have been treated with radiotherap y or surgery and remained stable 
for ≥ 4 weeks after treatment. Patients must be off corticosteroid therap y for ≥ 2 weeks
3.Carcinomatous meningitis
4.Patients with known hypersensitivity  to an y of the excipients of capmatinib 
(crospovidone, mannitol, microcry stalline cellulose, povidone, sodium laury l sulfate, 
magnesium stearate, colloidal silicon dioxide, and various coating premixes) or 
intolerance to docetaxel excipien ts (as per local product label)
5.History  of severe hy persensitivity  reactions to other monoclonal antibodies, which in the 
opinion of the investigator may  pose an increased risk of serious infusion reaction
6.Presence or history  of a malignant disease other t han NSCL C that has been diagnosed 
and/or required therap y within the past 2 y ears. Exceptions to this exclusion include: 
completely  resected basal cell and squamous cell skin cancers, and completely  resected 
carcinoma in situ of an y type
7.Use of hematopoiet ic colony -stimulating growth factors (e.g. G -CSF, GMCSF, M -CSF), 
thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior start of stud y 
treatment. If ery throid stimulating agents were initiated more than 2 weeks prior to the 
first dose of study  treatment and the patient is on a stable dose, they  can be maintained
8.Patients receiving treatment with medications that meet one of the following criteria and 
that cannot be discontinued at least 1 week prior to Cy cle 1 Day  1 and for the duration of 
the study :
Strong inhibitors of CYP3A4 (patients randomized to the docetaxel arm only  will 
need to compl y with this criterion for the whole duration of the study treatment)
Strong inducers of CYP3A4 (patients randomized to both capmatinib containing arm 
and docetaxel arm will need to compl y with this criterion for the whole duration of 
the study  treatment)
9.Use of an y live vaccines against infectious diseases within 3 months of initiation of study 
treatment. Patients randomized to the spartalizumab containin g arm will need to comply  
with this criterion for the whole duration of the study  treatment
10.Patients receiving treatment with any  enzy me-inducing anticonvulsant that cannot be 
discontinued at least 1 week before first dose of study  treatment, and for the d uration of 
the study . Patients on non -enzy me-inducing anticonvulsants are eligible

Novartis Confidential Page 37
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
11.Systemic chronic steroid therapy  (≥ 10 mg/day  prednisone or equivalent) or any  
immunosuppressive therapy  7 day s prior to planned date of first dose of study  treatment. 
Topic al, inhaled, nasal and ophthalmic steroids are allowed. Steroid premedication for 
docetaxel infusion does not apply
12. Concomitant medication(s) with a “Known Risk of Torsades de Pointes” per 
www.qtdrugs.org that cannot be discontinued or replaced b y safe alt ernative medication.
13.Clinically  significant, uncontrolled heart diseases:
Unstable angina within 6 months prior to screening
Myocardial infarction within 6 months prior to screening
History  of documented congestive heart failure (New York Heart Association
functional classification III -IV)
Uncontrolled h ypertension defined b y a S ystolic Blood Pressure (SBP) ≥ 160 mm Hg 
and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without 
antihy pertensive medication. I nitiation or adjustment of antihy pertensive
medication(s) is allowed prior to screening
Ventricular arrh ythmias
Supraventricular and nodal arrh ythmias not controlled with medication
Other cardiac arrh ythmia not controlled with medication
Fridericia QT correction formula (QTcF) ≥ 470 ms on the scree ning 
Electrocardiogram (ECG) (as mean of triplicate ECG)
Long QT s yndrome, family  history  of idiopathic sudden death or congenital long QT 
syndrome
14.Thoracic radiotherap y to lung fields ≤ 4 weeks prior to starting C ycle 1 Day 1 or patients 
who have not reco vered from radiotherap y-related toxicities. For all other anatomic sites 
(including radiotherap y to thoracic vertebrae and ribs), radiotherap y ≤ 2 weeks prior to 
Cycle 1 Day  1, or patients who have not recovered from radiotherapy -related toxicities. 
Pallia tive radiotherap y for bone lesions or radio- surgery  for isolated brain lesions ≤ 2 
weeks prior to C ycle 1 Day 1 is allowed
15.Major surgery  within 4 weeks prior to starting study  treatment (2 weeks for resection of 
brain metastases), or patients who have not recovered from the side effects of such a 
procedure. Video- assisted thoracic surgery  (VATS) and mediastinoscopy  will not be 
counted as major surgery and patients can be enrolled in the study  ≥1 week after the 
procedure
16.Impairment of GI function or GI disea se that may  significantl y alter the absorption of 
capmatinib 
17.Active, known or suspected autoimmune disease or a documented history  of autoimmune 
disease. Note: patients with vitiligo, controlled ty
pe I diabetes mellitus on stable insulin 
dose, residual autoimmune -related h ypoth yroidism only requiring hormone replacement, 
psoriasis not requiring s ystemic treatment, or conditions not expected to recur in the 
absence of an external trigger are permitted to enroll.
18.Previous anti -cancer and investigational agents within 4 weeks or ≤ 5 x half -life of the 
agent (whichever is longer) before first dose of study  treatment. If previous treatment is a 
monoclonal antibody or an anti PD -
(L)1 checkpoint inhibitor, then the treatment must be 

Novartis Confidential Page 38
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
discontinued at least 4 weeks b efore first dose of study  treatment. If previous treatment is 
an oral targeted agent, then the treatment must be discontinued at least 5 x half -life of the 
agent
19.History  of allogenic bone marrow or solid organ transplant
20.Presence or history  of interstitial lung disease or interstitial pneumonitis, including 
clinically  significant radiation pneumonitis (i.e., affecting activities of daily  living or 
requiring therapeutic intervention)
21.Other severe, acute, or chronic medical or ps ychotic conditions or laborato ry 
abnormalities that in the opinion of the investigator may  increase the risk associated with 
study  participation, or that may  interfere with the interpretation of study  results
22.Known history  of testing positive for Human Immunodeficiency  Virus (HIV) infe ction. 
Positive HI V test at screening where locally  required
23. Patients with active hepatitis B infection (HBsAg positive) will be excluded. Note: 
patients with antecedent events of hepatitis B (anti-HBc positive, HBsAg and HBV DNA 
negative) are eligible. Patients with active hepatitis B (HBsAg positive) must receive 
antiviral treatment with lamivudine, tenofovir, entecavir, or other antiviral agents before 
the initiations of study  treatment and show a suppressed viral replication (e.g. HBV DNA 
< 100 UI/ml) may be included. Indications for the screening/follow- up of hepatitis B and 
duration of proph ylactic antiviral therap y should be dictated b y institutional guidelines or 
specified in the protocol
24.Patients with positive test for hepatitis C ribonucleic acid (HCV RNA). Patients in whom 
Hepatitis C virus (HCV) infection resolved spontaneously  (positive HCV antibodies 
without detectable HCV RNA) or those that achieved a sustained virological response 
after antiviral treatment and show absence of detectable HCV RNA ≥ 6 months (with the 
use of IFN -free regimes) or ≥ 12 months (with the use of IFN- based regimes) after 
cessation of antiviral treatment are eligible
25.Pregnant or nursing (lactating) women confirmed by  a positive human chorionic 
gonadotrophin (hCG) laboratory  test within 72 hours prior to initiating study  treatment. 
Note: low levels of hCG may  also be considered a tumor marker, therefore if low hCG 
levels are detected, another blood sample at least 4 day s later must be taken to assess the 
kinetics of the increase and transvaginal ultrasound must be performed to rule out 
pregnancy
26.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during do sing and for 150 day s after stopping treatment with the spartalizumab in 
combination with capmatinib. For female patients treated with docetaxel, highl y effective 
contraception must be used during the study and for at least 6 months after stopping 
docetaxe l as per the locally  approved package label. Highl y effective contraception 
methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient). Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y, or tubal ligation at least six weeks before taking 

Novartis Confidential Page 39
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
study  treatme nt. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  follow -up hormone level assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner f or that patient
Use of oral, injected or implanted hormonal methods of contraception or placement of an 
intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for e xample hormone 
vaginal ring or transdermal hormone contraception. I n case of use of oral contraception 
women should have been stable on the same pill for a minimum of 3 months before taking 
study  treatment.Women are considered post- menopausal and not of ch ild bearing potential 
if they  have had 12 months of natural (spontaneous) amenorrhea with an appropriate 
clinical profile (i.e. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or without hy sterectomy ), tota l hysterectom y, or tubal 
ligation at least six weeks ago. In the case of oophorectom y alone, onl y when the 
reproductive status of the woman has been confirmed by  laboratory  assessment is she 
considered not of child bearing potential
27.Sexually  active males u nless they  use a condom during intercourse while on treatment and 
during the follow- up periods mentioned below. Sexually  active men should not father a 
child in these periods.
Male subjects who receive treatment with spartalizumab in combination with 
capma tinib must use a condom during intercourse for 7 day s after stopping treatment.
Male subjects who receive treatment with docetaxel must use a condom during 
intercourse for at least 6 months after the last dose of docetaxel or as per the locall y 
approved pa ckage label.
A condom is required to be used b y vasectomized men as well during intercourse in order 
to prevent delivery  of the drug via semen
28.Unable or unwilling to swallow tablets as per dosing schedule
29.Any other condition that would, in the investigator ’s judgment, contraindicate patient’s 
participation in the clinical study  due to safet y concerns or compliance with clinical study 
procedures, e.g., infection, inflammation, intestinal obstruction, social/ psychological 
issues, etc.
No additional exclusion s may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible subjects.
6 Treatment
6.1 Stud y treatment
For this stud y, the investigational drugs are capmatinib and spartalizumab. The stud y treatment 
isdefined as capmatinib in combination with spartalizumab, or docetaxel. Both investigational 
drugs will be labeled and provided to sites by Novartis in compliance with legal requirements 
for each country . Docetaxel will be procured locally  as it is commerc ially available in each 
participating country .

Novartis Confidential Page 40
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.1.1 Investigational and control drugs
The treatment period begins on Cycle 1 Day 1. In other words, the first dose of study  drug 
(capmatinib plus spartalizumab or docetaxel) is given on Day 1 of Cycle 1. Cycle 1 Day 1 
should occur no later than 3 days after registration into the IRT (Interactive Response 
Technology ) system.
All dosages prescribed and administered to subjects and all dose interruptions and changes 
during the study  must be recorded on the study  treatment eCRF (electronic Case Report/Record 
Form). Refer to Section 6.7.2 for study  drug prescribing and administration information.
Table 6-1 Investigational and control drugs
Investigational/Control 
Drugs 
(Name and Strength)Pharmaceutical 
Dosage FormRoute of 
Administration Drug packageSupplier 
(global or 
local)
Capmatinib (INC280) 150 
mg or 200 mgFilm-coated tablet Oral use Open -label subject 
specific; bottlesGlobal
Spartalizumab (PDR001) 
100mgConcentrate for 
solution for infusionIntravenous use Open -label subject 
specific; 4 x 100 mg 
vialsGlobal
Docetaxel (as per local 
product available)Concentrate for 
solution for infusionIntravenous use Open -label bulk supply; 
vialsLocal
6.1.2 Additional study treatments
Spartalizumab (Infusion Reactions)
If a subject experiences an infusion reaction, he/she may receive pre -medication on subsequent 
dosing days. The pre-medication should be chosen per institutional standard of care, at the 
discretion of the treating phy sician.
Acute allergic reactions should be treated as needed per institutional standard of care. In the 
event of anaphy lactic/anaphy lactoid reactions, this includes any therapy necessary  to restore 
normal cardiopulmonary  status.
If a subject experiences a Grade 3 infusion or anaphy lactic/anaph ylactoid reaction, the subject 
will discontinue spartalizumab treatment. Further guidelines on management of spartalizumab 
infusion reacti ons are provided in Section 6.5.3.
The CTCAE category of “Infusion related reaction” should be used to describe study  treatment 
related infusion reactions, unless the investigator considers another category, such as “Allerg ic 
reaction”, “Anaph ylaxis,” or “Cytokine release syndrome” more appropriate in a specific 
situation.
Docetaxel
Pre-medication schemes should follow local guidelines as per standard of care and product 
labels.

Novartis Confidential Page 41
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.1.3 Treatment arms/group
Part 1: Run -in
In the run-in part of the study , subjects will be treated with capmatinib and spartalizumab as 
described below.
Combination of capmatinib and spartalizumab
Capmatinib 400 mg (tablets) orall y twice daily (BID) with or without food followed 
by spartalizumab 400 mg int ravenously  (i.v.) every  28 day s
Capmatinib will be given as continuous daily  dosing, and the first dose is 
administered at the stud y center.
Spartalizumab will be administered on Day  1 of each 28 day  cycle.
A complete cy cle of treatment is defined as 28 da ys of continuous capmatinib 
treatment and an infusion of spartalizumab every  28 day s.
Part 2: Randomized
In the randomized part of the study , subjects will be assigned at Cycle 1 Day 1 to one of the 
following two treatment arms/groups in a ratio of 2:1 according to stratification.
Arm 1: Combination of capmatinib and spartalizumab
Capmatinib 400 mg (tablets) orall y twice daily (BID) with or without food followed 
by spartalizumab 400 mg intravenously  (i.v.) every  28 day s
Capmatinib will be given as contin uous daily  dosing, and the first dose is 
administered at the stud y center
Spartalizumab will be administered on Day  1 of each 28 day  cycle
A complete cy cle of treatment is defined as 28 days of continuous capmatinib 
treatment and an infusion of spartalizum ab every  28 day s.
Arm 2: Reference chemotherapy
Docetaxel 75 mg/m2intravenously (i.v.) following local guidelines as per standard of 
care and product labels (including steroid premedication)
First infusion day  defines Cy cle 1 Day  1
Administered every  21 d ays
A complete cy cle of treatment is defined as an infusion of docetaxel every  21 day s.
6.1.4 Guidelines for continuation of treatment
Guidelines on the management of common capmatinib -, spartalizumab- and docetaxel -
associated toxicities and dose modification instructions are provided in Section 6.5.3.
6.1.5 Treatment duration
Subjects will continue capmatinib and spartalizumab 
combination (for both Part 1: run-in and 
Part 2: randomized) or docetaxel until they experience any of the following: documented 
disease progression by RECIST 1.1 as assessed by the investigator, withdrawal of consent, 

Novartis Confidential Page 44
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.2 Other treatment(s)
6.2.1 Concomitant therapy
In general, the use of an y concomitant medication/therap y deemed necessary for the care of the 
subject (e.g. such as anti-emetics, anti -diarrhea) is permitted except when specifical ly 
prohibited (see Section 6.2.2 ).
The subject must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (excluding study  treatment and prior 
antineoplastic treatments), blood transfusions, surgeries and procedures (including physical 
therap y) administered within 28 days prior to the first dose administration of capmatinib and 
spartalizumab combination or docetaxel through 30 days after the lastdose of capmatinib and 
spartalizumab combination or docetaxel will be recorded in the concomitant medications or 
surgical and medical procedures eCRF, respectively . Medications include not only physician 
prescribed medications, but also all over-the counter medications, herbal medications, food 
supplements and vitamins.
The following restrictions apply  during the entire duration of the study :
No other investigational therapy should be given to subjects
No anticancer agents other than the stud y medication (capmatinib and spartalizumab 
combination or docetaxel) should be given to subjects.
Subjects are permitted to use the following medications while taking capmatinib and 
spartalizumab combination:
Oral or topical antibiotics
Medications to prevent or treat nausea, vomiting or diarrhea
Hematopoietic colon y-stimulating growth factors (e.g. G -CSF, GM -CSF, M -CSF), 
thrombopoietin mimetics or ery throid stimulating agents are allowed as per local or 
published guidelines; in case of anemia, thrombocy topenia or neutr openia, potential 
immune -mediated etiology  should be ruled out.
Treatment with bisphosphonates (please refer to Section 6.2.1.2)
Ox
ygen therap y and blood products or transfusions
Local radiotherap y (please refer to Section 6.2.1.2)
Anti
-diarrheal medications (e.g., loperamide) for subjects who develop diarrhea
Pain medication to allow the subject to be as comfortable as possible
Immunosuppressive agents to treat suspected irAEs
Nutritiona l support or appetite stimulants (e.g. megestrol)
Inactivated vaccines
Topical, inhaled, nasal and ophthalmic steroids are allowed.
The subject must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study drug. All medications (other than study  drug) and significant 
non-drug therapies (including physical therapy , herbal/natural medications and blood 
transfusions) administered during the study  must be listed on the concomitant medications 
eCRF.

Novartis Confidential Page 45
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.2.1.1 Permitted concomitant therapy  requiring caution and/or action
6.2.1.1.1 Capmatinib: permitted concomitant therapy requiring caution and/or action
Capmatinib is a moderate CYP1A2 inhibitor. Coadministration of capmatinib increased 
sensitive CYP1A2 probe substrate (caffeine) A UC by  135% (see Section 1.1.1). The dose 
of CYP1A2 substrates with a narrow therapeutic index may  need to be reduced when used 
concurrently
 with capmatinib as capmatinib may  increase their exposure. Consult the 
product information of the concomitant drug for dose adjustment.
Coadminstration of capmatinib increased Pgp substrate (digoxin) exposure (AUC and 
Cmax by  47% and 74%, respectivel y) and BCRP substrate (rosuvastatin) exposure (AUC 
and Cmax by  108% and 204%, respectivel y) (please refer to Section 1.1.1). Monitor 
subjects closely  for s ymptoms of increased exposure to Pgp or BCRP substrates. Consult 
the concomitant Pgp or BCRP substrate product information when considering dose 
adjustment.
Coadministration of capmatinib with a strong CYP3A4 inhibitor (itraconazole) increased 
capmatinib AUC by  42%. There is no change in capmatinib Cmax. Execute caution when 
use strong CYP3A4 inhibitors concurrently  with capmatinib.
While the data on the concu rrent use of PPI  and food have to be considered preliminary  as 
they have been generated in a small cohort of subjects of the study  [CINC280A2108], the 
decrease in exposure imposes caution on the use of PPI  when capmatinib is taken.
Short acting gastric aci d modulators containing aluminum hy droxide and magnesium 
hydroxide, or calcium carbonate can be taken; however, it is recommended to take these 
drugs at least 1 hour before or 2 hours after administration of capmatinib.
H2 receptor antagonists should be us
ed with caution. If subjects are using H2 receptor 
antagonists during the course of this study , capmatinib should be administered at least 3 
hours before or 6 hours after taking H2 receptor antagonists.
Capmatinib is a weak -to-moderate inhibitor of CYP2C8, CYP2C9 and CYP2C19 in vitro. 
Substrates of CYP2C8, CYP2C9 and CYP2C19 with a narrow therapeutic window should 
be administered with caution.
Refer to Table 6-2below for a list of the medications (presented by  mechanism of interaction) 
that require caution when concomitantly  used with capmatinib.
Table 6
-2 Capmatinib: drugs to be used with caution during co -administration
Mechanism of Interaction Drug Name
Strong CYP3A inhibitor ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak), indinavir/ritonavir, 
tipranavir/ritonavir, ritonavir, cobicistat, indinavir, ketoconazole, 
troleandomycin, telaprevir, danoprevir/ritonavir, eltegravir/ritonavir, 
saquinavir/ritonavir, lopinavir/ritonavir, itraconazole, voriconazole, mibefradil, 
posaconazole, telithromycin, grapefruit juice, conivaptan, nefazodone, 
nelfinavir, idelalisib, boceprevir, atazanavir/ritonavir, darunavir/ritonavir
CYP1A2 substrate with NTI theophylline, tizanidine
CYP2C9 substrate with NTI (S)-warfarin
CYP2C19 substrate with NTI (S)-mephenytoin

Novartis Confidential Page 46
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Mechanism of Interaction Drug Name
P-gp substrates afatinib, alfuzosin, aliskiren, alogliptin, ambrisentan, apixaban, apremilast, 
aprepitant, atorvastatin, , boceprevir, bosentan, carvedilol, caspofungin, 
ceritinib, colchicine, cyclosporine, dabigatran, digoxin, docetaxel, doxepin, 
doxorubicin, eribulin, everolimus, fentanyl, fexofenadine, fidaxomicin, 
fluvastat in, fosamprenavir, idelalisib, iloperidone, indacaterol, irbesartan, 
lacosamide, lapatinib, levetiracetam, linagliptin, linezolid, loperamide, losartan, 
maraviroc, mirabegron, nadolol, naloxegol, nateglinide, nevirapine, nintedanib, 
olodaterol, paclitaxel, pantoprazole, paroxetine, pazopanib, proguanil, 
posaconazole, pravastatin, ranolazine, ritonavir, riociguat, risperidone, 
rivaroxaban, saquinavir, silodosin, simeprevir, simvastatin, sirolimus, 
sitagliptin, sofosbuvir, sorafenib, tacrolimus, telaprevir, t enofovir, ticagrelor, 
tipranavir, tolvaptan, topotecan, umeclidinium, valsartan, vardenafil, 
vincristine, voriconazole
BCRP substrates atorvastatin daunorubicin, dolutegravir, doxorubicin, hematoporphyrin, 
imatinib, methotrexate, paritaprevir, pitavastati n, rosuvastatin, irinotecan, 
ethinyl estradiol, simvastatin, sofosbuvir, sulfasalazine, tenofovir, topotecan, 
venetoclax
Proton pump inhibitor esomeprazole, pantoprazole, omeprazole, lansoprazole, rabeprazole, 
dexlansoprazole
H2-receptor antagonists ranitidine, nizatidine, famotidine, cimetidine
Antacids aluminum hydroxide, aluminum carbonate, calcium hydroxide, calcium 
carbonate, bismuth subsalicylate
Source: The list is adapted from the Novartis Institutes for Biomedical PK Sciences internal memorandum (v01, 
2018): drug -drug interactions (DDI) database, which is compiled primarily from the Indiana University School of 
Medicine’s “Clinically Relevant” Table (medicine.iupui.edu/flockhart/table.htm), the University of W ashington’s 
Drug Interactio n Database (druginteractioninfo.org), and the FDA’s “Guidance for Industry, Drug Interaction 
Studies”.
NTI: narrow therapeutic index
6.2.1.1.2 Spartalizumab: permitted concomitant therapy requiring caution and/or 
action
If a subject is using erythropoiesis stimulat ing agents (ESAs) prior to enrollment (at least 2 
weeks before start of study treatment), he/she may  continue the treatment.
Anticoagulation and anti-aggregation agents are permitted if the subjects are alread y at stable 
doses for > 2 weeks at time of first dose and International Normalized Ratio (INR) should be 
monitored as clinically indicated per investigator’s discretion. However, ongoing anticoagulant 
therap y should be temporaril y discontinued to allow tumor sampling according to the 
institutional guidelines.
Topical, inhaled, nasal and ophthalmic steroids are allowed.
6.2.1.1.3 Docetaxel: permitted concomitant therapy requiring caution and/or action
Please follow local guidelines as per standard of care and product labels.
6.2.1.2 Use of bisphosphonates and local radiot herapy
Treatment with bisphosphonates for pre-existing bone metastases is permitted, if clinicall y 
indicated, and following existing local guidelines and documented discussion with Novartis. 
Treatment with bisphosphonates should preferably  begin before thestudy  treatment is initiated, 
but can also be initiated during therapy  only if absence of radiological bone disease progression 

Novartis Confidential Page 47
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
is well documented (in this case, the reason for its use must be clearl y documented; i.e. “pre-
existing, non-progressing, bone metastases”).
Local bone radiotherap y for analgesic purposes or for lytic lesions at risk of fracture may be 
carried out if required after documented discussion with Novartis. If palliative radiotherap y is 
initiated after start of study  treatment, the reason for its use must be clearly documented and 
progression as per RECIST 1.1 must be ruled out. The study  treatment must be interrupted on 
the days of radiotherap y and can be resumed the day after its completion. Caution is advised 
for radiation to fields that include lung tissue. The radiotherap y must be documented in the 
eCRF.
6.2.2 Prohibited medication
During the course of the study , subjects must not receive other antineoplastic therapies (e.g. 
investigational drugs, devices, chemotherap y, immunotherapies) orany other therapies that may 
be active against cancer or modulate the immune responses; however, limited -field palliative 
radiotherap y may be allowed as a concomitant therapy  (see Section 6.2.1.2).
Subjects enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies while on treatment.
6.2.2.1 Capmatinib: prohibited medication
Coadministration of capmatinib with a strong CYP3A4 inducer (rifampicin) has decreased 
capmatinib AUC by 67% and Cmax by 56%. Concurrent use of strong CYP3A4 inducers should 
be prohibited as decreased capmatinib exposure may lead to reduced efficacy  [capmatinib 
Investigator’s Brochure].
The prohibited medications are listed in the Table 6-3below.
Drugs with a known risk of Torsades de Pointes (TdP) are prohibited. For identification of drugs 
with known risk of TdP please refer to www.qtdrugs.org (refer t
o Table 6-4).
Table 6
-3 Capmatinib: prohibited drugs
Mechanism of Interaction Drug Name
Strong CYP3A4 inducer carbamazepine, enzalutamide, lumacaftor, phenobarbital, phenytoin, rifabutin, 
rifampicin, mitotane, St. John's wort ( Hypericum perforatum )
Source: The list is adapted from the Novartis Institutes for Biomedical PK Sciences internal memorandum (v01, 
2018): drug -drug interactions (DDI) database, which is compiled primarily from the Indiana University School of 
Medicine’s “Clinically Relevant” Table (medicine.iupui.edu/flockhart/table.htm), the University of W ashington’s 
Drug Interaction Database (druginteractioninfo.org), and the FDA’s “Guidance for Industry, Drug Interaction 
Studies”
Table 6-4 Drugs with a kno wn risk of Torsades de Pointes
TdP Risk Generic Names
Known amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin, chloroquine, 
chlorpromazine, cilostazol, ciprofloxacin, cisapride, citalopram, clarithromycin, disopyramide, 
dofetilide, domperidone, donepezil, dronedarone, droperidol, erythromycin, escitalopram, 
flecainide, fluconazole, gatifloxacin, halofantrine, haloperidol, ibutilide, levofloxacin, 
levomepr omazine, levosulpiride, methadone, moxifloxacin, ondansetron, oxaliplatin, papaverine 
HCl (intra -coronary), pentamidine, pimozide, procainamide, propofol, quinidine, roxithromycin, 
sevoflurane, sotalol, sulpiride, sultopride, terlipressin, terodiline, thio ridazine, vandetanib

Novartis Confidential Page 48
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
TdP Risk Generic Names
Check crediblemeds.org/healthcare -providers/drug -list for the most updated list.
6.2.2.2 Spartalizumab: prohibited medication
The use of systemic steroid therapy  and other immunosuppressive drugs is not allowed except 
for the treatment of infusion reaction, irAEs, and for prophy laxis against imaging contrast dy e 
allergy , standard pre-medication for chemotherapy  or replacement -dose steroids in the setting 
of adrenal insufficiency  (providing this is < 10 mg/da y prednisone or equivalent), or transient 
exacerbations of other underly ing diseases such as COPD requiring treatment. If systemic 
corticosteroids are required for the control of infusion reactions or irAEs, it must be tapered and 
be at non -immunosuppressive doses (< 10 mg/day of prednisone or equivalent) before the next 
administration of study  treatment. If the dose of prednisone or equivalent cannot be reduced to 
< 10 mg/day  before the administration of next dose of study  treatment then spartalizumab and 
capmatinib must be discontinued (note: next dose of spartalizumab can be delay ed up to 12 
weeks).
The use of live vaccines is not allowed through the whole duration of the study . Inactivated 
vaccines are allowed.
There are no prohibited therapies during the post -treatment follow -up period.
6.2.2.3 Docetaxel: prohibited medication
Please follow local guidelines as per standard of care and product labels.
6.3 Subject numbering, treatment assignment, randomization
6.3.1 Subject numbering
Each subject is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by Novartis/sponsor to the investigative site) with a 
sequential subject number suffixed to it, so that each 
subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form (ICF), the subject is assigned to the 
next sequential Sub ject No. available.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the subject to register them into the IRT. Once assigned, the Subject No. must 
not be reused for any  other subject. In case of re -screening a new Subject No. will be assigned 
to patient through the Clinical Data Management System interface and this new Subject No. 
will be provided to IRT for registration as re-screened patient. If the subject fails to be 
randomized or start treatment for any reason, the reason will be entered into the disposition 
page.
6.3.2 Treatment assignment, randomization
Prior to dosing, for all subjects who fulfill all inclusion/exclusion criteria, the investigator or 
his/her delegate will log on to the IRT system and confirm that the subject fulfills all the 

Novartis Confidential Page 49
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
inclusion/exclusion criteria b y completing the key eligibility criteria checklist embedded in the 
system.
Part 1: Run -in
During the run-in part, approximately  15 subjects will be enrolled via IRT for treatment with 
capmatinib and spartalizumab combination.
Part 2: Randomized
During the randomized part, approximately  90 subjects will be randomized via IRT to one of 
two treatment arms (capmatinib plus spartalizumab [n=60] or docetaxel [n=30]) in a 2:1 ratio.
During the randomized part, the I RT will assign a randomization number to the subject, which 
will be used to link the subject to a treatment arm and will specify  a unique medication number 
for the first package of study  treatment to be dispensed to the subject. The randomization 
number will not be communicated to the investigator or his/her delegate. The randomization
numbers will be generated using the following procedure to ensure that treatment assignment 
is unbiased. A subject randomization list will be produced by the IRT provider using a validated 
system that automates the random assignment of subject numbers to randomization numbers. 
Random permuted blocks scheme will be used for this study . The randomization numbers are 
linked to the different treatment arms, which in turn are linked to medication numbers. A 
separate medication randomization list will be produce d by or under the responsibility  of 
Novartis Global Clinical Supplies using a validated system that automates the random 
assignment of medication numbers to medication packs containing each of the study  treatments. 
Randomization will be stratified by  the n umber of prior lines of therapy  received. Please refer 
to Table 6-5for the number of prior lines of therapy  received.
During Part 1 and Part 2 of the study , the study  treatment phase begins on Cy cle 1, Day  1 with 
the first adm inistration of capmatinib and spartalizumab combination or the first administration 
of docetaxel. Cycle 1 Day 1 should occur no later than 3 days after registration into IRT system.
Table 6
-5 Number of prior lines of sy stemic therapy
Number of prior sy stemic therapies for 
eligibility  and stratification factors Definition
Treatment, which counts as chemotherapy for 
advanced/ metastatic diseasePlatinum chemotherapy for stage IIIB/IV NSCLC
Adjuvant/ neoadjuvant platinum chemotherapy and 
progressed within 12 months of end of therapy.
Treatment, which doesn’t count as 
chemotherapy for advanced/ metastatic 
diseaseAdjuvant/ neoadjuvant platinum chemotherapy and 
progressed > 12 mo nths of end of therapy.
Eligible number of prior therapies Eligible patients must have received one platinum 
chemotherapy AND one PD -(L)1 inhibitor
Enrolled as 2nd line population Platinum based chemotherapy and PD -(L)1 inhibitor were 
received concurrent ly or there was no PD between 
chemotherapy and PD -(L)1 inhibitor (therefore counted as 
one line)
Enrolled as 3rd line population Platinum based chemotherapy and PD -(L)1 inhibitor 
were received as sequencential therapies. There was a PD 
between chemotherapy and PD-(L)1 inhibitor

Novartis Confidential Page 50
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.4 Treatment blinding
Treatment assignment will be open to subjects, investigator staff, persons performing the 
assessments, and the Novartis repre sentatives from the Clinical Trial Team.
6.5 Dose escalation and dose modification
No dose escalations are permitted.
6.5.1 The run -in review  meeting
To assess the safet y and tolerability  of capmatinib and spartalizumab combination as well as 
preliminary  efficacy  prior to the randomized part of the study , the run -in part of the study  will 
enroll approximately  15 subjects who will be treated with the capmatinib 400 mg (BID) and 
spartalizumab 400 mg intravenousl y (i.v.) once every 28 days.
Subjects will be considered evaluable for tolerability  decision if the subject:
has received at least 1 infusion of spartalizumab and taken at least 50% of the planned 
dose of capmatinib in the first 56 day s (8 weeks) of treatment and
has safet y assessments for a minimum of 56 days (8 weeks) or has had a DLT during the 
first 8 weeks.
A review meeting will take place after all subjects have at least 24 weeks of follow -up. Decision 
on tolerability  will be made by Investigators and Novartis study  personnel. The decisions will 
be based on a synthesis of all relevant data available including safet y information, DLTs, all 
CTCAE v5.0 ≥ Grade 2 toxicity  data during the first 8 weeks (56 day s) of the study  treatment, 
pharmacokinetic data and preliminary  efficacy  data from evaluable subjects. T he decision will 
be 
guided by the BLRM with EWOC principle evaluating the probability  of DLT from all 
subjects enrolled in the run-in prior to opening the randomized phase. In particular, overall 
safet y will be assessed in the context of the known safet y data generated with the capmatinib 
and spartalizumab combination and will be used for decisions prior to opening the randomized 
phase.
6.5.1.1 Implementation of safety and tolerability  decisions
To implement tolerability  decisions, the available toxicity  informatio
n (including adverse 
events and laboratory  abnormalities that are not DLTs) and the recommendations from the 
BLRM will be evaluated by the Investigators and Novartis study  personnel (including the study 
physician and statistician) during a dose decision me eting b y teleconference.
6.5.1.2 Implementation of dose escalation decisions
Not applicable.
6.5.1.3 Intra -Subject dose escalation
Intra -subject dose escalation is not permitted at any  time.

Novartis Confidential Page 51
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.5.2 Definitions of dose limiting toxicities (DLTs)
A DLT is defined as an adverse event or abnormal laboratory  value assessed as unrelated to 
disease, disease progression, inter-current illness, or concomitant medications that occurs 
during the first 56 days (8 weeks) of treatment with capmatinib and spart alizumab and meets 
any of the criteria included in Table 6-6. The National Cancer Institute Common Terminology 
Criteria for Adverse events (NCI -CTCAE) v5.0 will be used for all grading. For the purpose of 
tolerability  decisions
, DLTs will be considered and included in the BLRM.
The investigator must notify  the sponsor immediately  of any unexpected CTCAE grade ≥ 3 
adverse events or laboratory  abnormalities.
Criteria for defining dose limiting toxicities (DL Ts)
Table 6-6 Criteria for defining dose limiting toxicities (DLTs)
TOXICITY DLT CRITERIA
Blood and lymphatic 
system disordersAnemia CTCAE Grade 4
Thrombocytopenia Grade 3 with clinically sign ificant bleeding
Thrombocytopenia CTCAE grade 3 (for ≥7 consecutive days)
Thrombocytopenia Grade 4
Neutropenia Grade 3 (for ≥ 7 consecutive days)
Neutropenia Grade 4
Febrile neutropenia CTCAE Grade ≥ 3
Cardiac Grade ≥ 3 or cardiac event that is symptomatic or requires medical intervention
Clinical signs of cardiac disease, such as unstable angina or myocardial 
infarction, or Grade ≥ 3 Troponin elevation
QTc interval prolonged Grade ≥ 3 (QTcF ≥ 501 ms) on at least two separate 
ECGs for > 7 consecu tive days
Vascular 
disorders/HypertensionPersistent hypertension CTCAE Grade 3 requiring more than one drug or more 
intensive therapy than previously administered.
Grade 4 Hypertension (any duration)
Gastrointestinal Nausea and vomiting:
● CTCAE grade ≥3 > 48 hours despite standard anti -emetics
● CTCAE grade 4
Diarrhea:
● Recurrence of CTCAE grade 2 (despite anti -diarrheal treatment)
● CTCAE grade ≥ 3 >48 hours despite maximal anti -diarrheal treatment
● CTCAE grade 4
Skin and subcutaneous 
tissueRash / photosensitivity CTCAE Grade ≥ 3 for > 7 consecutive days despite skin 
toxicity treatment
Stevens -Johnson syndrome, toxic epidermal necrolysis and other serious or life -
threatening skin reactions.
Hyperglycemia Hyperglycemia Grade 3 (FPG > 250 -500mg/ dL) for > 7 consecutive days despite 
anti-diabetic treatment Hyperglycemia Grade 4 (FPG > 500 mg/dL) 
Hyperglycemia leading to diabetic keto -acidosis, hospitalization for intravenous 
insulin infusion, or non -ketotic coma.
Infection CTCAE grade 3 infection or fever in the absence of neutropenia if they persist > 5 
days.
CTCAE Grade 4 infection of any duration.
Pneumonitis (interstitial 
lung disease)● CTCAE Grade 2 pneumonitis if it persists > 7 days despite treatment with 
corticosteroids.
● Grade 3 -4 pneum onitis of any duration

Novartis Confidential Page 52
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
TOXICITY DLT CRITERIA
Metabolism and nutrition 
disorders: Calcium -
phosphate heterostasis 
tCa x Pi increase● tCa x Pi > 55 mg2/dL2≤ 70 mg2/dL2for > 7 consecutive days
● tCa x Pi >70 mg2/dL2
Fatigue/Asthenia ● Fatigue/Asthenia CTCAE grade ≥ 3 and lasting > 7 consecutive days is a DLT
Immune -related toxicities 
(except pneumonitis)● CTCAE Grade 3 immune -related toxicities that persist > 14 days with same 
severity despite treatment with corticosteroids.
● Immune -related toxicities CTCAE Grade 4 of a ny duration
Other Adverse Events Other clinically significant toxicities, including a single event or multiple 
occurrences of the same event that lead to a dosing delay of > 7 days in cycles 1 
and 2, may be considered to be DLTs by the Investigators and N ovartis, even if 
not CTCAE grade 3 or higher.
Investigations Isolated total bilirubin* > 1.5 –3.0 x ULN for > 7 days
Isolated total bilirubin* > 3.0 x ULN
Isolated AST or ALT* > 5.0 – 10.0 x ULN for subjects with baseline value ≤3 x 
ULN (>10.0 -20.0 x ULN for subjects with liver metastases and baseline value 
>3.0-5.0 ULN) for >7 days
Isolated AST or ALT* > 10.0 ULN for subjects with baseline value ≤3 x ULN (> 
20.0 x ULN for subjects with liver metastases and baseline value >3.0 -5.0 ULN)
For subjects with normal baseline AST and ALT and total bilirubin value:
AST or ALT >3.0xULN combined** with total bilirubin >2.0 x ULN without 
evidence of cholestasis***
OR
For subjects with abnormal baseline AST or ALT or total bilirubin value:
[AST or ALT>2x baselin e AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], 
whichever is lower, combined with [total bilirubin > 2 x baseline AND > 2.0 x ULN]
Serum lipase and/or serum amylase (asymptomatic) CTCAE Grade 3 > 7 
consecutive days
Serum lipase and/or serum amylase (as ymptomatic) CTCAE Grade 4
Serum creatinine CTCAE Grade ≥ 3
Serum CK/CPK CTCAE Grade ≥ 3 for > 7 consecutive days
Serum CK/CPK CTCAE Grade 4
Symptomatic serum amylase or lipase elevation, requiring medical intervention.
*“Isolated total bilirubin” increase defined as: total bilirubin increase without ALT or AST increase; “isolated AST 
or ALT” increase defined as: AST or ALT increase without total bilirubin increase
**“Combined” defined as: total bilirubin increase to the defined threshold concurrent ly with ALT/AST increase to 
the defined threshold
***“Cholestasis” defined as: ALP elevation [>2.0 xULN and R value < 2] in subjects without bone metastasis, or 
elevation of ALP liver fraction in subjects with bone metastasis)
Note: (The R value is calcula ted by dividing the ALT by the ALP, using multiples of the ULN for both values. It 
denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R 
≥ 5), or mixed (R >2 and <5) liver injury)
6.5.3 Dose modifications
For subjects who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow subjects to continue 
the study  treatment.
There are no dose reductions allowed in this study for spartalizumab. Dose interruptions for 
spartalizumab are permitted per Section 6.5.3.1.
Dose reductions and interruptions are permitted for capmatinib 
per Section 6.5.3.1.

Novartis Confidential Page 53
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Dose reductions and interruptions are permitted for docetaxel per the investigator's judgment 
and local guidelines. Please refer to Section 6.5.3.2 .
Permanent treatment discontinuation is mandatory  for specific events as indicated in 
Section 6.5.3.1 (capmatinib and spartalizumab subjects) and Section 6.5.3.2 (docetaxel 
subjects).
Overall, AEs are to be graded according to NCI -CTCAE v5.0 (http://ctep.c ancer.gov). All dose 
reductions and interruptions and the reason for the dose reductions/interruptions must be 
documented in the eCRF.
6.5.3.1 Capmatinib/Spartalizumab dose modifications
Capmatinib dose reduction will follow the dose reduction steps described in Table 6-7. For each 
subject, a maximum of two dose level modifications is allowed a
fter which the subject must be 
discontinued from treatment with capmatinib. The lowest dose allowed, 200 mg BID in tablets, 
is expected to be pharmacologically  active, as the observed stead y state plasma trough 
concentrations ([CINC280X1101], [CINC280X2202], n=6) were above the concentration 
associated with full MET inhibition in xenograft mice models (IC90, 120 nM total 
concentration).
Table 6-7 Dose reduction steps for capmatinib
Starting dose level - 0 Dose level - 1 Dose level - 2
capmatinib 400 mg BID 300 mg BID 200 mg BID
* Dose reduction should be based on the worst toxicity demonstrated at the last dose.
** Dose reduction below 200 mg is not allowed.
No changes in dose of spartalizumab are allowed.
Overall, subjects with AEs suspected to be related to spartalizumab, including those of potential 
immune -medi ated etiology  (irAE), may need to interrupt or permanently  discontinue study 
treatment as outlined in this section. In general, study  treatment must be permanently 
discontinued in case of:
Any life-threatening adverse reactions (excluding endocrinopathies controlled with 
hormone replacement therap y)
Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies controlled with 
hormone replacement therap y) that do not recover to ≤ Grade 1
Inability  to reduce the dose of steroids (for the management of irAE) to 10 mg/day  or less 
of prednisone or equivalent (or as indicated in the tables below) within 12 weeks
Any severe or Grade 3 recurring treatment -related adverse reaction
The 12 weeks’ timeframe will begin from the time the irAE reaches a grade that leads to 
spartalizumab interruption. Investigators should refer to the latest [capmatinib Investigator’s 
Brochure] and [spartalizumab Investigator’s Brochure] for additional information regarding the 
background of capmatinib and spartalizumab and the manag ement of other AEs or potential 
safet y-related issues not specificall y mentioned in the protocol.

Novartis Confidential Page 54
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Identification and management requirement for A Es of potential immune -
mediated etiology  (irAE)
Adverse events of special interest (AESI) include AEs of a potential immune -mediated etiology 
(irAE) that are associated with spartalizumab treatment. Investigators must be vigilant and 
carefully  identify  AEs that may be suggestive of potential irAEs as their appearance may be 
sub-clinical and early diagnosis is critical for its adequate management and resolution. 
Collaboration with disease -specific subspecialties is encouraged; corticosteroids are the 
mainstay  of treatment for most irAEs.
An irAE may be of low grade and self-limited, most frequently  involving the GI tract (i.e. 
diarrhea/colitis), skin (i.e. rashes), liver (i.e. hepatitis), lung (i.e. pneumonitis), kidney s (i.e. 
nephritis) and endocrine systems (e.g. hypothyroidism, hyperthy roidism, type I diabetes, 
hypophy sitis including hy popituitarism and adrenal in sufficiency  variet y of endocrinopathies). 
Other immune -mediated AEs may rarely include the nervous system (e.g. encephalitis, 
Guillain -Barre syndrome, myasthenia gravis), eye (e.g. uveitis, vision changes), musculo-
skeletal system (e.g. myositis, arthritis), pancreas (e.g. pancreatitis), cardio -vascular system (e.g. 
vasculitis, myocarditis) or blood system (e.g. anemia, cytopenias), and severe skin reactions 
such as toxic epidermonecroly sis or Steven Johnson sy ndrome. Furthermore, complications in 
patients with bone marrow or solid organ transplant have been reported (e.g. organ rejection, 
severe graft -versus- host disease). However, nearly  all organs can be affected by immune -
mediated toxicities. irAEs often occur relativel y early  (mostl y within weeks to 3 months after 
treatment initiation), however, may develop at any time during treatment (even after several 
months), and may  also occur after treatment discontinuation.
Serological, immunological and histological assessments should be performed as deemed 
appropriate by the investigator, to verify  the potential immune -related nature of the AE, and 
exclude a neoplastic, infectious or metabolic origin of the AE.
Severe grade or persistent lower grade irAEs typically  require interrupting or permanentl y 
discontin uing treatment and administration of systemic steroids, and sometimes other 
immunosuppressive medications (i.e. tumor necrosis factor alpha antagonists, mycophenolate 
or tacrolimus, etc.). Early  recognition and work -up of irAEs and initiation of treatment are 
critical to reduce the risk of complications, since the majority  of irAEs are reversible with the 
use of steroids and other immune suppressants. Some events like endocrinopathies may require 
life-long hormonal replacement. Tapering of steroids should not be too rapid to avoid recurrence 
or worsening of irAEs. The management of irAEs may further include initiation of antibiotics 
for proph ylaxis against opportunistic infections.
Subjects should be instructed to return to the study  site as soon as possible (instead of waiting 
for their next scheduled visit) if they experience symptoms consistent with an irAE. Patients 
who experience a new or worsening irAE should be contacted and/or evaluated by the study 
site more frequently .
Based on experience and published guidelines on the management of irAEs in patients treated 
with immune checkpoint inhibitors (Brahmer et
al2018, Haanen et al2017 , NCC N 2018), 
instructions have been developed regarding how to manage irAEs that may occur in 
subjects 
receiving spartalizumab. Dose modification requirements and AE management guidelines for 
the potential irAEs are provided in the following tables: haematolog ical (Table 6-8), renal 

Novartis Confidential Page 55
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
(Table 6-9), hepatic (Table 6-10), metabolic (Table 6-11), cardiac (Table 6-12), gastrointestinal 
(Table 6-13), skin and subcutaneous tissue (Table 6-14), respiratory , thoracic and mediastinal 
(Table 6-15), endocrine (Table 6-16), general and administration site (Table 6-17), other 
potential immune -related adverse events (Table 6-18). Any Grade 4 irAE must result in 
permanent discontinuation of spartalizuma b. In addition, guidance for management of 
spartalizumab- infusion reaction and cy tokine release s yndrome is provided in Table 6-18.
Investigators are encouraged to contact the Sponsor as needed to discuss cases that warrant 
separate discussion outside of the scope of the current instructions.
The dosing modification requirements are mandatory , however, the AE management guidelines 
are recommendations and can be modified according to the local practices.
Table 6
-8 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Haematological A dverse 
Events
Hematological Adverse Events 
Grade (Worst Toxicity ) Dose Modification Recommended 
Clinical Management
Neutrophil Count Decreased (NCI-CTCAE v5.0)
Grade 1
(ANC < LLN -1500/mm3; 
< LLN -1.5 x 109/L)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines
Grade 2
(ANC < 1500 -1000/mm3; 
< 1.5 -1.0 x 109/L)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines
Grade 3
(ANC < 1000 -500/mm3; 
< 1.0 -0.5 x 109/L)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, resume capmatinib and 
spartalizumab treatment at the same dose level and 
schedule
If resolved in > 7 days, then restart capmatinib at ↓ 1 
dose level and spartalizumab at the normal dose and 
schedule.● Treat per 
local/institutional 
guidelines
Grade 4
(ANC < 500/mm3; < 0.5 x 
109/L)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 da ys, resume capmatinib and 
spartalizumab treatment at the same dose level and 
schedule
If resolved in > 7 days, then restart capmatinib at ↓ 1 
dose level and spartalizumab at the normal dose level 
and schedule.● Treat per 
local/institutional 
guidelines
Febrile Neutropenia
(ANC < 1000/mm3(< 1.0 
x 109/L), fever > 38.3°C)Mandatory: omit capmatinib and spartalizumab dose 
level until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, then restart capmatinib at ↓ 1 
dose level and spartalizumab at the normal dose level 
and schedule.
If resolved in > 7 days, discontinue subject from all 
study drug treatments● Treat per 
local/institutional 
guidelines
Platelet Count Decreased (Thrombocy topenia) (NCI -CTCAE v5.0)
Grade 1
(PLT < LLN -75,000/mm3; 
< LLN - 75 x 109/L)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines

Novartis Confidential Page 56
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Hematological Adverse Events 
Grade (Worst Toxicity ) Dose Modification Recommended 
Clinical Management
Grade 2
(PLT < 75,000 -
50,000/mm3; < 75 -50 x 
109/L)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines
Grade 3
(PLT < 50,000 -
25,000/mm3; < 50 -25 x 
109/L)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, resume capmatini b and 
spartalizumab treatment at the same dose level and 
schedule
If resolved in > 7 days, then restart capmatinib at ↓ 1 
dose level and spartalizumab at the normal dose and 
schedule.● Treat per 
local/institutional 
guidelines
Grade 4
(PLT < 25,000/mm3; <25 
x 109/L)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, restart capmatinib at ↓ 1 dose 
level and spartalizumab at the normal dose level and 
schedule.
If resolved in > 7 days, permanently di scontinue 
subject from all study drug treatments● Treat per 
local/institutional 
guidelines
Hemoglobin Decreased (Anemia) (NCI -CTCAE v5.0)
Grade 1
(Hgb < LLN -10.0 g/dL; < 
LLN - 6.2 mmol/L; < LLN -
100 g/L)Recommendation: maintain capmatinib and 
sparta lizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines
Grade 2
(Hgb < 10.0 -8.0 g/dL; < 
6.2 –4.9 mmol/L; < 100 -
80 g/L)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and schedule● Treat per 
local/institutional 
guidelines
Grade 3
(Hgb < 8.0 g/dL; < 4.9 
mmol/L; < 80 g/L)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, resume capmatinib and 
spartalizumab treatment at the same dose level and 
schedule
If resolved in > 7 days, then restart capmatinib at ↓ 1 
dose level and spartalizumab at the normal dose level 
and schedule.● Treat per 
local/institutional 
guidelines
Grade 4
(Life –threatening 
consequences, urgent 
intervention indicated)Mandatory: omit capmatinib and spartalizumab dose 
until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, resume capmatinib and 
spartalizumab treatment at the same dose level and 
schedule
If resolved in > 7 days, then restart capmatinib at ↓1 
dose level and spartalizumab at the normal dose level 
and schedule.
If toxicity recurs, permanently discontinue subject from 
all study drug treatments● Treat per 
local/institutional 
guidelines
Autoimmune hemoly tic 
anemia, hemoly tic 
uremic sy ndrome, or
acquired hemophilia 
grade ≥ 3Mandatory: permanently discontinue subject from all 
study drug treatments● Consult with 
specialist
● Consider 
systemic 
corticosteroids and 
other therapies as 
appropriate (e.g. 
transfusion) per 

Novartis Confidential Page 57
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Hematological Adverse Events 
Grade (Worst Toxicity ) Dose Modification Recommended 
Clinical Management
local institutional 
guidelines
All dose modifications should be based on the worst preceding toxicity.
Table 6-9 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Creatinine Increases
Renal Adverse Events 
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Creatinine Increased (NCI -CTCAE v5.0)
Grade 1
(> ULN -1.5 x ULN)Recommendation: maintain 
capmatinib and spartalizumab 
at normal dose level and 
schedule1. Monitor creatinine weekly
2. If creatinine returns to baseline resume routine 
creatinine monitoring per protocol
3. Promote hydration
4. Consider cessation of nephrotoxic drugs
Grade 2
(> 1.5 - 3.0x 
baseline, >1.5 -3.0 x 
ULN)Mandatory: omit capmatinib 
and spartalizumab dose until 
resolved to ≤ Grade 1, then 
resume treatment at same dose 
level and schedule1.Monitor creatinine every 2 to 3 days
2. Initiate 0.5 to 1 mg/kg/day prednisone or 
equivalents if other causes are ruled -out
3. If worsening or no improvement: 1 to 2 mg/kg/day 
prednisone or equivalents
4. Promote hydration and cessation of nephrotoxic 
drugs
5. Consult with specialist and consider renal biopsy
Rule-out other causes (e.g. flu ids, medications, IV 
contrast)
If worsening or no improvement: 1 to 2 mg/kg/d 
prednisone or equivalents
Grade 3
(>3 x baseline, > 3.0 
-6.0 x ULN)
AND
Grade 4(> 6.0 x 
ULN)Mandatory:
Permanently discontinue 
subject from all study drug 
treatments1. Monitor creatinine every 1 to 2 days
2. Start 1 to 2 mg/kg/day prednisone or equivalents.
Once event improves to Grade ≤1, slowly taper 
steroids over at least 4 -6 weeks
3. Promote hydration and cessation of nephrotoxic 
drugs
4. Consult with specialist and consider renal biopsy
All dose modifications should be based on the worst preceding toxicity.
Table 6-10 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for liver la boratory  alterations
Hepatic Adverse Events 
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Blood Bilirubin Increased d(NCI-CTCAE v5.0)
Grade 1
(> 1.5 x ULN if 
baseline was 
normal; >1.0 -1.5 x 
ULN if baseline was 
abnormal)Recommendation: maintain 
capmatinib and spartalizumab 
at normal dose level and 
schedule● Monitor LFTs per protocol or more frequently if 
clinically indicated

Novartis Confidential Page 58
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Hepatic Adverse Events 
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 2
(> 1.5 - 3.0 x ULN if 
baseline was 
normal; > 1.5 -3.0 x 
ULN if baseline was 
abnormal)Mandatory: omit capmatinib 
and spartalizumab dose until 
resolved to ≤ Grade 1, then 
restart capmatinib at ↓ 1 dose 
level and spartalizumab at the 
normal dose level and 
schedule.● Frequent monitoring of LFTs, (every 2 -3 days) 
until resolved to ≤ 1.5 x ULN
● Rule-out alternative causes (e.g. concomitant 
medications, infection, disease progression)
Grade 3
(> 3.0 - 10.0 x ULN if 
baseline was 
normal; > 3.0 - 10.0 
x ULN if baseline 
was abnormal)Mandatory: permanently 
discontinue subject from all 
study drug tr eatments● Frequent monitoring of LFTs, (every 2 -3 days), 
until resolved to ≤ baseline. If resolved in > 7 days, 
after discontinuing the subject from capmatinib 
permanently, the subject should be monitored 
weekly (including LFTs), or more frequently if 
clinically indicated, until total bilirubin have resolved 
to baseline or stabilization over 4 weeks
Grade 4
(> 10.0 x ULN 
baseline was 
normal; > 10.0 x 
ULN baseline was 
abnormal)Mandatory: permanently 
discontinue subject from all 
study drug treatments● After permanently discontinuing the subject from 
study treatment, the subject should be monitored 
weekly (including LFTs), or more frequently if 
clinically indicated, until total bilirubin have resolved 
to baseline or stabilization over 4 weeks. See 
additiona l recommendation below for AST/ALT 
Grade 3/4.
Isolated AST or ALT Elevation (Alanine Aminotransferase Increased or Aspartate Aminotransferase 
Increased) (NCI -CTCAE v5.0)
Grade 1
(> 3.0 x ULN if 
baseline was 
normal; >1.5 –3.0 x 
ULN if baseline was 
abnorm al)Recommendation: maintain 
capmatinib and spartalizumab 
at normal dose level and 
scheduleTreat per local/institutional guidelines
Grade 2
(> 3.0 - 5.0 x ULN if 
baseline was 
normal;> 3.0 -5.0 x 
ULN if baseline was 
abnormal)Mandatory: omit capmatinib 
andspartalizumab dose until 
resolved to ≤ Grade 1, then 
restart capmatinib at ↓ 1 dose 
level and spartalizumab at the 
normal dose level and 
schedule.
Patients with baseline grade 2 
AST/ALT value (>3.0 -5.0 x 
ULN) may continue treatment● For subjects with bas eline value ≤ 3.0 x ULN: 
repeat LFTs as soon as possible, preferably within 
48-72 hours from awareness of the abnormal 
results; if abnormal lab values are confirmed upon 
the repeated test, then monitor LFTs weekly, or 
more frequently if clinically indicate d, until resolved 
to ≤ 3.0 x ULN
● For subjects with baseline value > 3.0 - 5.0 x ULN: 
monitor LFTs per protocol or more frequently if 
clinically indicated

Novartis Confidential Page 59
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Hepatic Adverse Events 
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 3
(> 5.0 - 20.0 x ULN if 
baseline was 
normal;> 5.0 -20.0 x 
ULN if baseline was 
abnormal)Mandatory: permanently 
discontinue subject from all 
study drug treatments1. Monitor hepatic laboratory tests daily until 
returned to baseline values.
2.Consider viral serology i.e. hepatitis A/B/C, CMV.
3. Rule out other potential cause of liver injury such 
as conmeds or alcohol
4. Consult with hepatologist and perform liver biopsy 
to establish etiology of hepatic injury
5. If after 2 -3 days liver assessment shows 
worsening of laboratory tests consider to initiate 
treatment with steroids prednisone 1 -2 mg/kg/ day or 
i.v. equivalents.
6. Add prophylactic antibiotics for opportunistic 
infections as appropriate
7. When symptoms/liver function tests improve to 
Grade ≤1, taper steroids over at least 4 weeks.
8. If serum transaminase levels or bilirubin do not 
decrea se 48 hours after initiation of systemic 
steroids, oral mycophenolate mofetil 500 mg every 
12 hours may be given as per local treatment 
guidance.
Infliximab is not recommended due to its potential 
for hepatotoxicity
Grade 4
(> 20.0 x ULN if 
baseline was 
normal; > 20.0 x 
ULN if baseline was 
abnormal)Mandatory: permanently 
discontinue subject from all 
study drug treatmentsAs for Grade 3 toxicity above.

Novartis Confidential Page 60
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Hepatic Adverse Events 
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Combined elevations of AST or ALT and Total Bilirubin a, c
Any Grade
For subjects with 
normal baseline ALT 
and AST and total 
bilirubin value:
AST or ALT > 3.0 x 
ULN combined with 
total bilirubin > 2.0 x 
ULN without 
evidence of 
cholestasis b
OR
For subjects with 
elevated baseline 
AST or ALT or total 
bilirubin value:
[AST or ALT > 2 x 
baseline AND > 3.0 
x ULN] OR [AST or 
ALT > 8.0 x ULN], 
whichever is lower, 
combined with total 
bilirubin > 2 x 
baseline AND > 2.0 
x ULNMandatory: permanently 
discontinue subject from all 
study drug treatmentsPatients 
with baseline grade 2 AST/ALT 
value (>3.0 5.0 ULN) may 
contin uespartalizumab treatme
ntsAfter permanently discontinuing the subject from 
study treatment, repeat LFTs as soon as possible, 
preferably within 48 hours from awareness of the 
abnormal results, then with weekly monitoring of 
LFTs, or more frequently if cli nically indicated, until 
AST, ALT, or bilirubin have resolved to baseline or 
stabilization over 4 weeks
All dose modifications should be based on the worst preceding toxicity. 
a“Combined” defined as: total bilirubin increase to the defined threshold con currently with ALT/AST 
increase to the defined threshold
b“Cholestasis” defined as: ALP elevation (> 2.0 x ULN and R value (ALT/ALP in x ULN) < 2.0) in 
subjects without bone metastasis, or elevation of ALP liver fraction in subjects with bone metastasis
cIf combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please 
follow the instructions for isolated elevation of total bilirubin and isolated elevation of AST/ALT, and 
take a conservative action based on the degree of the elevations (e.g. discontinue treatment at the 
situation when omit dose is needed for one parameter and discontinue treatment is required for 
another parameter). After all elevations resolve to the defined thresholds that allow treatment re -
initiation, re -start the treatment either at the same dose or at one dose lower if meeting a criterion for 
dose reduction
dIf total bilirubin > 3.0 x ULN is due to the indirect (non -conjugated) component only, and hemolysis as 
the etiology has been ruled out as per i nstitutional guidelines (e.g., review of peripheral blood smear 
and haptoglobin determination), then ↓ 1 dose level and continue treatment at the discretion of the 
investigator.

Novartis Confidential Page 61
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 6-11 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for A mylase and/or Lipase 
Elevation Related A dverse Events
Metabolic Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Symptomatic 
Amylase and/or 
Lipase elevation of 
any gradeMandatory: permanently discontinue 
subject from all study drug treatments● Test weekly (or more frequently) until 
≤ CTCAE Grade 2.
● A CT scan or equivalent imaging 
procedure to assess t he pancreas, liver, 
and gallbladder is recommended within 
7 days of the first occurrence of any ≥ 
CTCAE Grade 3 result, to exclude 
disease progression or potential other 
liver or pancreatic disease.
Asymptomatic Am ylase and/or Lipase elevation
Grade 1
(>ULN -1.5 x ULN)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and 
scheduleTreat per local/institutional guidelines
Grade 2
(> 1.5 - 2.0 x ULN)Recommendation: interrupt study 
treatments until recovery to ≤ Grade 1 or 
baseli neTreat per local/institutional guidelines
Grade 3
(> 2.0 - 5.0 x ULN)Mandatory: omit capmatinib and 
spartalizumab dose until resolved to ≤ 
Grade 1, then:
If resolved in ≤14 days, resume capmatinib 
and spartalizumab treatment at the same 
dose level and schedule
If resolved in >14 days, then restart 
capmatinib at ↓ 1 dose level and 
spartalizumab at the normal dose level and 
schedule.
If toxicity recurs permanently discontinue 
subject from all study drug treatmentsTreat per local/institutional guidelines
Grade 4
(> 5.0 x ULN)Mandatory: permanently discontinue 
subject from all study drug treatmentsTreat per local/institutional guidelines
All dose modifications should be based on the worst preceding toxicity.
Table 6-12 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Cardiac Related A dverse 
Events
Cardiac Related Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Fridericia QT correction formula (QTcF) interval prolonged (NCI-CTCAE v5.0)
Grade 1
(QTcF 450 -480 ms)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and 
scheduleTreat per local/institutional guidelines
Grade 2
(QTcF 481 -500 ms)Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and 
scheduleTreat per local/institutional guidelines

Novartis Confidential Page 62
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Cardiac Related Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 3
(QTcF ≥ 501 ms on 
at least two separate 
ECGs)Mandatory: omit capmatinib and 
spartalizumab dose until resolved to ≤ 
Grade 2, then:
If resolved in ≤7 days, resume capmatinib 
and spartalizumab treatment at the same 
dose level and schedule
If resolved in >7 days, then restart 
capmatinib at ↓ 1 dose level and 
spartalizumab at the normal dose level a nd 
schedule.
If toxicity recurs permanently discontinue 
subject from all study drug treatments● When QTcF ≥ 501 ms (Grade 3), 
perform the following: 
● Request an immediate manual 
read of the ECG.
● Perform an analysis of serum 
potassium, calcium, phosp horus, and 
magnesium, and if below lower limit of 
normal, correct with supplements to 
within normal limits.
● Review concomitant medication 
usage for the potential to inhibit 
CYP3A4/5 (Table 6 -2 ) and/or to prolong 
the QT-interval (Table 6-4).
● Check compliance with correct 
dose and administration of capmatinib.
● Perform a repeat ECG within one 
hour of the first QTcF of ≥501 ms.
● If QTcF remains ≥ 501 ms, repeat 
ECG as clinically indica ted, but at least 
once daily until the QTcF returns to < 
501 ms.
● Repeat ECGs 7 days and 14 days 
(and then every 21 days) after dose 
resumption for all subjects who had 
therapy interrupted due to QTcF ≥ 501 
ms.
● If QTcF of ≥ 501 ms recurs, repeat 
ECGs a s described above.
Notes:
The investigator should contact the 
Novartis Medical Lead or designee 
regarding any questions that arise if a 
subject with QTcF prolongation should 
be maintained on study.
If the ECG report shows a QTcF ≥ 501 
msec (not previously documented on 
the site machine), contact the subject 
and instruct him/her to suspend 
capmatinib and return to repeat the 
ECG as soon as possible. The ECG 
reader should be called for a manual 
read of the repeat ECG immediately, 
and the above guidance follow ed.
Grade 4
(QTcF ≥ 501 or > 60 
ms change from 
baseline and 
Torsades de pointes 
or polymorphic 
ventricular 
tachycardia or 
signs/symptoms of 
serious arrhythmia)Mandatory: permanently discontinue 
subject from all study drug treatmentsAs for Grade 3 toxici ty above

Novartis Confidential Page 63
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Cardiac Related Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Myocarditis grade 
≥2 or other cardiac 
event grade ≥3Mandatory: permanently discontinue 
subject from all study drug treatments1. Initiate systemic corticosteroids 
(prednisone or equivalent) at a dose of 
1-2 mg/kg QD
2. Consult with cardiologist 
hospitalization as indicated
All dose modifications should be based on the worst preceding toxicity.
Table 6-13 Dose Modifications of Capmatinib and Spartalizumab and 
Reco mmended Clinical Management for Gastrointestinal A dverse 
Events
Gastrointestinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Pancreatitis
Grade 2 Recommendation:
see Table 6-11● Evaluate for pancreatitis (clinical 
assessment, abdominal imaging and/or 
MRCP as appropriate) PDR001 may be 
continued in case of asymptomatic, isolated 
enzyme elevations without evidence for 
pancreatitis
Treat per local/institutional guidelines
Grade ≥3 Mandatory: permanently discontinue 
subject from all study drug treatmentsTreat per local/institutional guidelines
Diarrhea and/or Colitis a
Grade 1
(despite appropriate 
anti-diarrheal 
medication)Recommendation: maintain 
capmatinib and spartalizumab at 
normal dose level and scheduleSymptomatic treatment (loperamide, 
hydration, diet)
● Investigate potential concomitant 
medication, food or comorbidity driven 
causes of diarrhea (including infectious 
causes) and remedy for these causes if 
possible (e.g. dis continuation of concomitant 
medication, dietary modification, treatment of 
comorbidity).
● The subject should be monitored for signs 
of dehydration and instructed to take 
preventive measures against dehydration as 
soon as diarrhea occurs. Antidiarrheal 
medication must be initiated at the first sign 
of abdominal cramping, loose stools or overt 
diarrhea. Concomitant medication for the 
treatment of diarrhea should follow local 
practice and the investigator’s best judgment 
and may follow the "recommended guidel ines 
for the treatment of cancer treatment -induced 
diarrhea” (Benson et al 2004 ).

Novartis Confidential Page 64
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Gastrointestinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Pancreatitis
Grade 2
(despite maximal 
anti-diarrheal 
medication)Mandatory:
1stoccurrence:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then 
resume treatment at same dose level 
and schedule
2ndoccurrence:
If toxicity recurs, omit capmatinib and 
spartalizumab dose until resolved to ≤ 
Grade 1, then resume capmatinib at ↓ 
1 dose level and spartalizumab at the 
normal dose level and schedule.1. Consult with GI specialist
2. Stool evaluation, imaging and endoscopy 
as clinically indicated
3. Symptomatic treatment (loperamid, 
hydration, diet)
4. Commence steroids (0.5 -1 mg/kg/d 
prednisone or IV equivalent) until recovery to 
Grade 1, pa rticularly in case of 
persisting/worsening symptoms, ulcerations 
or bleeding seen on endoscopy, or blood in 
stool. If no improvement within few days, 
manage as per Grade 3.
5. Slowly taper steroids once symptoms 
improve to Grade 1 (i.e. over 4 -6 weeks) as 
per Section 6.5.3.1.1
Grade 3
(despite appropriate 
anti-diarrheal 
medication)Mandatory:
1st occurrence: Omit capmatinib and 
spartalizumab dose until resolved to ≤ 
Grade 1, then resume capmatinib at ↓ 
1 dose level and spartalizumab at the 
normal dose level and schedule.
2ndoccurrence: permanently 
discontinue subject from all study drug 
treatments● Consider hospitalization; rule out bowel 
perforation and initiate IV hydration as 
needed
● Consultation with GI specialist ; 
consider endoscopy and biopsy
● In addition to symptomatic treatment initial 
treatment with IV steroids (1 to 2 mg/kg/d 
ofmethylprednisolone or equivalent)
● Consider antibiotics as appropriate
● If no improvement in 2 -3 days: consider 
initiating infliximab 5 mg/kg and continue 
steroids. (infliximab is contraindicated in 
patients with sepsis/perforation)
● Slowly taper steroids once symptoms 
improve to Grade 1 (4 to 6 weeks)
● If symptoms worsen during steroid 
reduction, re -escalate as needed follo wed by 
more prolonged taper and consider infliximab
Grade 4: Life -
threatening 
consequences; 
urgent intervention 
indicatedMandatory: permanently discontinue 
subject from all study drug treatmentsUrgent hospitalization, supportive care and 
specialist cons ultation as outlined above in 
Grade 3
Vomiting
Grade 1 (despite 
appropriate anti -
emetics)Recommendation: maintain 
capmatinib and spartalizumab at 
normal dose level and scheduleIndividualized supportive and anti -emetic 
treatment should be initiated, as appropriate, 
at the first signs and/or symptoms of these 
AEs. In subjects with vomiting, the subject 
should be monitored for signs of dehydration 
and instructed to take preventive measures 
against dehydration.
Concomitant medication for the treatment of 
nausea and/or vomiting should follow local 
practice and the investigator`s best 
judgement.

Novartis Confidential Page 65
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Gastrointestinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Pancreatitis
Grade 2 (despite 
appropriate anti -
emetics)Mandatory:
1stoccurrence:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then 
resume treatment at sam e dose level 
and schedule
2ndoccurrence:
If toxicity recurs > Grade 2 omit 
capmatinib and spartalizumab dose 
until resolved to ≤ Grade 1, then 
resume capmatinib at ↓ 1 dose level 
and spartalizumab at the normal dose 
level and schedule.As for Grade 1 toxi city above
Grade 3 (despite 
appropriate anti -
emetics)Mandatory:
1stoccurrence:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then 
resume treatment at same dose level 
and schedule
2ndoccurrence:
If toxicity recurs > Grade 2 omit 
capmatinib and spartalizumab dose 
until resolved to ≤ Grade 1, then 
resume capmatinib at ↓ 1 dose level 
and spartalizumab at the normal dose 
level and schedule.Treat per local/institutional guidelines
Grade 4 (despite 
appropriate anti -
emetics)Mandatory:
1stoccurrence:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then 
resume treatment at same dose level 
and schedule.
2ndoccurrence:
If toxicity recurs > Grade 2 omit 
capmatinib and spartalizumab dose 
until resolved to ≤ Grade 1, then 
resume capmatinib at ↓ 1 dose level 
and spartalizumab at the normal dose 
level and schedule.Treat per local/institutional guidelines
Nausea
Grade 1 or 2 
(despite appropriate 
anti-emetics)Recommendation: maintain 
capmatinib and spartalizumab at 
normal dose level and scheduleTreat per local/institutional guidelines

Novartis Confidential Page 66
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Gastrointestinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Pancreatitis
Grade 3 (despite 
appropriate anti -
emetics)Mandatory:
1stoccurrence
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then 
resume treatment at same dose level 
and sche dule
2ndoccurrence:
If toxicity recurs > Grade 2 omit 
capmatinib and spartalizumab dose 
until resolved to ≤ grade 1, then 
resume capmatinib at ↓ 1 dose level 
and spartalizumab at the normal dose 
level and schedule.Treat per local/institutional guidelines
All dose modifications should be based on the worst preceding toxicity. 
aAntidiarrheal medication is recommended at the first sign of abdominal cramping, loose stools or 
overt diarrhea
● Loperamide: initially 4 mg, followed by 2 mg ever y four hours or after ever y unformed stool; 
maximum 16 mg/day. Continue until diarrhea free for 12 hours;
● Diarrhea > 24 hours: loperamide 2 mg every two hours; maximum 16 mg/day. Consider adding oral 
antibiotics.
● Diarrhea > 48 hours: loperamide 2 mg every two hours; m axim um 16 m g/day. Consider other 
second -line therapies for diarrhea (e.g: octreotide, oral diphenoxylate) and oral antibiotics
Table 6-14 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Skin and Subcutaneous 
Tissue A dverse Events
Skin and Subcutaneous Tissue Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Rash/Photosensitivit y
During the whole duration of treatment with capmatinib, the subject is recommended to use precautionary 
measures against ultraviolet exposure (e.g., use of sunscreen, protective clothing and avoid sunbathing or 
using a solarium intensively).
Grade 1
Rash covering < 
10% Body Surface 
Area (BSA)Recommendation: maintain 
capmatinib and spartalizumab at 
normal dose level and schedule1. Monitor weekly
2. Initiate prophylactic and symptomatic 
treatment measures.
3. Consider use of antihistamines and /or 
topical corticoster oids or urea containing 
creams in combination with oral antipruritics 
or moderate strength topical steroid 
(hydrocortisone 2.5% cream or fluticasone 
propionate 0.5% cream)
4. Reassess after 2 weeks.

Novartis Confidential Page 67
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Skin and Subcutaneous Tissue Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 2
Rash covering 10 -
30% of BSARecommendation: consider dose 
interruption until tolerable or recovery 
to Grade ≤1 or baseline; once 
recovered resume treatment at the 
same dose and schedule
Mandatory: in case of bullous 
dermatitis, acute generalized 
exanthematous pustulosis or Drug 
Rash with Eosinophili a and Systemic 
Symptoms, interrupt capmatinib and 
spartalizumab until recovery to Grade 
≤1 or baseline.1. Monitor weekly
2. Consider to initiate systemic steroids (e.g. 
oral prednisolone 0.5 -1mg/kg daily). In 
addition, treat with topical emollients, oral 
antihistamines, and medium/high -potency 
topical steroids
3. If symptoms persist or recur consider skin 
biopsy.
Grade 3
Rash covering more 
than 30% of BSA, 
despite skin toxicity 
therapy
Other severe 
cutaneous adverse 
reactions
Bullous dermatitisMandatory:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then, 
if resolved in ≤7 days resume 
treatment at same dose level and 
schedule.
If resolved in > 7 days (despite 
appropriate skin toxicity therapy), then 
discontinue subject from all study drug 
treatments
For patients with severe cutaneous 
adverse reaction or bullous dermatitis, 
risk/benefit before resuming treatment 
should be carefully considered1. Monitor daily
2. Consult with dermatologist and consider 
skin biopsy.
3. Initiate systemic steroids (1 mg/kg/d 
prednisone or IV equivalent); consider 
increasing if no improvement
4. High-potency topical steroids
5. Topical emollients, oral antihistamines as 
indicated
6. Consider GABA agonists or aprepitant in 
case of severe pruritus
Grade 4
Life-threateningMandatory: permanently discontinue 
subject from all study drug treatmentsUrgent dermatologic consultation and 
additional measures as per local guidelines
Stevens -Johnson 
syndrome, toxic 
epidermal necrolysisMandatory: permanently discontinu e 
subject from all study drug treatmentsHospitalization and urgent dermatology 
consultation
Institute supportive care immediately as per 
local/institutional guidelines
All dose modifications should be based on the worst preceding toxicity.
Table 6-15 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Respiratory , Thoracic and 
Mediastinal A dverse Events
Respiratory , Thoracic and Medias tinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
ILD and 
pneumonitis aMandatory: interrupt capmatinib and 
spartalizumab during diagnostic work 
up for ILD/ pneumonitis.Subjects on combination therapy with 
capmatinib and spartalizumab should be 
monitored for pulmonary symptoms indicative 
of ILD/pneumonitis.
In addition, withhold capmatinib and 
spartalizumab for acute onset of new or 
progressive unexplained pulmonary symptoms, 
such as dyspnea, cough and fever and during 
diagnostic workup for ILD/pneumonitis to 
exclude alternative causes such as, but not 
limited to infections, lymphangitic 
carcinomatosis, cardiogenic edema, or 
pulmonary hemorrhage.

Novartis Confidential Page 68
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Respiratory , Thoracic and Medias tinal Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 1
Radiographic 
changes only -
asymptomaticMandatory: interrupt capmatinib and 
spartalizumab during diagnostic work 
up for ILD/ pneumonitis.
In presence of a diagnosis of 
ILD/pneumonitis after diagnostic 
workup, it is mandatory to 
permanently discontinue capmatinib 
and spartalizumab.
Only in the absence of a diagnosis of 
ILD/pneumonitis, capmatinib and 
spartalizumab may be restarted at 
the same dose level and schedule.
2ndoccurrence
If it recurs after resumption of study 
drug it is mandatory to permanently 
discontinue both study drugs.1. Exclude infections o r other etiologies
2. CT scan (high -resolution with lung windows) 
recommended, with serial imaging to monitor 
for resolution or progression -re-image at least 
every 3 weeks
3. Monitor for symptoms every 2-3 days
4. Clinical evaluation and laboratory work -up 
for infection
5. Monitoring of oxygenation via pulse oximetry 
recommended
6. Consultation with pulmonologist 
recommended
Grade 2
Symptomatic; 
medical intervention 
indicated; limiting 
instrumental Activity 
daily living (ADL)Mandatory: interrupt capmatin ib and 
spartalizumab during diagnostic work 
up for ILD/pneumonitis.
In presence of a diagnosis of 
ILD/pneumonitis after diagnostic 
workup, it is mandatory to 
permanently discontinue capmatinib 
and spartalizumab.
Only in the absence of a diagnosis of 
ILD/pn eumonitis, capmatinib and 
spartalizumab may be restarted at 
the same dose level and schedule
2ndoccurrence
If it recurs after resumption of study 
drug it is mandatory to permanently 
discontinue both study drugs.1. Exclude infections or other etiologies
2. CT scan (high -resolution with lung windows)
3. Monitor symptoms daily, consider 
hospitalization
4. Clinical evaluation and laboratory work up 
for infection
5. Consult pulmonologist
6. Pulmonary function tests b-if normal at 
baseline, repeat every 8 wee ks
7. Bronchoscopy dwith biopsy and/or BAL 
recommended
8. Symptomatic therapy including 
corticosteroids c if clinically indicated (1 to 2 
mg/kg/day prednisone or equivalent as 
clinically indicated).
Grade 3 or 4
Severe symptoms; 
limiting self care 
ADL; o xygen 
indicated or life -
threatening 
respiratory 
compromise; urgent 
intervention 
indicated (e.g., 
tracheotomy or 
intubation)Mandatory: permanently discontinue 
subject from all study drug 
treatments1. CT scan (high -resolution with lung windows)
2. Clinical evaluation and laboratory work -up 
for infection
3. Commence oxygen therapy
4. Consult pulmonologist
5. Pulmonary function tests b -if < normal, 
repeat every 8 weeks until ≥ normal
6. Bronchoscopy dwith biopsy and/or BAL if 
possible
7. Treat with i.v. ste roids c(methylprednisolone 
125 mg) as indicated. W hen symptoms 
improve to ≤ Grade 1, a high dose oral steroid 
(prednisone 1 to 2 mg/kg once per day or 
dexamethasone 4 mg every 4 hours).
8. If i.v. steroids followed by high dose oral 
steroids do not reduce initial symptoms within 
48 to 72 hours, consider non -corticosteroid 
immunosuppressive medication

Novartis Confidential Page 69
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
All dose modifications should be based on the worst preceding toxicity. 
aNote: except if the subject is grade 2 at baseline in which case: it is ≥ CTCAE gr ade 3. 
bPulmonary function tests to include: diffusing capacity corrected for hemoglobin (DLCO); spirometry; 
resting oxygen saturation. Guideline for significant deterioration in lung function: Decrease in 
spirometry  and/or DLCO of 30% and/or O 2saturati on ≤ 88% at rest on room air. 
cDuration and dose of course of corticosteroids will vary according to circumstances but should be as 
limited as possible. Consider tapering dosage at end. 
dIf bronchoscopy is performed, bronchoalveolar lavage (BAL) should be done where possible to 
exclude alveolar hemorrhage, opportunistic infections, cell count + determination ly mphocy te CD4/8 
count where possible.
Table 6-16 Dose Modificat ions of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Endocrine A dverse Events
Endocrine Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 1
Asymptomatic , 
intervention not 
indicated (e.g. 
hyperthyroidism or 
hypothyroidism)Recommendation: maintain 
capmatinib and spartalizumab at 
normal dose level and schedule1. If TSH <0.5x LLN, or TSH >2x ULN, or 
consistently out of range in two subsequent 
measurements, check free T4 at subsequent 
cycles as clinically indicated
2. Consider endocrinologist consultation.
3. If hypophysitis is suspected, consider 
pituitary gland imaging (MRIs with gadolinium 
and sellar cuts); evaluate hormone levels as 
clinically indicated
4. Repeat labs in 1 to 3 weeks/MRI in 1 
month if laboratory abnormalities persist but 
normal lab/pituitary scan

Novartis Confidential Page 70
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Endocrine Adverse Events
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management
Grade 2 or 3
Symptomatic 
endocrinopathy 
(e.g., hypophysitis, 
adrenal insufficiency, 
hypothyroidism, 
hyperthyroidism)Mandatory: interrupt capmatinib and 
spartalizumab until diagnosis 
established and/or recovery to mild or 
no symptoms and controlled with 
hormone replacement therapy, then 
restart capmatinib and spartalizumab 
at the normal dose level and schedule.
Recommended: hypothyroidism may 
be managed with replacement therapy 
without treatment interruption (unless 
life-threatening)
Mandatory: permanently discontinue 
subject from all study treatments for 
life-threatening endocrinotherapies 
(i.e. hyperthyroidism, adrenal 
insufficiency, hypophysitis) or recurring 
severe/l ife-threatening events not 
controlled by hormone replacement 
therapy.1. Endocrine laboratory panel (TSH, T4, 
ACTH, FSH, LH, Prolactin, serum cortisol, 
aldosterone) and imaging (e.g. brain MRI) as 
clinically indicated
2. Consider endocrinologist consultati on
3. If hypophysitis is considered, pituitary 
gland imaging should be considered (MRIs 
with gadolinium and selective cuts of the 
pituitary can show enlargement or 
heterogeneity and confirm the diagnosis)
4. Repeat labs in 1 to 3 weeks, MRI in 1 
month if l aboratory abnormalities persist but 
normal lab/pituitary scan
5. Rule out infection/sepsis and other 
alternative causes with appropriate cultures 
and imaging
6. Treat with an initial dose of 
methylprednisolone 1 to 2 mg/kg 
intravenously followed by oral pr ednisone 1 
to 2 mg/kg per day in case of severe 
hypophysitis or thyrotoxicosis.
7. Consider beta -blocker in case of severe 
hyper-thyroidism
8. Replacement of appropriate hormones 
may be required as the steroid dose is 
tapered
9. Hypophysitis with clinicall y significant 
adrenal insufficiency and hypotension, 
dehydration, and electrolyte abnormalities 
(such as hyponatremia and hyperkalemia) 
constitutes adrenal crisis
10. Consider hospitalization (e.g. in case of 
severe adrenal insufficiency/crisis), fluid 
replacement, and other supportive measures 
as clinically indicated
Autoimmune 
diabetes
(Grade 3 or 
symptomatic 
hyperglycemia)
Autoimmune 
diabetes
(Grade 4 
hyperglycemia or 
life-threatening 
complications)Mandatory:
Omit capmatinib and spartalizumab 
dose unti l resolved to ≤ Grade 1 or 
baseline, then resume treatment at 
same dose level and schedule.
2ndoccurrence: in case of recurring 
severe/life -threatening events not 
controlled by anti -glycemic therapy, 
permanently discontinue subject from 
all study drug tre atment1. Initiate anti-glycemic therapy (i.e. insulin) 
as medically indicated
2. Monitor glucose levels regularly until 
metabolic control is achieved
3. Consider endocrinology consultation
4. Evaluate for ketoacidosis as medically 
indicated
5. Consider ho spitalization (e.g. in case of 
ketoacidosis)
All dose modifications should be based on the worst preceding toxicity.

Novartis Confidential Page 71
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 6-17 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for General and A dministration 
Site A dverse Events
General and Administration Site Adverse Events
Grade Dose ModificationRecommended Clinical 
Management
Fatigue/ Asthenia
Grade 1 or 2 Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and scheduleTreat per local/institutional 
guidelines
Grade 3 Mandatory: omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1, then:
If resolved in ≤7 days, resume capmatinib and 
spartalizumab treatment at the same dose level 
and schedule
If resolved in >7 days, then restart capmatinib at 
↓ 1 dose level and spartalizumab at the normal 
dose level and schedule.Treat per local/institutional 
guidelines
Peripheral edema
Grade 1 or 2 Recommendation: maintain capmatinib and 
spartalizumab at normal dose level and scheduleConsider conservative measures 
such as leg elevation, compression 
stockings and dietary salt 
modification as clinically indicated
Grade 3 Mandatory: omit capmatinib an d spartalizumab 
dose until resolved to ≤ Grade 1 or baseline, 
then resume treatment at same dose level and 
schedule.Intensify as above and treat per 
local/institutional guidelines
Grade 4 Mandatory: permanently discontinue subject 
from all study drug tre atmentsIntensify as above and treat per 
local/institutional guidelines
Other adverse events
Grade 1 or 2 Recommendation:
Continue capmatinib and spartalizumab at 
normal dose level and schedule
For any intolerable Grade 2 (e.g.: limiting 
instrumental ADL), consider omitting the dose 
until resolved to ≤ grade 1, then↓ capmatinib 1 
dose level and continue spartalizumab at normal 
dose level and scheduleTreat per local/institutional 
guidelines
Grade 3 Mandatory: omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 2, then resume 
treatment at same dose level and schedule.Treat per local/institutional 
guidelines
Grade 4 Mandatory: permanently discontinue subject 
from all study drug treatmentsTreat per local/institutional 
guidelines
All dose modifications should be based on the worst preceding toxicity.
Table 6-18 Dose Modifications of Capmatinib and Spartalizumab and 
Recommended Clinical Management for Other Potential Immune -
Related A dverse Events of Special Interest including Cy tokine 
Release Sy ndrome
Other Potential Immune -Related Adverse Events (e.g. Autoimmune neuropathy , demy elinating 
polyneuropath y, Guillain Barre, My asthenia Gravis -like syndrome, encephalitis, non -infectious 
myocarditis, pericarditis, pancreatitis, grade 3 fatigue with rapid onset in absence of disease 
progression, etc.)
Grade (Worst 
Toxicity ) Dose Modification Recommended Clinical Management

Novartis Confidential Page 72
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Grade 1 (Mild, 
asymptomatic)Recomme ndation: maintain 
capmatinib and spartalizumab at 
normal dose levels and schedulesTreat per local/institutional guidelines
Grade 2 Mandatory: omit capmatinib and 
spartalizumab dose until resolved to ≤ 
Grade 1 or baseline, then resume 
treatment at same dose level and 
schedule.1. Ensure adequate evaluation to confirm 
etiology or exclude other causes
2. Provide symptomatic treatment
3. Systemic corticosteroids may be indicated
4. Consider biopsy for confirmation of 
diagnosis
5. A specialist should be cons ulted
Grade 3 Mandatory:
Omit capmatinib and spartalizumab 
dose until resolved to ≤ Grade 1 or 
baseline May restart treatment at the 
same dose and schedule taking into 
account the risks and benefits;
2ndoccurrence:
If toxicity recurs > Grade 2 
permanently discontinue subject from 
all study drug treatments1. Ensure adequate evaluation to confirm 
etiology or exclude other causes
2. Provide symptomatic treatment
3. Initiate systemic corticosteroids 
(prednisone at a dose of 1 -2 mg/kg/d or 
equivalen t) and other therapies as 
appropriate
4. Consider biopsy for confirmation of 
diagnosis
5. A specialist should be consulted
Grade 4 Mandatory: permanently discontinue 
subject from all study drug treatments1. Hospitalization and consult with specialist
2. Initiate systemic corticosteroids 
(prednisone a dose of 1 -2 mg/kg/d or 
equivalent) and other therapies as 
appropriate
Encephalitis or aseptic meningitis 
Any Grade Mandatory: permanently discontinue 
subject from all study drug treatments1. Rule out infectious or other causes of 
moderate to severe neurologic deterioration
2. Consult with specialist.
3. If other etiologies are ruled out, administer 
corticosteroids at a dose of 1 to 2 mg/kg/day 
prednisone equivalents.
Guillain-Barre 
Severe peripheral or autonomic neuropathy , or transverse my elitis
Any Grade Mandatory: permanently discontinue 
subject from all study drug treatments1. Rule out infectious or other causes of 
moderate to severe neurologic deterioration, 
and consult with specialist.
2. If other etiologies are ruled out, administer 
corticosteroids at a dose of 1 to 2 mg/kg/day 
prednisone equivalents
Myasthenia gravis
Grade 2 Mandatory: omit capmatinib and 
spartalizumab dose until resolved to 
≤Grade 1 or baseline, then resume 
treatment at s ame dose level and 
schedule.1. Consult with specialist
2. Consider pyridostigmine and systemic 
corticosteroids (prednisone or equivalent) at 
a dose of 1 -2 mg/kg/d; other therapies as 
appropriate (e.g. i.v. immunoglobulin)
3. Hospitalization in case of sev ere cases
Grade 3 and 4 Mandatory: permanently discontinue 
subject from all study drug treatmentsAs Grade 2 toxicity above
Ocular events
Grade 2 Mandatory: omit capmatinib and 
spartalizumab dose until resolved to 
≤Grade 1 or baseline, then resume 
treatment at same dose level and 
schedule.Consult with ophthalmologist
Grade 3 and 4 Mandatory: permanently discontinue 
subject from all study drug treatmentsAs Grade 2 toxicity above

Novartis Confidential Page 73
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Infusion Related Reactions
Grade 1 Recommendation: maintain 
spartal izumab at normal dose level 
and schedule.Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of the 
investigator.
Consider slowing infusion rate until recovery 
of symptoms
Grade 2 Mandatory: Permanently discontinue 
of spartalizumab in case of recurring 
infusion related reaction despite 
adequate premedication and 
prolonged/slow infusion1. Stop Infusion
2. Additional appropriate medical therapy as 
per local institutional guidelines m ay include 
but is not limited to:
● i.v. fluids
● Antihistamines
● NSAIDS
● Acetaminophen
● Narcotics
● Oxygen and corticosteroids as 
indicated
3. Increase monitoring of vital signs/pulse 
oximetry as medically indicated until patient 
is deemed medica lly stable
If symptoms resolve, the infusion may be 
restarted at 50% of the original infusion rate.
4. Premedicate patient ~ 1.5h prior to next 
infusion of spartalizumab with:
● Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).
● Acetaminop hen 500 -1000 mg po (or 
equivalent dose of analgesic).
● Or as per local institutional guidelines
Grade 3 or 4 Mandatory: permanently discontinue 
subject from all study drug treatments1. Stop Infusion
2. Additional medical therapy as per local 
institutional guidelines that may include:
● IV fluids
● Antihistamines
● NSAIDS, acetaminophen
● Narcotics
● Oxygen
● Corticosteroids
● Epinephrine
3. Close monitoring of vital signs, pulse 
oximetry and ECG as medically indicated 
until the patient is deemed medically stable
4. Hospitalization may be indicated.
All dose modifications should be based on the worst preceding toxicity.
6.5.3.1.1 Guidance for corticosteroids tapering for management of immune -related 
AEs
Consultation with disease -specific experts i s recommended. Steroids should be tapered slowly  
and based on response/recovery  of clinical symptoms. Consider complete tapering over a period 
of at least 4 weeks (sometime 6 -8 weeks or longer) to present recurrent irAEs. Slower tapering 
or re-escalation of corticosteroids therap y may be needed if the adverse event is not showing 
improvement. Once corticosteroid tapering is achieved at a level of 10 mg of prednisone/day 
(or equivalent) or less, spartalizumab can be restarted as indicated in the dose modific ation 
tables.

Novartis Confidential Page 74
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.5.3.2 Docetaxel dose modifications
Every  attempt should be made to maintain the treatment dosing cycle schedule of every  21 days. 
For subjects who are unable to tolerate the protocol -specified dosing schedule, dose adjustments 
are permitted per the local approved label in order to keep the subject on treatment. For 
toxicities outlined below, docetaxel dose reduction will follow the local guidelines and 
approved product label. For each subject, a maximum of two dose modifications is allowed, 
after which the subject should be discontinued from treatment with docetaxel. If a subject 
misses more than two cycles of treatment, the subject should be discontinued from the study. 
However, if the Investigator and the Sponsor conclude that a subject, who has experienced a 
treatment interruption more than two cycles, could benefit from additional treatment, 
continuation may  be allowed. 
According to the manufacturer’s label:
A new cy cle of docetaxel will NOT be initiated if:
Bilirubin > ULN, or
AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN or
Neutrophils < 1.5 x 109/L or
Platelets < 100 x 109/L.
Subjects who are dosed initially  at 75 mg/m2and who experience any of the following should 
have treatment withheld until resolution of the toxicity  and then resume at the reduced dose as 
per Table 6-18:
Febrile neutropenia,
Neutrophils < 500 cells/mm3for more than one week,
Severe or cumulative cutaneous reactions,
Other Grade 3 or 4 non -hematological toxicities.
Subjects who develop ≥ Grade 3 peripheral neuropathy  should have docetaxel treatment 
discontinued entirel y.
Dose changes must be recorded on the stud y treatment eCRF.
Table 6
-19 Criteria for interruption and re -initiation of docetaxel treatment
Worst toxicity  (CTCAE v5.0 Grade) Dose Modifications for Docetaxel
HEMATOLOGICAL –Neutropenia (ANC)
Nadir ANC <500/mm3and nadir platelets ≥ 
50,000/mm3.Withhold until ANC is ≥ 1500 cells/mm3and platelet count is ≥ 
100,000 cells/mm3, then resume at 75% of previous dose
Nadir platelets <50,000/mm3without bleeding 
regardless of nadir ANCWithhold until ANC is ≥ 1500 cells/mm3and platelet count is ≥ 
100,000 cells/mm3, then resume at 75% of previous dose
Nadir platelets <50,000/mm3with bleeding, 
regardless of nadir ANCWithhold until ANC is ≥ 1500 cells/mm3and platelet count is ≥ 
100,000 cells/mm3, then resume at 50% of previous dose
NONHEMATOLOGICAL (excluding neurotoxicity )
Any Grade 3 or 4 toxicities except mucositis Withhold until resolution to ≤ the pre -therapy value, then 
resume at 75% of previous dose
Any diarrhea requiring hospitalization 
(irrespective of Grade) or Grade 3 or 4 
diarrheaWithhold until resolution to ≤ to the pre -therapy value, then 
resume at 75% of previous dose

Novartis Confidential Page 75
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Grade 3 or 4 mucositis Withhold until resolution to ≤ to the pre -therapy value, then 
resume at 50% of previous dose
NEUROTOXICITY
Grade 3, 4 Discontinue
6.5.4 Follow -up for toxicities
Capmatinib and spartalizumab
Subjects whose treatment is interrupted or permanently  discontinued due to an adverse event or 
clinically  significant laboratory  value, must be followed up at least once a week (or more 
frequentl y if required by institutional practices, or if clinically  indicated) for four weeks, and 
subsequently  at approximately  four week intervals, until resolution or stabilization of the event, 
whichever comes first. Appropriate clinical experts such as ophthalmologists, endocrinol ogists, 
dermatologists, psychiatrists etc. should be consulted as deemed necessary . Further guidelines 
and recommendations for the management of specific study  drug combination induced 
toxicities (hypergl ycemia, diarrhea and skin toxicity ) are provided in Section 6.5.3. All subjects 
must be followed for adverse events and serious adverse events after discontinuation of 
spartalizumab and capmatinib. Please refer to Section 9.2.1 for additional details. 
The emergence of irAE may be anticipated based on the mechanism of action of 
immunomodulatory
 therapies.
Serologic, histologic (tumor sample) and immunological assessments should be performed as 
deemed appropriate by the investigator to verify  the immune -related nature of the AE and to 
exclude alternative explanations. Recommendations (Section 6.5.3) have been developed to 
assist investigators in assessing and managing the most frequen
tly occurring irAEs.
Subjects whose treatment is interrupted or permanently  discontinued due to an irAE, AE or 
clinically  significant laboratory  value, must be followed-up at least once a week (or more 
frequentl y if required by institutional practices, or if clinically  indicated) for 30 days, and 
subsequently  at approximately  30 day  intervals (or more frequently  if required by  institutional 
practices, or if clinicall y indicated), until resolution or stabilization of the event, whichever 
comes first. Appropriate clinical experts should 
be consulted as deemed necessary .
If an AE is suspected to be immune -related the relevant immunological assessments (e.g. 
rheumatoid factor, anti-DNA Ab, etc.) should be performed. If cytokine release syndrome is 
suspected, the assessments outlined in Table 6-17 must be performed.
Table 6-8, Table 6-9, Table 6-10, Table 6 -11, Table 6-12, Table 6 -13, Table 6-14, Table 6 -15, 
Table 6-16, Table 6-17, Table 6-18outline the follow - up evaluations recommended for selected 
toxicities.
Docetaxel
Safety  follow -up for toxicities related to docetaxel should follow the local guidelines and 
approved product label. All subjects must be followed for adverse events and serious adverse 
events after discontinuation of docetaxel. Please refer to Section 9.2.1 for additional details.

Novartis Confidential Page 76
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.5.4.1 Follow up on potential drug -induced liver injury (DILI) cases
Subjects with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important event.
The threshold for potential DILI may depend on the subject’s baseline AST/AL T and TBIL 
value; subjects meeting any of the following criteria will requi re further follow -up as outlined 
below:
For subjects with normal AL T and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For subjects with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or AL T > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in subjects without bone metastasis, or elevation 
of AL P liver fraction in subjects with bone metastasis.
Note: the R value is calculated by dividing the ALT by the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury .
In the absence of cholestasis, these subjects should be immediately  discontinued from study 
treatment, and repeat LFT testing as soon as possible, preferabl ywithin 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-
existing liver 
conditions or risk factors, should be collected.
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary  
tract) may  be warranted.
4.PK samples should be obtained, as close as possible to last dose of, if PK analy sis is 
performed in the stud y.
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant ”, thus, met the definition of SAE and reported as SAE using the term “potential 
drug-induced liver injury ”. All events should be followed up with the outcome clearl y 
documented.

Novartis Confidential Page 77
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
6.6 Additional treatment guidance
6.6.1 Treatment compliance
Every  time the study  treat ment is to be administered, I RT needs to be accessed (please refer to 
the IRT manual). The date and time of stud y treatment administration during the stud y and an y 
deviations from the protocol treatment schedule will be captured on the appropriate study 
treatment dispensing form. The investigator must promote compliance by instructing the subject 
to take the study  treatment exactly  as prescribed and by stating that compliance is necessar y for 
the subject’s safety  and the validity  of the stud y. The subject m ust also be instructed to contact 
the investigator if he/she is unable for an y reason to take the study  treatment as prescribed.
For treatment with spartalizumab or with docetaxel: exposure to the study treatment will be 
based on the number of injections administered. Compliance with the study  treatment will be 
assessed by the Clinical Research Associate (CRA) at each visit using vial counts and 
information provided by the pharmacist or by the investigator. All study  treatment dispensed 
and returned must be recorded in a drug accountability  log.
For treatment with capmatinib: compliance will be assessed by the investigator and/or study 
personnel at each visit using pill counts and information provided by the subject. This 
information should be captured in the source document at each visit. All study  treatment 
dispensed and returned must be recorded in a drug accountabilit y log.
Pharmacokinetic parameters will be determined in all subjects treated with capmatinib and 
spartalizumab combination, as detailed in pharmacokinetics section. Please refer to 
Section 8.5.2.
6.6.2 Emergency  breaking of assigned treatment code
Not applicable.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs 
Section 6.1.1.
Capmatinib
The investigator or responsible site personnel must instruct the subject or caregiver to take the 
study  treatment as per protocol. Study  treatment will be dis pensed to the subject by  authorized 
site personnel onl y. All dosages prescribed to the subject and all dose changes during the stud y 
must be recorded on the study  treatment eCRF.
A unique medication number is printed on the study
 medication label.
Investigator staff will identify  the study  medication kits to dispense to the subject by contacting 
the IRT system and obtaining the medication number(s). The study  medication has a two-part 
label (base plus tear-off label). I mmediatel y before dispensing the medic ation kit to the subject, 
site personnel will detach the outer part of the label from the packaging and affix it to the source 
document.

Novartis Confidential Page 78
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Spartalizumab
Study  treatment will be dispensed and administered to the subject by  authorized site personnel 
only. All dosages prescribed to the subject and all dose changes during the study  must be 
recorded on the study  treatment eCRF. A unique medication number is printed on the study 
medication label.
Investigator staff will identify  the study  medication kits to dispens e to the subject by contacting 
the IRT system and obtaining the medication number(s). The study  medication has a two-part 
label (base plus tear -off label), immediatel y before dispensing the medication kit to the subject, 
site personnel will detach the outer part of the label from the packaging and affix it to the source 
document.
Spartalizumab will be administered intravenously  as a 30 minute infusion (up to 2 hours, if 
clinically  indicated). Infusion must take place in a facilit y with appropriate resuscita tion 
equipment available at the bedside and a physician readily  available during the period of drug 
administration. Clinical monitoring during and post infusion should be performed according to 
local practice and institutional guidelines, and as outlined i
n Section 6.7.2.2. Further 
instructions for the preparation and dispensation of spartalizumab are described in the [Study 
Pharmacy  Manual].
Docetaxel
Preparation and dispensation of docetaxel should follow local guideline s as per standard of care 
and product labels.
6.7.1 Handling of study
 treatment and additional treatment
6.7.1.1 Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels and in the [capmatinib Investigator’s Brochure] and
[spartaliz umab Investigator’s Brochure]. Clinical supplies are to be dispensed only in 
accordance with the protocol. Technical complaints are to be reported to the respective 
Novartis Country  Organisation Quality  Assurance.
Medication labels will be in the local lan guage and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the subject except for the medication number .
The investigator must maintain an accurate record of the shipm ent and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
monitors during site visits or remotely and at the completion of the trial. Subjects will be asked 
to return all unused study  treatme nt and packaging at the end of the study  or at the time of 
discontinuation of study  treatment.
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug label s, and a copy of the completed drug 

Novartis Confidential Page 79
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
accountability  log to the Novartis monitor or to the Novartis address provided in the 
investigator folder at each site.
6.7.1.2 Handling of additional treatment
Not applicable.
6.7.2 Instruction for prescribing and taking study treatment
All kits of study  treatment assigned by  the IRT will be recorded in the IRT sy stem.
Table 6
-20 Dose and treatment schedule
Investigational / Control 
Drug DoseFrequency  and/or 
Regimen
Capmatinib (INC280)
150 mg or 200 mg400 mg orally
(2 x 200 mg or 2 x 150 mg [if dose is reduced 
to 300 mg BID] or 1 x 200 mg [if dose is 
reduced to 200 mg BID], if applicable)Twice daily 
(28 day cycles)
Spartalizumab (PDR001)
100 mg400mg i.v.
(4 x 100 mg vials)Once every 28 days
Docetaxel (as per local product 
available)75 mg/m2 i.v. infusion per product label and 
local guidelines (as per standard of care)Once every 21 days
6.7.2.1 Capmatinib
Capmatinib tablets will be administered orally on a continuous twice daily  (BID) dosing 
schedule, from Day  1 till Day  28 of each 28 day  cycle. The starting dose of capmatinib will be 
400 mg BID (total daily  dose: 800 mg) on a flat scale of mg/day  and not individually  adjusted 
by weight or body  surface area. A complete cycle of treatment is defined as 28 days of twice 
daily  treatment with capmatinib. The investigator must instruct the subject to take the study  
drug exactly as prescribed.
Including day s of PK sampling, subjects should take 400 mg of capm atinib tablets twice 
daily  (BID) at approximately  the same time each day  starting at Cy cle 1 Day  1.
Each dose of capmatinib is to be taken with a glass of water (at least 8 ounces –
approximately  250 mL) and consumed over as short a time as possible (i.e., not slower 
than 1 tablet every  2 minutes).
Subjects should be instructed to swallow the tablets whole and not to chew them.
Capmatinib can be administered with or without food. The morning and the evening doses 
should be taken 12 (± 4) hours apart, althou gh a 12- hour interval is highly  recommended. 
The morning dose should be taken at the same time each morning. If a dose is not taken 
within 4 hours of the planned dosing time, the missed dose should not be replaced.
On day s of co -administration of capmatinib with spartalizumab, subjects should be 
instructed to take the morning dose of capmatinib during the clinic visit, when instructed 
by site personnel. Capmatinib will be administered prior to spartalizumab infusion along 
with its pre -medication (if pre- medication is necessary ). The sequence will allow 
consistent time of daily  dosing for capmatinib. A minimum of 1 hour must pass from the 
time of capmatinib (morning dose) administration to the administration of spartalizumab.

Novartis Confidential Page 80
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
On day s when PK blood samples are to be collected, subjects will be instructed to hold 
their dose until arrival at the study  center. Capmatinib will be administered at the site in 
the morning prior to the post- dose PK sample blood draws supervised b y a member of the 
research team. The pre -dose PK samples will be taken right before capmatinib 
administration. The exact time of drug administration should be recorded in the 
appropriate eCRF. If a subject vomits within 4 hours of capmatinib dosing, the time of 
vomiting should be recorded on the eCRF.
Subjects should be instructed not to make up for missed doses or partial doses (i.e., when 
the entire dose is not taken as instructed). A missed or partial dose will be defined when 
the full dose is not taken within 4 hours of the scheduled twice daily  dosing. If that occurs, 
then the dose (or part of the remaining dose) should not be taken and dosing should restart 
with the next scheduled dose. If vomiting occurs, no attempt should be made to replace the 
vomited dose before the next scheduled dose .
During the whole duration of treatment with capmatinib, the subject is recommended to 
use precautionary  measures against ultraviolet exposure (e.g., use of sunscreen, protective 
clothing, avoid sunbathing or using a solarium).
The investigator should instruct the subject to take capmatinib exactly as prescribed. All 
dosages prescribed and dispensed to the subject and all dose changes during the study  must be 
recorded on the stud y treatment eCRF.
The orally administered film -coated tablet formulation will be provided in up to two strengths 
of 150 mg and 200 mg free base equivalent. For the list of excipients, please refer to the current 
[capmatinib I nvestigator’s Brochure].
6.7.2.2 Spartalizumab
Spartalizumab will be supplied in a vial as liquid solution for infusi on. Spartalizumab (liquid) 
will be diluted in dextrose 5% in water (D5W). Due to incompatibility , 0.9% sodium chloride 
must not be used.
The dose of spartalizumab is 400 mg every  4 weeks given as a 30 minute infusion (up to 2 hours, 
if clinically  indicated ). A dose may be delay ed by up to seven days. If a dose cannot be 
administered within the planned window then the dose on that cycle should be skipped. The 
dose may be interrupted for up to 12 weeks. The safet y assessments (as per Table 8-2) should 
be performed according to the actual day  of infusion.
Infusion must take place in a facility  with appropriate resuscitation equipment available at the 
bedside, and a ph ysician readil y available during the period of drug administration .
Subjects should be closely  observed for potential infusion
-related reactions including rigors, 
chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever, and vital signs 
monitored more frequently  if clinically  indicated, during and for at least 2 hours after the first 
two spartalizumab infusions. The same may apply for the subsequent spartalizumab infusions 
if medicall y indicated. Subjects should be further provided instructions to notify  study 
personnel if s ymptoms of infusion reactio n occur after an y spartalizumab infusion.
On days when PK blood samples are to be collected, study  visits should be scheduled in the 
morning so that a predose PK blood sample can be collected. The exact time of drug 
administration should be recorded in the appropriate eCRF.

Novartis Confidential Page 82
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
A copy of the approved version of all consent forms must be provided to Novartis/sponsor after 
IRB/IEC approval.
Subjects will be asked to complet e an optional questionnaire to provide feedback on their 
clinical trial experience. (Please refer to Section 8.5.1 ).
8 Visit schedule and assessments
Assessment schedules Table 8-2(capmatinib and spartalizumab treated subjects [including run-
in]) and Table 8-3(docetaxel treated subjects) list all of the assessments and indicate with an 
“X” or “S” the visits when they  are performed. All data obtained fr om these assessments must 
be supported in the subject’s source documentation.
Written informed consent must be obtained before any study  specific assessments are 
performed. Main screening evaluations and baseline radiological tumor assessments should be 
performed within 28 days of treatment start. All visits are to be scheduled according to the 
appropriate number of calendar days from Cycle 1 Day 1
 of study  drug administration. Visit 
windows per Table 8-1are allowed.
Table 8
-1 Allowable windo w for subject assessments
Visit name Window allowed
Screening -28 days from 1stdose of study drug
C1D1 Within 3 days after enrollment (part 1) or rando mization (part 
2)
C1D15 ± 1 day
C2D1 ± 3 days
C3D1 ± 3 days
C3D4 ± 1 day (applicable only to intensive PK group)
C3D8 ± 1 day (applicable only to intensive PK group)
C3D15 ± 1 day
C4D1 ± 3 days
Day 1 visit of all subsequent cycles ± 3 days
Imaging evaluations ± 7 days
EOT ≤ 7 days after stopping study treatment
30 day safety follow -up visit + 7 days
60, 90, 120 day follow -up phone call/onsite 
visit± 14 days
150 day follow -up phone call/onsite visit + 14 days
Survival follow -up ± 14 days
Every  effort must be made to follow the schedule of assessments within the windows outlined 
in the protocol. If a given visit is out of window, the next visit should be performed with 
reference to the day of first dose in order to get the subject back on schedule. If an off -schedule 
imaging assessment is performed, subsequent imaging assessments should be performed in 
accordance with the original imaging schedule. Missed or rescheduled visits should not lead to 
automatic discontinuation. Subjects who premat urely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, during which all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconcile d, and the adverse event and concomitant medications recorded on the eCRF.

Novartis Confidential Page 83
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 8-2 Assessment Schedule, Run -in and A rm 1 (capmatinib and spartalizumab combination) -length of a cy cle is 28 
days
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
Informed consent X
ICF for treatment 
beyond 
progressionX (subjects who meet the criteria outlined in Section 6.1.5.1 )
Inclusion / 
Exclusion criteriaX
IRT Eligibility 
checkS
HIV history S
Demography X
Medical 
history/current 
medical 
conditionsX
Diagnosis and 
extent of cancerX
Smoking history X
Prior 
antineoplastic 
therapyX
Prior medications X

Novartis Confidential Page 84
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
Concomitant 
medicationsX (from 28 days prior to starting treatment until 150 day safety follow -up or start of new antineoplastic medication 
(ANP), whichever is sooner. If new ANP is started, only medications relative to suspected AEs/SAEs that are rep orted 
should be collected)
IRT registration X1S2S2S2S2S2S2S3
Physical 
Examination4S S (if clinically indicated)
Targeted Physical 
ExaminationS S S S S S S S
Body Height X
Body W eight X X X X X X X X X
Vital signs X X X X X X X X X X
Performance 
statusX X X X X X X X X
Hematology X X X X X X X X X X X
Chemistry X X X X X X X X X X X
Coagulation Panel X X (if clinically indicated)
Serum Pregnancy 
testS (within 
72h prior 
to first 
dose)S S S
Urine Pregnancy 
testS S S S S S S S S
Urinalysis S S (if clinically indicated)
Thyroid 
stimulating 
hormoneX X X X X X X X X

Novartis Confidential Page 85
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
Thyroid Panel –
Free T3 and Free 
T4X X (only if TSH is abnormal)
Hepatitis screen X X (if clinically indicated)
HIV testing if 
locally requiredS
Cytokines X X (anytime when a suspected cytokine release syndrome occurs, immediately after the AE, and one week 
after occurrence of the AE)
CT/MRI of chest 
and abdomen 
(with intravenous 
contrast 
enhancement)X X X X5X6X5
CT/MRI of pelvis 
and brainX X7X7X7X7X7
Whole body bone 
scanX X (if clinically indicated)
Localized bone 
scan (CT, MRI or 
X-ray)X8X7X7X7X7X7
CT/MRI of other 
metastatic sitesX (if 
clinically 
indicated)X7X7X7X7X7
Photography for 
any skin lesion X X7X7X7X7X7

Novartis Confidential Page 86
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
Electrocardiogram 
(ECG)X X X 
(onl
y 
Run
-in)X 
(onl
y 
Run
-in)X 
(onl
y 
Run
-in)X X (every 
subsequent 
third cycle)X
Adverse Events X (suspected AEs up to Day 150; non -suspected AEs up to Day 150 or start of new post treatment anti -neoplastic 
medication, whichever is sooner)
Serious Adverse 
EventsX (suspected SAEs up to Day 150 and beyond; non -suspected SAEs up to Day 150 or start of new post treatment anti-
neoplastic medication, whichever is sooner)X (SAEs related to study 
treatment)
Newly obtained 
tumor biopsy 
(preferred) or 
archival tumor 
sampleX
Optional and if not 
already provided: 
additional tissue 
material or block 
collected after 
disease 
progression on 
PD-(L)1 
checkpoint 
inhibitor treatmentX

Novartis Confidential Page 87
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
Blood for 
circulating tumor 
DNAX X X X X (every
subsequent 
third cycle)X (at the time of first disease progression prior to the 
initiation of new anti -cancer therapies)
Blood for cytokine 
analysisX X X X X X (at the time of first disease progression prior to the 
initiation of new anti-cancer therapies)
Blood for gene 
expressionX X X X (at the time of first disease progression prior to the 
initiation of new anti -cancer therapies)
Trial Feedback 
QuestionnaireS S S
PK blood 
collection -sparseX X X X X X X X (at C8, 
C10, C12 
and every 6 
cycles 
thereafter) X X X9

Novartis Confidential Page 88
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
PK blood 
collection -
intensiveX X X X X X X X X X (at C8, 
C10, C12 
and every 6 
cycles 
thereafter) X X X9
Immunogenicity X X X X X X (at C8, 
C10, C12 
and every 6 
cycles 
thereafter) X X X9
Study drug 
administration: 
capmatinibX (continuous twice daily (BID) dosing)
Study drug 
administration: 
spartalizumabX X X X X X X
Disposition X X
Antineoplastic 
therapies since 
discontinuation of 
study treatmentX
Safety follow -up X 
(visit)X 
(call)X 
(call)X 
(call)X 
(visit 
or 
call)9
Survival status X

Novartis Confidential Page 89
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
PeriodScreenin
g Treatment Safety  Follow -Up (FUP)Efficacy  FUP 
(until PD)Survival 
FUP
Visit NameScreenin
g C1 C2 C3 C4 C5 C6Subsequent 
cycles EOT30 
day60 
day90 
day120 
day150 
day - -
Days -28 to -1 D1D15 D1 D1D
4D8 D15 D1 D1 D1 D1 - - - - - -every  8 weeks 
until PDevery  8 
weeks
XAssessment to be recorded in the clinical database
SAssessment to be recorded in the source documentation only
1For Arm1 only: randomization at Cycle 1 Day 1, see Section 6.1.1
2For dispensing visit 
3For permanent drug discontinuation
4Including neu rological exams
5Every 8 weeks for the first 12 months and every 12 weeks thereafter until confirmed progressive disease per RECIST 1.1
6If not done within 28 days
7If lesions were documented at screening, follow the same schedule as CT/MRI of the chest and abdomen, or if clinically indicated
8Mandated at Screening for lesions identified on whole body bone scan that are not visible on CT/MRI of chest, abdomen, and pe lvis
9Visit for child -bearing women with serum pregnancy test, if possible

Novartis Confidential Page 90
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 8-3 Assessment Schedule, A rm 2 (Docetaxel) -length of a cy cle is 21 days
Period Screening TreatmentSafety  
FUP Efficacy  FUPSurvival 
FUP
Visit Name Screening C1 C2 C3 C4 Subsequent cy cles EOT 30 day - -
Days -28 to -1 D1 D15 D1 D1 D15 D1 D1 - -every  8 weeks 
until PDevery  8 
weeks
Informed consent X
ICF for treatment beyond progression X (subjects who meet the criteria outlined in Section 
6.1.5.1 )
Inclusion / Exclusion criteria X
IRT Eligibility check S
HIV history S
Demography X
Medical history/current medical conditions X
Diagnosis and extent of cancer X
Smoking history X
Prior antineoplastic therapy X
Prior medications X
Concomitant medications X (from 28 days prior to starting treatment until 30 day safety follow -up or start of new 
antineoplastic medication (ANP), whichever is sooner. If new ANP is started, only 
medications relative to suspected AEs/SAEs that are reported should be collected)
IRT registration X1S2S2S2S2S3
Physical Examination4S S (if clinically indicated)
Targeted Physical Examination S S S S S S
Body Height X
Body Weight X X X X X X X
Vital signs X X X X X X X X
Performance status X X X X X X X
Hematology X X X X X X X X X
Chemistry X X X X X X X X X

Novartis Confidential Page 91
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Period Screening TreatmentSafety  
FUP Efficacy  FUPSurvival 
FUP
Visit Name Screening C1 C2 C3 C4 Subsequent cy cles EOT 30 day - -
Days -28 to -1 D1 D15 D1 D1 D15 D1 D1 - -every  8 weeks 
until PDevery  8 
weeks
Coagulation Panel X X (if clinically indicated)
Serum pregnancy test S (within 
72h prior 
to first 
dose)S S
Urine Pregnancy test S S S S
Urinalysis S S (if clinically indicated)
Hepatitis screen X X (if clinically indicated)
HIV testing if locally required S
CT/MRI of chest and abdomen (with intravenous 
contrast enhancement)X X X5X6X5
CT/MRI of pelvis and brain X X7X7X7X7
Whole body bone scan X X (if clinically indicated)
Localized bone scan (CT, MRI or X -ray) X8X7X7X7X7
CT/MRI of other metastatic sites X (if 
clinically 
indicated)X7X7X7X7
Photography for any skin lesion X X7X7X7X7
Electrocardiogram (ECG) X X X X (every subsequent 
third cycle)X
Adverse Events X (suspected AEs up to Day 30; non -suspected AEs up to Day 30 or start of new 
post treatment anti -neoplastic medication, whichever is sooner)
Serious Adverse Events X (suspected SAEs up to Day 30 and beyond; non -suspected SAEs up to Day 30 or 
start of new post treatment anti-neoplastic medication, whichever is sooner)X (SAEs related to study 
treatment)
Newly obtained tumor biopsy (preferred) or archival 
tumor sampleX

Novartis Confidential Page 92
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Period Screening TreatmentSafety  
FUP Efficacy  FUPSurvival 
FUP
Visit Name Screening C1 C2 C3 C4 Subsequent cy cles EOT 30 day - -
Days -28 to -1 D1 D15 D1 D1 D15 D1 D1 - -every  8 weeks 
until PDevery  8 
weeks
Optional and if not already provided: additional 
tissue material or block collected after disease 
progression on PD -(L)1 checkpoint inhibitor 
treatmentX
Blood for circulating tumor DNA X X X X (every subsequent 
third cycle)X (at the time of first disease 
progression prior to the initiation of 
new anti -cancer therapies)
Blood for cytokine analysis X X X X X X (at the time of first disease 
progression prior to the initiation of 
new anti -cancer therapies)
Trial Feedback Questionnaire S S S
Study drug administration: docetaxel X X X X X
Disposition X X
Antineoplastic therapies since discontinuation of 
study treatmentX
Safety follow -up X (visit)
Survival status X

Novartis Confidential Page 93
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Period Screening TreatmentSafety  
FUP Efficacy  FUPSurvival 
FUP
Visit Name Screening C1 C2 C3 C4 Subsequent cy cles EOT 30 day - -
Days -28 to -1 D1 D15 D1 D1 D15 D1 D1 - -every  8 weeks 
until PDevery  8 
weeks
XAssessment to be recorded in the clinical database
SAssessment to be recorded in the source documentation only
1Randomization at cycle 1 day 1, see section 6.1.1
2For dispensing visit 
3For permanent drug discontinuation
4Including neurological exams
5Every 8 weeks for the first 12 months and every 12 weeks thereafter until confirmed progressive disease per REC IST 1.1
6If not done within 28 days
7If lesions were documented at screening, follow the same schedule as CT/MRI of the chest and abdomen, or if clinically indica ted
8Mandated at Screening for lesions identified on whole body bone scan that are not visi ble on CT/MRI of chest, abdomen, and pelvis

Novartis Confidential Page 94
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8.1 Screening
All subjects must provide a signed main ICF prior to performing any screening procedures to 
determine subject eligibility . Subjects will be evaluated against all study  inclusion and 
exclusion criteria. Baseline evaluations must be performed within 4 weeks ( ≤ 28 day s) prior to 
the first dose of stud y drug.
After signing the study  ICF, the screening assessments will be done within 1 to 28 days prior 
to the first dose of study  drug. Laboratory  parameters may be retested within the 28 day 
screening window (Day -28 to Da y -1) period for an individual subject if such paramete rs meet 
an exclusion criterion when initially  tested. Laboratory  assessments performed as part of the 
screening evaluations will not be required to be repeated prior to dosing (except serum 
pregnancy  test if not done within 72 hours prior to treatment star t, and hematology/chemistry if 
not done within 7 days prior to treatment start) unless deemed clinically necessary  by the 
investigator and/or required as per local institutional policies. The cardiac eligibility  criteria 
should be assessed with the ECG report. Imaging assessments will be performed at screening 
between Day -28 and Day -1. Imaging assessments alread y completed during the regular work -
up of the subject within 28 days prior to start of treatment, including before signing the main 
study  ICF can be considered as the baseline images for this study . Any imaging assessments 
obtained after first dose of study  treatment cannot be considered baseline images. For details 
on screening assessments, refer to Table 8-2and Table 8-3.
A new ICF will need to be signed if the investigator chooses to re-screen the subject after a 
subject has screen failed. A new subject number will be assigned to the patient. The rescreen 
form will have to be completed in the eCRF and in I RT to provide the original subject number. 
All required screening activities must be performed when the subject is re-screened for 
participation in the study. An individual subject may only be re-screened once for the study . 
Once the numbe r of subjects screened and enrolled is likely  to 
ensure target enrollment, the 
Sponsor may close the study  to further screening. In this case, the subjects who screen failed 
will not be permitted to re- screen.
Subjects who are randomized and fail to start treatment, e.g. subjects randomized in error, will 
be considered as earl y terminations. The reason for earl y termination should be recorded on the 
appropriate eCRF.
8.1.1 Eligibility  screening
When all screening procedures are completed and once the subject’s eligibility  has been 
checked and confirmed (i.e., all inclusion/exclusion criteria have been verified), the key 
eligibility  criteria checklist will be completed prior to the first dose of study  drug in the IRT 
system by the investigator or designee. The eligibility  check will be embedded in the IRT 
system. For the randomized part of the study , allocation to one of the two study  arms will also 
be registered via IRT.
Please refer to Section 6.3.2 and as well as comply with detai led guidelines in the I RT manual.

Novartis Confidential Page 97
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
CT/MRI  of the brain
Whole body  bone scan
Localized bone CT, MRI or x -ray, for any  lesions identified on the whole body  bone scan 
that are not visible on the chest, abdomen and pelvis CT or MRI
CT or MRI  of other metastatic sites (e.g., neck), if clinically  indicated
Color photograph y with a scale /ruler for any  skin lesions present
If a subject is known to have a contraindication to CT intravenous (i.v.) contrast media or 
develops a contraindication during the trial, a non-contrast CT of the chest plus a contrast -
enhanced MRI  (if possible) of the abdomen and pelvis should be performed (MRI  is not 
recommended due to respiratory  artifacts, however if CT is not feasible per local regulations, 
MRI  can be performed instead).
Brain MRI or CT must be completed. Contrast enhanced brain MRI  is preferred; however, if 
MRI  contrast is contraindicated, then MRI without contrast or CT with/without contrast is 
acceptable.
A whole bod y bone scan must be performed per institutional standard of care (e.g., Tc -99 bone 
scan, whole body  bone MRI , Fluorodeox yglucose posit ron emission tomograph y [FDG -PET] 
or sodium fluoride [NaF] PET). Localized CT, MRI or X-rays should be acquired for all skeletal 
lesions identified on the screening whole body  bone scan, which are not visible on the chest, 
abdomen, pelvis or brain CT/MRI .
If clinicall y indicated, CT or MRI of other areas of disease (e.g., neck), as appropriate, must be 
performed.
If skin lesions are present at screening, color photograph y must be acquired using a digital 
camera in clear focus, including a scale/ruler, in su ch a way that the size of the lesion(s) can be 
determined from the photograph.
Combined PET/CT may be used only if the CT is of similar diagnostic quality  as a CT 
performed without PET, including the utilization of i.v. contrast media. At the discretion of the 
investigators, FDG -PET scans may be performed to document progressive disease per RECI ST 
1.1 (Section 16.1).
Any potentially  measurable lesion that has been previously  treated with radiotherap y should be 
considered as a
non-measurable lesion. However, if a lesion previously  treated with 
radiotherap y has clearly  progressed since the radiotherapy , it can be considered as a measurable 
lesion.
Chest x -rays and ultrasound should not be used to measure tumor lesions.
Post -baseline imaging assessments
Imaging assessments as described in Table 8
-4should be performed using the same imaging 
modality  used at baseline, irrespective of study  treatment interruption or actual dosing (see 
Table 8-1) and will be performed every  8  weeks (+/- 7 days) for the first 12 months and then 
every  12 weeks until study  discontinuation criteria are met per Section 9.1. Each lesion that is 
measured at base line must be measured b y the same method and, when possible, the same local 
radiologist/ph ysician throughout the study  so that the comparison is consistent. The same is true 

Novartis Confidential Page 98
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
for any new lesions that occur after start of treatment. They  should be imaged using the same 
modality  at each subsequent time point. Imaging assessments should be scheduled using the 
date of first dose of study  treatment as the reference date (not the date of the previous tumor 
assessment), and should be respected regardless of whether study  treatment is temporarily 
withheld or unscheduled assessments performed. If an unscheduled imaging assessment is 
performed because progression is suspected, subsequent imaging assessments should be 
performed in accordance with the original imaging sc hedule.
Additional imaging assessments may be performed at any time during the study  at the 
investigator’s discretion to support the efficacy  evaluations for a subject, as necessary .
Treatment bey ond disease progression
Following determination of disease progression, if the investigator believes the subject may 
derive benefit from continuing study  treatment, the subject will be permitted to continue 
treatment beyond initial disease progression as per RECI ST 1.1. Please see Section
6.1.5.1 for 
additional information.
Efficacy  follow -up
For subjects who discontinue treatment for reasons other than initial disease progression as per 
RECI ST 1.1, tumor assessments must continue to be performed as outlined in Table 8-2and 
Table 8-3. Please refer to Section 9.2.2 for additional information.
Overall survival
All Subjects will enter the survival follow -up period once they complete the safet y follow -up 
and efficacy  follow -up after treatment discontinuation (whichever is longer).Survival status will 
be collected every  8 weeks regardless of treatment discontinuation reason (except if consent is 
withdrawn or subject is lost to follow -up) until death, lost to follow -up, or withdrawal of consent 
for survival follow -up. Additional survival assessments may  be performed outside the 8 weeks 
follow -up schedules if a survival update is required for an interim assessment to meet safety  or 
regulatory  needs. Survival information can be obtained via phone, and information will be 
documented in the source documents and relevant eCRFs.Information on the therapies received 
for NSCL C, if an y, after study  treatment has been completed will be collected.
8.3.2 Appropriatene ss of efficacy  assessments
Tumor response as specified in Section 8.3.1 will be assessed locall y according to the Novartis 
guideline version 3.2 based on RECI ST 1.1 ( Section 16.1) ( Eisenhauer et al2009)  
 Tumor assessments every  8-
12 weeks are 
consistent with the standard clinical practice. National Comprehensive Cancer Network 
(NCCN) guidelines for NSCLC recommend response assessment every 6 -12 weeks. In patients 
with NSCL C previousl y treated with platinum chemotherap y, the median PFS is approximately 
4 months or 16 weeks. 

Novartis Confidential Page 99
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8.4 Safet y
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to Section 10.1.1.
Table 8
-5 Physical A ssessments
Assessments Specification
Physical 
examinationSignificant findings that were present prior to the signing of informed consent must be 
included as medical history on the subject’s eC RF. Significant new findings that begin or 
worsen after informed consent must be recorded as an adverse event on the appropriate 
eCRF.
Physical examination
At screening, a complete physical examination will be performed including the examination 
of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, 
abdomen, back, lymph nodes, extremities, vascular, and neurological systems. More 
frequent examinations may be performed at the discretion of the investigator and if medic ally 
indicated. Information about the physical examination must be present in the source 
documentation.
Targeted phy sical examination
A targeted physical exam will be performed at all visits as indicated in Table 8-2and 
Table 8-3  during treatment except where a complete physical examination is required (see 
above). It will include at least the examination of general appearance and vital signs (blood 
pressure [SBP and DBP] and pulse). If indicated based on symptoms, additional exams will 
be performed.
Information for all physical examinations must be included in the source documentation at 
the study site and additionally reported in appropriate eCRF pages for blood pressure (SBP 
and DBP), vital signs, height and weight.
Vital signs Vital signs include blood pressure (supine position preferred when ECG is collected), pulse 
measurement, and body temperature . They will be measured at screening and at 
subsequent time points as specified in Table 8-2andTable 8-3.
Height and 
weightHeight will be measured at screening.
Body weight (in indoor clothing, but without shoes) will be measured at screening and at 
subsequent time points as specified in Table 8-2and Table 8-3.
Performance 
statusThe performance status will be assessed according to the Eastern Cooperative Oncology 
Group (ECOG) Performance Status Scale as specified in Table 8-6following the schedule 
given in Table 8-2and Table 8-3. 
Table 8-6 ECOG Performance Status
Grade ECOG status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature e.g., light house work, office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
8.4.1 Laboratory  evaluations
Central laboratories will be used for the analysis of scheduled hematology, biochemistry  and 
other blood specimens collected as part of safety  monitoring (as detailed in Table 8-2and 

Novartis Confidential Page 100
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 8-3). Additional time points should b e added as deemed necessary  per the investigator's 
best judgment to make sure the toxicity  profile is sufficiently  characterized and dose 
adjustments are performed to safeguard the safety  of the subject.
Dipstick urinalysis (macroscopic panel) will be perf ormed at the site. In the event of an
y out of 
range parameters, a local laboratory  microscopic panel will be performed.
Laboratory  values obtained during the screening phase from the central laboratory will be used 
to assess the subject’s eligibility  and w ill not be required to be repeated prior to dosing (except 
seum pregnancy  test if not done within 72 hours prior to treatment 
start, andhematology/chemistry if not done within 7 days prior to treatment start) unless 
deemed clinically  necessary  bytheinvestigator and/or required as per local institutional 
policies. The time windows granted for laboratory  evaluations are identical to the corresponding 
visit time windows for each visit (refer to Table 8-1) except as stated above.
The site does not need to wait for the results of centrally -analyzed laboratory  assessments when 
an immediate clinical decision needs to be made (e.g. confirmation of eligibility , study  drug 
interruption, re-initiation, and/or termination) and in those ca
ses locally  unscheduled testing 
may be performed and used for eligibility  assessments. Details on the collection, shipment of 
samples and reporting of results by the central laboratory  are provided to investigators 
separately  in the central laboratory  manual. Visit windows are allowed for all visits. Please refer 
to Table 8-1.
If at any time a subject has laboratory  parameters obtained from a different (outside) laboratory , 
Novartis must be provided with a copy  of the normal ranges and units for this laboratory  and 
the laboratory  certification, when possible. The investigator is responsible for reviewing all 
laboratory  reports for subjects 
in the study  and evaluating any abnormalities for clinical 
significance.
The results of the local laboratory  will be recorded in the eCRF if any  the following criteria are 
met:
A treatment decision was made based on the local results, or
There are no concomitant central results available, or
Local lab results document an AE not reported b y the c entral lab, or
Local lab results document an AE where the severity  is worse than the one reported b y the 
central lab.
At any time during the study up to safet y follow -up, abnormal laboratory parameters which are 
clinically  relevant and require an action tobe taken with study  treatment (e.g., require dose 
modification and/or interruption of study  treatment, lead to clinical symptoms or signs, or 
require therapeutic intervention), whether specifically  requested in the protocol or not, will be 
recorded on the adverse event eCRF page. The severity of laboratory data will be graded using 
the Common Terminology Criteria for Adverse events (CTCAE) v5.0. (See Section 10.1 for 
additional information.) Additional analy ses are left to t he discretion of the investigator.

Novartis Confidential Page 101
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 8-7 Laboratory  Assessments
Test Category Test Name
Hematology Hemoglobin, Platelets, Hematocrit, White blood cells, Differential (Basophils, 
Eosinophils, Lymphocytes, Monocytes, Neutrophils, Bands, Other (absolute value 
preferred, %s are acceptable))
Chemistry Albumin, Alkaline Phosphatase, ALT, Amylase, AST, Calcium, Creatinine, Creatinine 
Clearance, Total Bilirubin, Direct Bilirubin (only if total bilirubin is ≥ grade 2), Indirect 
Bilirubin, Prothrombin Time, GGT, Lipase, Magnesium, Sodium, Potassium, fasting 
Glucose (non -fasting glucose allowed post -baseline), Blood Urea Nitrogen (BUN) or 
Urea, Bicarbonate, Chloride and Ur ic Acid: at screening and thereafter as clinically 
indicated, Lactate dehydrogenase (LDH), Phosphorus, Creatine kinase, Total 
Cholesterol
Urinalysis Local Laboratory: Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, 
Ketones, Leukocytes este rase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)
If dipstick is abnormal then perform local laboratory Microscopic Panel (Red Blood 
Cells, W hite Blood Cells, Casts, Crystals, Bacteria, Epithelial cells)
Coagulation Activated Partial Thromboplas tin Time (aPTT), International Normalised Ratio (INR)
Thyroid TSH (Thyroid Stimulation Hormone), Free T3 and Free T4. At the subsequent visits as 
indicated in Table 8-2: TSH only. If TSH is abnormal, central lab will test Free T3 and 
Free T4
Hepatitis marker HBV DNA, HbsAg, HbsAb, HbcAb, HCV RNA -PCR
Safety cytokines (for 
cytokine release 
syndrome)IFN-γ, IL-6, IL-1,TNF -α
Pregnancy Test A serum pregnancy test must be performed at screening (at the local laboratory) within 
≤ 72 hours before first dose of study treatment, then the schedule of serum and urine 
pregnancy tests should be performed as indicated in Section 8.4.3 . If local 
requirements dictate otherwise, local regulations should be followed.
8.4.1.1 Hematology
Hematology  tests are to be performed according to the Visit Schedules outlined in Table 8-2
and Table 8-3. For details of the hematology  panel refer to Table 8-7. Hematology  should be 
assessed on the actual scheduled day , even if study  drug is being withheld.
Laboratory  assessment done ≤ 7 days of first dose of study treatment are permitted to be used 
as Cy cle 1 Day  1 labs and do not need to be repeated.
More frequent hematology  testing may also be performed as medicall y necessary . Additional 
results from unscheduled hematology  lab evaluations should be recorded on the appropriate 
unscheduled visit eCRF.
8.4.1.2 Clinical chemistry
Clinical chemistry  tests are to be performed according to the visit schedule outlined in Table 8-2
and Table 8
-3. For details of the biochemistry  panel see Table 8 -7. Biochemistry  should be 
assessed on the actual scheduled day , even if study  drug is being withheld.
Laboratory  assessment done ≤ 7 days of first dose of study  treatment are 
permitted to be used 
as Cy cle 1 Day  1 labs and do not need to be repeated.
More frequent chemistry testing may also be performed as medically  necessary . Additional 
results from unscheduled chemistry  lab evaluations should be recorded on the appropriate 
unscheduled visit eCRF.

Novartis Confidential Page 102
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8.4.1.3 Urinaly sis
Urinaly sis is to be performed according to the visit schedules outlined in Table 8-2and 
Table 8-3. For details of the urinal ysis panel see Table 8-7.
8.4.1.4 Coagulation
INR and aPTT are to be performed according to the visit schedule outlined in Table 8-2and 
Table 8-3.
8.4.1.5 Thyroid function
Thyroid function will be performed at:
Screening/base line: TSH, Free T3, Free T4
Day 1 of subsequent cy cles, EOT, 30 day  safet y follow -up: TSH
If TSH is abnormal, central lab will test Free T3 and Free T4.
8.4.1.6 Hepatitis marker
Hepatitis panels outlined in Table 8-7will be performed at screening and as clinically  indicated 
while on study  treatment as per the assessment schedule in Table 8-2and Table 8-3. HBV DNA 
serology  (including HBV DNA, HBsAg, HBsAb, HBcAb) and HCV RNA -PCR test will be 
performed at baseline screening (≤ 28 days prior to start of study  treatment) and as clinically 
indicated (hepatitis markers should be evaluated for precautionary  safety monitoring of viral re-
activation while on study trea tment.)
During the screening period, subjects must be screened for HBV and HCV (current or past 
history  of infection). Careful medical history  must be taken for all subjects to look for risk 
factors (family  history  of HBV and HCV, intravenous drug abuse, unprotected sex, dialy sis, 
blood transfusions, etc.) and any past or present HBV symptoms (e.g., jaundice, dark urine, 
light colored stools, right upper quadrant pain).
Hepatitis B: 
At screening, all subjects will be tested for:
HBV DNA level
Hepatitis B s urface antigen (HBsAg)
Hepatitis B core antibody  (HBcAb)
Hepatitis B surface antibody  (HBsAb)
Hepatitis C: 
At screening, all subjects will be tested for quantitative HCV RNA -
PCR. After start of the study  
treatment and until 30 day  safety  follow -up, testing for HBV and HCV should be performed if 
clinically  indicated. (e.g., criteria of hepatitis reactivation, rule out viral causality  in case of 
DILI).

Novartis Confidential Page 103
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8.4.1.7 Cytokine analy sis
Samples for safet y cytokine panel at screening will be stored below -70°C and analy zed onl y if 
post-screening samples are received. Cytokine panel is to be performed according to the visit 
schedules outlined in Table 8-2.
8.4.2 Electrocardiogram (ECG)
ECGs should be recorded after the subject has been resting for 10 minutes in the supine position 
to ensure a stable baseline, followed by the first ECG recording over the next 5 minutes. 
Triplicate ECGs should be performed approximately  2
 minutes apart prior to the time point 
indicated in Table 8-8, Table 8-9, and Table 8-10below. ECGs should be performed within 
20 minutes prior to the collection of PK sample where applica ble. The preferred sequence of 
cardiovascular data collection during study  visits is ECG collection first, followed by vital signs, 
and blood sampling.
The Fridericia QT correction formula (QTcF) should be used for clinical decisions. The QTcF 
values from the triplicate ECGs will be averaged for each time point.
Triplicate ECGs for assessment will be collected at certain visits and whenever abnormalit y 
occurs at an y time. Clinically significant ECG findings must be recorded as adverse events.
Table 8-
8 ECG collection plan Part 1: Run -in
Cycle Day Time ECG T ype
Screening Anytime 12 Lead, triplicate
1 1 Pre-dose 12 Lead, triplicate
1 15 Pre-dose 12 Lead, triplicate
2 1 1h post spartalizumab end of infusion 12 Lead, triplicate
3 1 Pre-dose and 1h post spartalizumab end of infusion 12 Lead, triplicate
4 1 Anytime 12 Lead, triplicate
Every subsequent third 
cycleAnytime 12 Lead, triplicate
End of treatment Anytime 12 Lead, triplicate
Unscheduled ECG Anytime if clinically indicated 12 Lead, triplicate
Table 8-9 ECG collection plan Part 2: Randomized to A rm 1: capmatinib and 
spartalizumab combination
Cycle Day Time ECG T ype
Screening Anytime 12 Lead, triplicate
1 1 Anytime 12 Lead, triplicate
4 1 Anytime 12 Lead, triplicate
Every subsequent third 
cycleAnytime 12 Lead, triplicate
End of treatment Anytime 12 Lead, triplicate
Unscheduled ECG Anytime if clinically indicated 12 Lead, triplicate
Table 8-10 ECG collection plan Part 2: Randomized to A rm 2: docetaxel
Cycle Day Time ECG T ype
Screening Anytime 12 Lead, triplicate

Novartis Confidential Page 104
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Cycle Day Time ECG T ype
1 1 Anytime 12 Lead, triplicate
4 1 Anytime 12 Lead, triplicate
Every subsequent third 
cycleAnytime 12 Lead, triplicate
End of treatment Anytime 12 Lead, triplicate
Unscheduled ECG Anytime if clinically indicated 12 Lead, triplicate
Note: An unscheduled ECG may be repeated at the discretion of the investigator at any time 
during the study  and as clinically  indicated. Unscheduled ECGs with clinically  significant 
findings should be collected in triplicate. Interpretation ofthe tracing must be made by a 
qualified phy sician and documented on the ECG eCRF page.
Each ECG tracing should be labeled with the study  number, subject initials (where regulations 
permit), subject number and date and kept in the source documents at the study  site. Clinically 
significant ECG abnormalities present at screening should be reported on the medical history 
eCRF page. New or worsened clinicall y significant findings occurring after informed consent 
must be recorded on the adverse events eCRF page.
8.4.3 Pregnancy  and assessments of fertility
All sexually  active males and sexually  active females of child- bearing potential are required to 
use highl y effective methods of contraception during the study  and for the follow -up time period 
as specified in Section 5.2. For a definition of highl y effective contraception, assessment of 
fertility  (males and females), and the definition of post- menopausal, please refer to Section 5.2.
All women of child -bearing potential will have a serum pregnancy test within 72 hours prior to 
the first dose of study  treatment. hCG may also be considered a tumor marker, therefore if hCG 
levels are detected, another blood sample at least 4 days later must be taken to assess the kinetics 
of the increase, and a transvaginal ultrasound must be performed to rule out pregnancy .
Women treated with capmatinib and spartalizumab combination
Monthly  urine pregnancy  tests will then be required to be performed on Day 1
 of every  cycle 
beginning with C ycle 2, followed by serum pregnancy test at the end of treatment visit, 30 day 
and 150 day  safet y follow -up visit. During the follow -up period after the 30 day  safety  follow -
up visit through the 120 day  safet y follow -up telephone call, women o f child -bearing potential 
will perform at-home urine pregnancy  testing every  30 days using kits provided. Every  effort 
must be made for the women of child- bearing potential to return to the site for the final 
pregnancy  test. However, if the subject is unab le to return then the subject will administer the 
urine pregnancy  test at home using the kit provided. For all pregnancy  tests performed at home, 
the site personnel will follow -up with the subject via telephone call to collect the date and the 
test results and document the information in the subject’s source documents. If the subject 
returns to the site for the serum pregnancy test at the 150 day safet y follow -up, the results must 
be documented in the subject’s source documents.
Women of child- bearing potential will be instructed to contact the site immediatel y at an y time 
during the stud y (on -treatment or during follow- up) should they have a positive pregnancy test. 
In case of positive urine pregnancy testing, additional testing must be performed to confirm the 
pregnancy , and, if confirmed, follow the reporting requirements as described in Section 10.1.4. 

Novartis Confidential Page 105
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
A positive pregnancy  test requires immediate discontinuation of study  treatment. If a positive 
pregnancy  test is performe d in between study  visits, the subject must immediately  notify  the 
investigator. Male subjects must notify  the investigator in case their partner is confirmed with 
positive pregnancy  test results during the treatment period. See Section 10.1.4 for pregnancy 
reporting.
Local pregnancy  test and associated results will not be collected on the eCRF.
Women treated with docetaxel
Monthly  urine pregnancy  tests will then be required to be performed on Day 1 of every  cycle 
beginning with C ycle 2, followed by a serum pregnancy test at the end of treatment visit and at 
the 30 day safety follow -up visit. Every  effort must be made for the women of child- bearing 
potential to return to the site for the final pregnancy test.
Women of child- bearing potential will be instructed to contact the site immediatel y at an y time 
during the stud y (on -treatment or during follow- up) should they have a positive pregnancy test. 
In case of positive urine pregnancy testing, additional testing must be performed to confirm the 
pregnancy , and, if confirmed, follow reporting requirements as described in Section 10.1.4. A 
positive pregnancy  test requires immediate discontinuation of study  treatment. If a positive 
pregnancy  test isperformed in between study  visits, the subject must immediately  notify  the 
investigator. Male subjects must notify  the investigator in case their partner is confirmed with 
positive pregnancy  test results during the treatment period. See Section 10.1.4 for pregnancy 
reporting.
Local pregnancy  test and associated results will not be collected on the eCRF.
Assessments of fertility
For both treatment arms, when non-child -bearing potential status is determined during the study ,
further pregnancy  testing will not be continued. For further details on the assessment of fertility , 
please refer to the study exclusion criteria in Section 5.2.
If local requirements dictate otherwise, local regulations sho uld be followed.
8.4.4 Appropriateness of safety  measurements
The safet y assessments selected are standard for this indication/subject population.
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
Trial Feedback Questionnaire (TFQ)
This trial will inclu
de an anon ymized questionnaire, the "Trial Feedback Questionnaire," for 
subjects to provide feedback on their clinical trial experience. Individual subject level responses 
will not be reviewed by investigators. Responses may be used by the sponsor (Novarti s) to 
understand where improvements can be made in the clinical trial process. This questionnaire 
does not collect data about the subject's disease, sy mptoms, treatment effect or adverse events, 
and, therefore, will not be trial data.

Novartis Confidential Page 106
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 108
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8.5.2.1 Pharmacokinetic blood collection and handling
The exact date and clock times of drug administration and PK blood draw will be recorded on 
the appropr iate eCRF page. If vomiting occurs within 4 hours following capmatinib 
administration on the day of post dose PK blood sampling, the clock time of vomiting should 
be recorded in the dosage administration PK eCRF page.
Blood samples will be taken by  either direct venipuncture or an indwelling cannula inserted in 
a forearm vein. A total of 3 mL of blood will be collected at specified time points for capmatinib 
and CMN288 analy sis in plasma. Another 2 mL of blood will be collected for spartalizumab 
analysis in serum and 3.5 mL  will be collected for IG analysis in serum. For time points when 
spartalizumab PK and IG are to be measured, a single blood sample will be collected for both 
IG and spartalizumab PK. Blood samples should be collected from the arm opposite from 
the investigational drug infusion, or from another site. Refer to the study 's laboratory  manual 
for detailed instructions for the collection, handling, and shipment of PK and IG samples.
If subjects experience a SAE or an AE leading to the discontinu ation of the study treatment, an 
unscheduled PK blood sample should be obtained whenever possible. The date and time of the 
last dose and the time of PK blood draw should be recorded.
8.5.2.2 Pharmacokinetic sampling for capmatinib
PK blood samples for capmatinib and CMN288 are outlined in Table 8-11 and Table 8-12. The 
first 10 subjects who receive treatment dose for both capmatinib (BID) and spartalizumab for 
at least 12 weeks will be involved in the intensive PK cohort. If the 10 subjects are not 
recruited 
to the intensive PK cohort from the run -in part, the recruitment for the intensive PK cohort can 
extend into the randomized part of the stud y.
Table 8-11 Intensive PK cohort: Schedule of blood collection (plasma) for 
capmatinib (BID) PK
Cycle Day Scheduled Time (hours) Dose Reference ID Sample Number
3 1 Predosea1/101b111
3 1 0.5 h (±5 minutes) 1 112
3 1 1 h (±10 minutes) 1 113
3 1 2 h (±15 minutes) 1 114
3 1 4 h (±30 minutes) 1 115
3 1 8 h (±2 hr) 1 116
4 1 Predosea2/201b117
4 1 1 h (±10 minutes) 2 118
6 1 Predosea3/301b119
6 1 1 h (±10 minutes) 3 120
8 1 Predosea4 121
8 1 1 h(±10 minutes) 4/401b122
Unscheduled Anytime 1001+
a Take samples immediately prior to administration of capmatinib
bThe first Dose Reference ID (DRID) is for last dose the subject received prior to the collection of the PK 
sample, while the second DRID is for the current dose

Novartis Confidential Page 109
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 8-12 Sparse PK cohort: Schedule of blood collection (plasma) for 
capmatinib (BID) PK
Cycle Day Scheduled Time (hours) Dose Reference ID Sample Number
3 1 Predosea1/101b211
3 1 1 h (±10 minutes) 1 212
4 1 Predosea2/201b213
4 1 1 h (±10 minutes) 2 214
6 1 Predosea3/301b215
6 1 1 h (±10 minutes) 3 216
8 1 Predosea4 217
8 1 1 h(±10 minutes) 4/401b218
Unscheduled Anytime 2001+
a Take samples immediately prior to administration of capmatinib
bThe first Dose Reference ID (DRID) is for last dose the subject received prior to the collection of the PK 
sample, while the second DRID is for the current dose
8.5.2.3 Pharmacokinetic and immunogenicity  (IG) sampling for Spartalizumab
Blood samples for spartalizumab and IG analysis will be collected as outlined in Table 8-13
and  Table 8-14. The first 10 subjects who receive treatment dose for both capmatinib (BID) 
and spartali zumab for at least 12 weeks will be involved in intensive PK cohort. If the 10 
subjects are not recruited to the intensive PK cohort from the run-in part, the recruitment 
for the 
intensive PK cohort can extend into the randomized part of the stud y.
If the dosing of Cycle 3 Day 1 is delay ed, the PK sampling for the full PK profile should be 
delay ed accordingl y to match the scheduled time points for Cycle 3 as outlined in Table 8-13. 
PK and IG samples will be collected also at the end of treatment visit and in the event of a 
clinically  significant AE (such as infusion reaction/anaph ylaxis) or if IG is suspected. After the 
cut-off 
for the primary  analysis is reached, no additional PK and IG samples will be collected 
for the subject s still ongoing in the study .
Table 8-13 Intensive PK cohort: schedule of blood collection (serum) for 
spartalizumab PK and IG
Cycle DayScheduled 
Time 
(hours)**Anal ytesDose 
Reference IDPK 
Sample 
NumberIG 
Sample 
Number
1 1 PredoseaPK/IG*11 41 51
1 15 336 h (± 24h) PK 11 42
2 1 PredoseaPK/IG*11/12c43 52
3 1 PredoseaPK/IG*12/13c44 53
3 1 1 h (± 5 min)bPK 13 45
3 4 72 h (± 8h) PK 13 46
3 8 168 h (± 8h) PK 13 47
3 15 336 h (± 24h) PK 13 48
4 1 PredoseaPK/IG*13/14c49 54
6 1 PredoseaPK/IG*15/16c50 55
8 1 PredoseaPK/IG*17/18c51 56
10 1 PredoseaPK/IG*19/20c52 57

Novartis Confidential Page 110
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Cycle DayScheduled 
Time 
(hours)**Anal ytesDose 
Reference IDPK 
Sample 
NumberIG 
Sample 
Number
12 1 PredoseaPK/IG*21/22c53 58
Every 6 cycles after C12D1 
until discontinuation of study 
treatment1 PredoseaPK/IG*23/24c,d411+e511+f
EOT Anytime PK/IG*401 501
30-day safety follow -up PredoseaPK/IG*402 502
150-day safety follow -upgPredoseaPK/IG*403 404
Unscheduled Anytime PK/IG*4001+ 5001+
*IG samples are collected together with PK samples.
**PK samples are collected from the arm opposite from infusion site, or alternatively, the infusion site will need 
to be flushed with 10 mL of saline.
a Take samples immediately prior to the administration of spartalizumab.
bAfter completion of the infusion.
cThe first Dose Reference ID (DRID) is for last dose the subject received prior to the collection of the PK 
sample, while the second DRID is for the current dose.
dDose reference ID will be labeled se quentially from 25, 26…. ….before EOT
ePK sample number will be labeled sequentially from 412, 413, 414, …. ….before EOT
fIG sample number will be labeled sequentially from 512, 513, 514, …. ….before EOT
g For patients who return to the site for 150-day onsite serum pregnancy test
Table 8-14 Sparse PK cohort: schedule of blood collection (serum) for 
spartalizumab PK and IG
Cycle DayScheduled 
Time 
(hours)**Anal ytesDose 
Reference IDPK 
Sample 
NumberIG 
Sample 
Number
1 1 PredoseaPK/IG*11 61 71
1 15 336 h (± 24h) PK 11 62
2 1 PredoseaPK/IG*11/12b63 72
3 1 PredoseaPK/IG*12/13b64 73
3 15 336 h (± 24h) PK 13 65
4 1 PredoseaPK/IG*13/14b66 74
6 1 PredoseaPK/IG*15/16b67 75
8 1 PredoseaPK/IG*17/18b68 76
10 1 PredoseaPK/IG*19/20b69 77
12 1 PredoseaPK/IG*21/22b70 78
Every 6 cycles after C12D1 
until discontinuation of study 
treatment1 PredoseaPK/IG*23/24b,c611+d711+e
EOT Anytime PK/IG*601 701
30-day safety follow -up PredoseaPK/IG*602 702
150-day safety follow -upfPredoseaPK/IG*603 703
Unscheduled Anytime PK/IG*6001+ 7001+
*IG samples are collected together with PK samples.
**PK samples are collected from the arm opposite from infusion site, or alternatively, the infusion site will need 
to be flushed with 10 mL of saline.

Novartis Confidential Page 111
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Cycle DayScheduled 
Time 
(hours)**Anal ytesDose 
Reference IDPK 
Sample 
NumberIG 
Sample 
Number
a Take samples immediately prior to the administration of spartalizumab.
bThe first Dose Reference ID (DRID) is for last dose the subject received prio r to the collection of the PK 
sample, while the second DRID is for the current dose.
cDose reference ID will be labeled sequentially from 25, 26…. ….before EOT
dPK sample number will be labeled sequentially from 612, 613, 614, …. ….before EOT
eIG sample number will be labeled sequentially from 712, 713, 714, …. ….before EOT
fFor patients who return to the site for 150-day onsite serum pregnancy test
8.5.2.4 Analytical methods
Pharmacokinetic samples for spartalizumab, capmatinib and its metabolite CMN288 will be 
quantified using validated LC/MS/MS assay s. The assay  to quantify  and assess the IG will be 
a validated homogeneous ELISA.

Novartis Confidential Page 112
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 113
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 114
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
9 Study  discontinuation and completion
9.1 Discontinuation
9.1.1 Discontinuation of study treatment
Subjects may  voluntaril y discontinue from the study treatment for an y reason at an y time.
Discontinuation of study  treatment for a subject occurs when study treatment is stopped earlier 
than the protocol planned duration and can be initiated b y either the subject or the investigator. 
The investigator must discontinue study  treatment for a given subject if, he/she believes that 
continuation would negatively  impact the subject's well-being. An end of treatment visit will 
be performed when subjects permanently  discontinue the study  treatment to which they were 
assigned at study  entry .
Study  treatment must be disc ontinued under the following circumstances
Subject/guardian decision
Investigator decision
Any situation in which study  participation might result in a safet y risk to the subject
Adverse event requiring permanent discontinuation of study treatment as per 
Section 6.5.3.1 andSection 6.5.3.2
Progressive disease per RECI ST 1.1  (with the exception of 
continuation of treatment bey ond disease progression.). Please see Section 8.3and 
Section 6.1.5.1 for additional information.
Protocol deviation that results in significant risk to subject’s safet y
Use of prohibited treatment as per Section 6.2.2
Pregnancy  (Pregnancy  may  be followed for outcome as per Section 10.1.4)
Withdraw of consent (Please see Section
9.1.2)
Study  is terminated by  the sponsor (Please see Section 9.1.4)
If premature discontinuation of study  treatment occurs, the investigator should make a 
reasonable effort to understand the primary  reason for the 
subject’s discontinuation of study 

Novartis Confidential Page 115
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
treatment and record this information. The investigator must also contact IRT to register the 
subject’s discontinuation from study  treatment.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see withdraw of informed consent Section 9.1.2). Where possible, they should 
return for the assessments indicated in the assessment schedule (refer to Table 8-2and 
Table 8-3). If they fail to return for these assessments for unknown reasons, every  effort (e.g. 
telephone, e-mail, letter) should be made to contact the subject/pre -designated contact as 
specified in the lost to follow -up section. This contact should preferabl y be done according to 
the study  visit schedule.
If the s ubject cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact should preferabl y be done according to the study  visit schedule (refer to 
Table 8-2and Table 8-3).
All subjects who discontinue study treatment should return for the safet y assessments indicated 
in Section 9.2.1, and if applicable, for the efficacy  assessments indicated in  Section 9.2.2.
9.1.2 Withdrawal of informed consent
Subjects may voluntarily  withdraw 
consent to participate in the study  for any reason at any time. 
Withdrawal of consent oc curs onl y when a subject:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the prima ry reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered mis sing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as detailed in the 
assessment table.
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicabl e 
law.
For US and Japan: All biological samples not y et anal yzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW : All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  applicable law. They will be stored according to applicable 
legal requirements.

Novartis Confidential Page 116
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for s tudy visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed .
9.1.4 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
Novartis will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contacting the 
subject, when the subject should stop taking drug, when the subject should come for a final 
visit) and treated as a prematurel y withdrawn subject. The investigator may be informe d of 
additional procedures to be followed in order to ensure that adequate consideration is given to 
the protection of the subject’s interests. The investigator or sponsor, depending on the local 
regulations, will be responsible for informing IRBs/IECs of the earl y termination of the trial.
9.2 Stud y completion and post -
study  treatment
The primary  analysis will be conducted when approximately  60 overall survival events are 
observed in the randomized phase of the study . The primary  analysis data will be summariz ed 
in the primary  clinical study  report (CSR). Following the cut -off date for the analy sis reported 
in the primary  CSR, the study  will remain open. As long as subjects derive benefit from study 
treatment, ongoing subjects will continue to receive study  treatment and be followed as per the 
schedule of assessments, except for , PK assessments, and the Trial Feedback 
Questionnaire which will no longer be required.
The end of stud y is defined as the earliest occurrence of one of the following:
All subjects have died or discontinued from the study .
Another clinical stud y becomes available that can continue to provide capmatinib and 
spartalizumab combination in this subject population, and all subjects ongoing are eligible 
to be transferred to tha t clinical study .
At the end of the study , every  effort will be made to continue provision of study  treatment 
outside this study  through an alternative setting (e.g. Novartis managed access program) to 
subjects who, in the opinion of the investigator, are still deriving clinical benefit. The final 
analysis will occur at the end of the stud y. All available data from all subjects up to this cut -off 
date will be anal yzed and summarized in a final CSR.
At the time of the end of this study , subjects continuing t o derive benefit from docetaxel in the 
opinion of the investigator may continue such treatment at the Investigator’s discretion 
according to local clinical practice, and ever y effort will be made to continue provision of study 
treatment outside this study  through an alternative setting (e.g. Novartis managed access 
program) to subjects who, in the opinion of the investigator, are still deriving clinical benefit.

Novartis Confidential Page 117
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
All treated subjects should have a safet y follow -up visit conducted 30 days after last 
administr ation of study  treatment. Due to the half -life of spartalizumab and the possible delay ed 
onset of ADRs, subjects will be followed for safety  up to 150 days after the last dose of 
spartalizumab. Please refer to Section 9.2.1.
9.2.1 Follow up for safety  evaluations
After treatment discontinuation, all subjects will be followed for safet y evaluations and should 
have a safet y follow
-up after the last administration of the study  treatment as per below:
Subjects treated with the capmati nib and spartalizumab combination
Due to the half -life of spartalizumab and the possible delay ed onset of ADRs, subjects will be 
followed for safety up to 150 days after the last dose of spartalizumab or up to 30 days after the 
last dose of capmatinib, whichever was stopped last. All subjects will have a 30 day  (+ 7 day s) 
onsite safety  follow -up visit, following which, subjects will be followed (via telephone call or 
onsite visit if subject happens to be visiting the site) at 60 (± 14 days), 90 (± 14 days),120 (± 
14 days) and 150 (+ 14) days after the last dose of spartalizumab. All safet y assessments should 
be completed as per Table 8-2. For female subjects of child- bearing potential, a pregnancy  test 
will be performed at the time points listed inTable 8-2. Please refer to the safety  follow - up flow 
diagram in Section 16.3.
If the subject begins any post-treatment antineoplastic medication before the 150 day safety 
follow-
up period is complete, the collection of new SAEs and AEs unrelated to the capmatinib 
and spartalizumab combination will stop, and, thereafter, only suspected AEs and suspected 
SAEs will continue to be collected up to day 150. Suspected SAEs will conti nue to be collected 
beyond the 150 day  safety  visit.
Data collected should be added to the appropriate eCRF pages. 
Subjects treated with docetaxel
Subjects randomized to the docetaxel arm will be contacted for an onsite safet y follow -up 30 
days after the last dose of docetaxel. For female subjects of child- bearing potential, a pregnancy 
test will be performed as listed in Table 8-3. If the subject begins any post treatment 
antineoplastic medication before the 30 day  safety  foll
ow-up period is complete, the collection 
of new SAEs and AEs unrelated to docetaxel will stop, and, thereafter, only suspected AEs and 
suspected SAEs will continue to be collected up to day 30. Suspected SAEs will continue to be 
collected bey ond the 30 day safet y visit.
Data collected should be added to the appropriate eCRF pages.
9.2.2 Follow up for efficacy evaluations
All subjects who discontinue study treatment for reasons other than initial disease progression 
as per RECI ST 1.1, should continue tumor assessm ents at the same intervals as per Table 8-2
and Table 8-3until treatment discontinuation criteria are met per Section 9.1.
All subjects may be permitted to continue s tudy treatment beyond initial disease progression as 
per RECI ST 1.1. Please refer to Section 6.1.5.1 for details.

Novartis Confidential Page 118
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
9.2.3 Survival follow  up
Subjects will enter the survival follow -up period once they complete the safety  follow -up and 
efficacy  follow -up after treatment discontinuation (whichever is longer). Subjects will then be 
contacted by telephone every  8  w eeks to follow -up on their survival status. Any new 
antineoplastic therapies that have been started since the last contact date will also be collected 
during these phone calls.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
uninte nded sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associ ated with the use of a 
medicinal (investigational) product. The investigator has the responsibility for managing the 
safet y of the individual subject and identify ing adverse events. Novartis qualified medical 
personnel will be readily  available to advise o n trial -related medical questions or problems.
The occurrence of adverse events must be sought by non -directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events (including lab abnormalities that constitute AEs) must be recorded in the 
adverse events eCRF under the signs, symptoms or diagnosis a ssociated with them, rather than 
individual underly ing signs and symptoms and must be accompanied by the following 
information (as far as possible) (if the event is serious refer to Section
10.1.2):
Adverse events will be assessed and graded according to the Common Terminology  
Criteria for Adverse Events (CTCAE) v5.0 
Grade 1 to 4 will be used to characterize the severity
 of the Adverse Event. If CTCAE 
grading does not exist for an adverse event, the severity  of mild, moderate, severe, 
and life -threatening (corresponding respectively  to Grades 1 - 4) will be used.
Its relationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indicatio n) the assessment of causalit y 
will usually  be "not suspected". The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and /or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single subject.
Its duration (start and end dates) or if the event is ongoing. An outcome of not 
recovered/not resolved must be reported.
Whether it constitutes a SAE (see Section 10.1.2 for the definition of a SAE) and which 
seriousness criteria have been met.

Novartis Confidential Page 119
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Action taken regarding with study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose reduced/increased
Drug interrupted/withdrawn
Its outcome 
Not recovered/not resolved;
Recovered/resolved;
Recovered/resolved with sequelae;
Fatal; or unknown.
If the event worsens, the event should be reported a second time in the eCRF noting the start 
date when the event worsens in toxicity . For Grade 3 and 4 adverse events only, if improvement 
to a lower grade is determined, a new entry  for this event should be reporte d in the eCRF noting 
the start date when the event improved from having been Grade 3 or Grade 4. Conditions that 
were alread y present at the time of informed consent should be recorded in medical history 
eCRF of the subject.
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent (e.g. continuing at the end of the study), and assessment must be made at each visit 
(or more frequentl y, if necessary ) of any changes in severity , the suspected relationship to the 
interventions required to treat it, and the outcome.
Progression of malignancy (including fatal outcomes), if documented b y use of the appropriate 
method (e.g., as per RECI ST criteria for solid tumors), should not be reported as an adverse 
event, except if the investigator considers that progression of malignancy is related to study  
treatment. Adverse events separate from the progression of malignancy  (for example, deep vein 
thrombosis at the time of progression or hemopty sis concurrent with finding of disease 
progression) will be reported as per usual guidelines used for such events with proper attribution 
regarding relatedness to the drug.
Abnormal laboratory  values or test results constitute AEs only  if they  fulfill at least one of the 
following criteria:
They induce clinical signs or sy mptoms
They  are considered clinically  significant
They  require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notabl e ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in subjects with 
the underl ying disease.
Following the last dose of study  treatment, AE monitoring should be continued as described 
inSection 9.2.1.

Novartis Confidential Page 120
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Any AEs experienced after thefollow -up safety  evaluations timeframe as specified in 
Section 9.2.1 should only be reported to Novartis Safety  if the investigator suspects a causal
relationship to study  treatment.
Information about adverse drug reactions for the investigational drugs can be found in the 
[capmatinib I nvestigator's Brochure] and [spartalizumab I nvestigator's Brochure].
10.1.1.1 Adverse events of special interest
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by
 the investigator to the sponsor may  be 
appropriate. Such events may require further investigation in order to characterize and 
understand them.
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. and include:
For capmatinib: 
Hepatotoxic ity,
Pneumonitis/ILD,
Central nervous s ystem toxicity ,
Renal dy sfunction,
Pancreatitis,
QTc interval prolongation,
Teratogenicity ,
Phototoxicity ,
Drug -drug interactions with strong CYP3A4 inducers
For spartalizumab: 
Endocrinopathies (i.e. h ypothy roidism, hyperthy roidism, diabetes, hy pophysitis and 
hypopituitarism, adrenal insufficiency ),
Pneumonitis,
Colitis,
Hepatitis,
Nephritis,
Encephalitis,
Rash,
Other immune-mediated events,
Infusion reactions
Details regarding these adverse events are provided in the [capmatinib Investigator’s Brochure] 
and the [spartalizumab Investigator’s Brochure]. Potential emergent new AEs will be monitored 
during the course of the study .

Novartis Confidential Page 121
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
10.1.2 Serious adverse events
A SAE is defined as any adverse event [appearance of (or worsening ofany pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following 
criteria:
Fatal
Life-threatening 
Life-threatening in the context of a SAE refers to a reaction in which the subject was 
at risk of death at t he time of the reaction; it does not refer to a reaction that 
hypothetically  might have caused death if it were more severe (please refer to the 
ICH-E2D Guidelines)
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Requires subject hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (e.g. loss of response , treatment failure) 
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
Treatment on an emergency  out
-subject basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
Is medicall y significant, e.g. defined as an event that jeopard izes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medic ally significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  or abuse.
All malignant neoplas ms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met, and the malignant neoplasm is not a disease progression of the 
study  indication (progression of malignancy  [including fatal outcomes], if documented by use 
oftheappropriate method [e.g. for example, as per RECI ST criteria for solid tumors], should 
not be reported as a serious adverse event.)
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.

Novartis Confidential Page 122
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
10.1.3 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent must be reported to Novartis safet y within 24 hours of learning of 
its occurrence. Detailed instructions regarding the submission process and requirements are to 
be found in the investigator folder provided to each sit e.
The following SAE reporting time frames appl y:
1. Screen Failures (e.g. a subject who is screened but is not treated or randomized): SAEs 
occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must b e reported to Novartis
2.Randomized OR Treated Subjects: SAEs collected between the time the subject signs ICF 
until the timeframes specified in Section 9.2.1 after the subject has discontinued or 
stopped study  treatment.
Allfollow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. A SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new
occurrence) and is thought to be related to the study  treatment, a CMO&PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after thefollow -up safety  evaluations timeframe as specified in 
Section 9.2.1 should only be reported to Novartis Safety  if the investigator suspects a causal 
relationship to study  treatment.
10.1.4 Pregnancy  reporting
To ensure subject safety, each pregnancy occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the Novartis Chief Medical 
Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study  treatment any 
pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.

Novartis Confidential Page 123
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the dose administration eCRF irrespective of whether or not associated with an AE/SAE and 
reported to Safet y only if associated with an SAE. Misuse or abuse will be collected and 
reported in the safet y database irrespective of it being associated with an AE/SAE within 24 
hours of the investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error ty peDocument in Dose Administration 
(DAR) eCRF (Yes/No)Document in AE 
eCRF Complete SAE form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated 
with an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a 
SAE
For more information on AE and SAE definition and reporting requirements, please see 
Section 10.1.1 and Section 10.1.2.
10.2 Additional Safety  Monitoring
Not applicable.
11 Data Collection and Dat
abase management
11.1 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 11 requirements. Investigator site staff will not 
be given access to the EDC system until they have been trained. Automatic validation programs 
check for data discrepancies in the eCRFs and allow modification and/or verification of the 
entered data b y the investigator staff.

Novartis Confidential Page 125
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
subject’s file. The investigator must also keep the original in formed consent form signed by the 
subject (a signed cop y is given to the subject), in case of wet signature.
The investigator must give the CRA access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the eCRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
12 Data analy sis and statistical methods
The primary  efficacy  and safet y analysis will be performed when approximately  60 overall 
survival events are observed in the randomized part. In the primary  analysis, analysis of all 
primary , secondary ,  objectives will be carried out.
12.1 Analysis sets
The Full Anal ysis Set (FAS) comprises all subjects in the run -in who received at least one dose 
of any component of study  treatment and all subjects in the randomized part to whom study 
treatment has been assigned by randomization. In the randomized part according to the intent 
to treat principle, subjects will be anal yzed according to the treatment they  have been assigned 
to during the randomization procedure.
The Safet y Set includes all subjects who received at least one dose of study  treatment (i.e. at 
least one dose of spartalizumab [including incomplete infusion or of capmatinib], or at least one 
dose of docetaxel [including incomplete infusion]). Subjects will be analy zed according to the 
study  treatment received, where treatment received is defined as the randomized treatme nt if 
the subject took at least one dose of that treatment or the first treatment received if the 
randomized treatment was never received.
The Dose -Determining Set (DDS) includes all patients from the Safet y Set in the run-in part 
who met the minimum expos ure criterion and had sufficient safety evaluations, or experienced 
a dose limiting toxicity  (DL T) during the first 56 day s (8 weeks) of dosing.
A subject has met the minimum exposure criterion if the subject receives at least 1 infusion of 
spartalizumab a nd takes at least 50% of the planned dose of capmatinib within the first 8 weeks 
of treatment.
Subjects who do not experience a DLT during the first 56 days of dosing are considered to have 
sufficient safet y evaluations if they  have been observed for ≥ 56 days following the first dose, 
and are considered by both the sponsor and investigators to have enough safety  data to conclude 
that a DLT did not occur.
The capmatinib pharmacokinetic analysis set (PAS -INC280) includes all subjects who provide 
at least one evaluable capmatinib PK concentration. For a concentration to be evaluable, 
subjects are required to:
Take a planned dose of capmatinib prior to sampling.

Novartis Confidential Page 126
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
For pre -dose samples, do not vomit within 4 hours after the dosing of capmatinib prior to 
sampling; for post -dose samples, do not vomit within 4 hours after the dosing of 
capmatinib.
For pre -dose sample, have the sample collected before the next dose administration and 9-
15 hours after the last dose administration.
The spartalizumab pharmacokinetic analysis set (PAS -PDR001) includes all subjects who 
provide at least one evaluable spartalizumab PK concentration. For a concentration to be 
evaluable, subjects are required to:
Receive one of the planned treatments of spartalizumab prior to sampling.
For pre -dose samples, have the sample collected before the next dose administration.
For end -
of-infusion samples, have the sample collected within 2 hours post end of 
infusion.
The immunogenicit y (IG) set includes two parts: IG prevalence set and IG incidence set:
The IG prevalence set includes all subjects in the Full anal ysis set with a determinant 
baseline IG sample or at least one determinant post- baseline IG sample.
The IG incidence set includes all subjects in the IG prevalence set with a determinant 
baseline IG sample and at least one determinant post -baseline IG sample.
12.2 Subject demographics and other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively b y treatment group for the FAS and safet y set.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented. For selected parameters, 
25th and 75th percentiles will also be prese nted.
Relevant medical histories and current medical conditions at baseline will be summarized 
separately  by system organ class and preferred term, by  treatment group.
12.3 Treatments
The Safety  Set will be used for the analyses below. Categorical data will be summarized as 
frequencies and percentages. For continuous data, mean, standard deviation, median, 25th and 
75th percentiles, minimum, and maximum will be presented.
The duration of exposure in weeks to spartalizumab and capmatinib as well as the dose intensity  
(computed as the ratio of actual cumulative dose received and actual duration of exposure) and 
relative dose intensit y (computed as the ratio of dose intensity  and planned dose intensity ) will 
be summarized by  means of descriptive statistics using the Safety  Set.
The duration of exposure will also be presented for the study  treatment by  arm.
The number of subjects with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized by treatment group, and all dosing data 
will be listed.

Novartis Confidential Page 127
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem, by  treatment group.
12.4 Analysis of the primary  endpoint(s)
Primary  Objectives
Part 1: Run -in
To assess safet y and tolerability of capmatinib and spartalizumab combination in subjects with 
NSCL C, who have received one or more prior lines of systemic therapy  for the locally 
advanced/metastatic stage of disease and are potential candidates for docetaxel single agent 
chemotherap y.
Part 2: Randomized
To assess the overall survival of combination of capmatinib and spartalizumab in comparison 
to docetaxel.
12.4.1 Definition of pri mary  endpoint(s)
Part 1: Run -in
Incidence of DLTs during the first 8 weeks (56 days) of treatment for patients in the DDS.
Safety: Incidence and severity  of AEs and SAEs, including changes in laboratory  values, vital 
signs, and ECGs.
Tolerability: Dose int erruptions, reductions, and dose intensity .
Part 2: Randomized
Overall Survival (OS) is defined as the time from date of randomization to date of death due to 
any cause. 
12.4.2 Statistical model, hypothesis, and method of analy sis
Part 1: Run -in
Assessing the safety  and tolerability  of capmatinib and spartalizumab combination will be based 
on the safet y data including dose administration, adverse event, lab, vital signs and ECG data 
when all patients in this phase have at least 24 weeks of follow -up, pharmacoki netic data and 
preliminary  efficacy  data from all enrolled subjects in run-in phase. All dose administration 
data, safet y, pharmacokinetic, and preliminary  efficacy  data will be listed for all subjects 
enrolled in the run -in.
The safety  and tolerability  assessment in run -in will be guided by  a Bayesian anal ysis of DLT 
data for capmatinib and spartalizumab combination in the first 8 weeks (56 day s) of treatment 
for subjects in the DDS. The relationship between dose and the probability  of DL T is modeled 
using Bayesian logistic regression model (BL RM).

Novartis Confidential Page 128
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
The dose-limiting toxicity  (DLT) relationship is modeled by a  5 -parameter BLRM that 
comprises single -agent toxicity  parts and interaction part to describe the two-way drug safet y 
interactions. Single agent toxici ty is modeled using logistic regression for the probability  of a 
subject 
experiencing a DLT against log-dose. The odds of a DLT for each dose regimen are 
then calculated under no interaction for the two single agent toxicities, and interaction is 
accounted for by adjusting these odds with additional model parameter (odds multiplier). 
Details of the model are provided in Section 16.4 .
After the run-in, posterior distributions for the risk of DLT will be summarized to provide the 
posterior probability  that the risk of DLT lies within the following intervals:
Under -dosing: [0, 16%)
Targeted toxicity : [16%, 33%)
Excessive toxicity : [33%, 100%]
Assessing the safet y and tolerability  of the combination is guided by the EWOC principle
(Rogatko et al 2007). A dose may be considered tolerable if the risk of excessive toxicity  at that 
dose is < 25%.
Listing of DLTs
DLTs will be listed, and their incidence summarized b y system organ class and preferred term, 
and worst grade (CTCAE v5.0 grades). Listings and summaries will be based on the DDS.
Part 2: Randomized
The primary  analysis will be carried out when approximately  60 overall survival events are 
observed in the randomized phase of the study . The analysis of OS will be based on full analy sis 
set which includes all randomized subjects. For the primary  endpoint of OS, all the data 
collected up to the cut-off date for the analysis will be included. If a patient is not known to 
have died at the time of an
alysis cut-off, OS will be censored at the date of last contact. The 
estimated hazard ratio (HR) between capmatinib and spartalizumab combination and docetaxel 
and exact 80% confidence interval will be provided.
Capmatinib and spartalizumab combination is considered to have clinicall y relevant activity  if 
the following two criterion are satisfied:
1. The observed HR of OS for capmatinib and spartalizumab combination vs docetaxel is ≤ 
0.667.
2. The upper limit of two sided 80% CI of HR of OS for capmatinib and spa rtalizumab 
combination vs docetaxel is < 1.0.
Other efficacy  data such as ORR, PFS, DCR, TTR, and DOR may  be taken into consideration 
to assess clinically  relevant activity .
12.4.3 Handling of missing values/censoring/discontinuations
Part 1: Run -in
Subjects who are excluded from the DDS will be excluded from the BLRM analy sis of run -in 
part, although their data will be used for all the remaining analy ses.
Part 2: Randomized

Novartis Confidential Page 129
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
OS will be censored if no OS event is observed prior to the anal ysis cut -off date.
If a patient is not known to have died at the time of analysis cut-off, or lost to follow - up, OS 
will be censored at the date of last contact.
12.4.4 Sensitivity and supportive analy ses
Sensitivity  and supportive analy ses may be conducted for the primary  objective in the 
randomized part, if appropriate, and the details of these anal yses will be defined in the SAP.
12.5 Analysis of secondary  endpoints
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
The secondary  efficacy  endpoints, objective response rate (ORR), disease control rate (DCR), 
progression free survival (PFS), time to response (TTR), duration of response (DOR) and 
disease control rate (DCR) based on the investigator assessed as per RECIST 1.1 as described 
in Section 16.1 will be analy zed. Analy sis of all secondary  efficacy  endpoints will be performed 
using the FAS.
ORR is defined as the proportion of subjects with best overall response (BOR) of 
complete response (CR) or partial response (PR).
Disease control rate (DCR) is defined as the proportion of subjects with best overall 
response of CR or PR or SD.
Progression free survival (PFS) is defined as the time from the date of randomization 
(randomized part) o r start of treatment (run- in part) to the date of the first documented 
radiological progression or death due to an y cause.
Time to response (TTR) is defined as the time from the date of randomization 
(randomized part) or start of treatment (run-in part) to the first documented response of 
either CR or PR, which must be subsequently  confirmed (although date of initial response 
is used, not date of confirmation).
Duration of response (DOR) only  applies to subjects for whom best overall response is 
complete re sponse (CR) or partial response (PR). DOR is defined as the time between the 
date of first documented response (CR or PR) and the date of first documented 
progression or death due to underly ing cancer. If progression or death due to underly ing 
cancer has not occurred, then the subject is censored at the date of last adequate tumor 
assessment.
ORR and DCR will be summarized with accompanying 95% confidence interval (CI). PFS, 
TTR, DOR and the Kaplan -Meier curves, medians and 95% confidence intervals of the medians 
will be presented.
Individual lesion measurements and overall response assessments per RECIST 1.1 will be listed 
by assessment date. Best overall response per RECI ST 1.1 will also be listed.
12.5.2 Safety  endpoints
For all safet y analyses, the Safety  Set w ill be used. All listings and tables will be presented by 
treatment group.

Novartis Confidential Page 130
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change fr om 
baseline summaries). In addition, a separate summary  for death including on treatment and post-
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on-treatment events, with a start date during the on-treatment period 
(treatment -emergent 
AEs).
The overall observation period will be divided into three mutually  exclusive segments:
1.Pre-treatment period: from the day of the subject’s informed consent to the day before the 
first dose of study  treatment.
2.On-treatment period: from the day of the first dose of study  medication to 150 days after 
the last dose of spartalizumab, or 30 days after the last dose of capmatinib, whichever is 
later for the spartalizumab and capmatinib arm, or from the day of the first dose of study 
medication to 30 day s after the last dose of docetaxel (including start and stop dates).
3.Post-treatment period: starting at 151 days after last dose of spartalizumab, or 31 days after 
last dose of capmatinib, whichever is later and 31 day s after the last dose of docetaxel.
Adverse events
Summary  tables for adverse events (AEs) will include only AEs that started or worsened during 
the on- treatment period (the treatment -emergent AEs).
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, and relation to study  treatment.
Serious adverse events, non- serious adverse events and adverse events of 
special interest
(AESI) during the on -treatment period will be tabulated.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.
Spartalizumab specific AESI s are defined in the case retrieval strategy (CRS) with regular 
updates whenever necessary , see also Section 10.1.1.1. For each specified AESI, number and 
percentage of subjects with at least one adverse event (Preferred term) corresponding to the 
AESI  will be reported.
Vital signs
All vital signs data will be listed by  treatment group, subject, and visit/time , and, if ranges are 
available, abnormalities will be flagged. Summary  statistics will be provided by  treatment and 
visit/time.
12-lead ECG

Novartis Confidential Page 131
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
12-lead ECGs including PR, QRS, QT, QTcF intervals and heart rate (HR) will be 
obtained for each subject during the study . ECG data will be read and interpreted locall y.
Categorical Analy sis of QT/QTc interval data based on the number of subjects meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from 
baseline will be presented. I n addition, a listing of these subjects will be produced (by  
treatment group).
Clinical laboratory  evaluations
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 5.0. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account. CTCAE Grade 0 will be assigned for all non -missing values not graded as 
1 or higher. Grade 5 will not be applicable. For laboratory  tests where grades are not defined 
by CTCAE v5.0, results will be categorized as low/normal/high based on laboratory  normal 
ranges. The following listings/summaries will be generated separatel y for hematology , and 
biochemistry  tests:
Listing of al l laboratory  data with values flagged to show the corresponding CTCAE v5.0 
grades if applicable and the classifications relative to the laboratory  normal ranges.
For laboratory  tests where grades are defined by  CTCAE v5.0:
Worst post -baseline CTCAE grade ( regardless of the baseline status). Each subject will be 
counted only  once for the worst grade observed post -baseline.
Shift tables using CTCAE v5.0 grades to compare baseline to the worst on -treatment 
value.
For laboratory  tests where grades are not defin ed by  CTCAE v5.0:
Shift tables using the low/normal/high/ (low and high) classification to compare baseline 
to the worst on -treatment value.
Listing of all laboratory data with values flagged to show the corresponding CTCAE v5.0 
grades, if applicable, and the classifications relative to the laboratory  normal ranges will be 
presented.
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots, might 
be specified in the statistical anal ysis plan (SAP).
Immunogenicity
Immunogenicit y will be characterized descriptively  by tabulating anti-drug antibodies (ADA) 
prevalence at baseline and ADA incidence on -treatment.
The impact of immunogenic ity on PK, safet y, and efficac y may be explored, and further details 
will be specified in the SAP.
12.5.3 Pharmacokinetics
The respective PAS for each study
 drug will be used in the pharmacokinetic data anal ysis.

Novartis Confidential Page 132
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Descriptive statistics (n, m number of non-zero concentrations, mean, CV%, SD, median, 
geometric mean, geometric CV%, minimum and maximum) for spartalizumab and capmatinib 
concentrations will be presented at each scheduled time point. All concentration data for 
spartalizumab and capmatinib will be display ed graphicall y.
Concentrations below LLOQ will be display ed in listings as zero with a flag and handled as 
zero in an y calculations of summary statistics, but handled as missing for the calculation of the 
geometric means and their CV. Individual concentrat ion-time profiles as well as mean 
concentration -time profile will be plotted when applicable.
PK parameters will be determined for intensive PK cohort in randomized part by appl ying non -
compartmental method(s) using Phoenix WinNonlin version 6.4 or above (Pharsight, Mountain 
View, CA). The descriptive statistics (n, mean, CV%, standard deviation [SD], median, 
geometric mean, geometric CV%, minimum and maximum) will be presented for all PK 
parameters, including but not limited to those listed in Table 12-1 except Tmax, where onl y n, 
median, minimum and maximum will be presented. Any  missing PK parameter data will not to 
be imputed.
Table 12
-1 Non-compartmental pharmacokinetic parameters  
AUClast The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x 
volume -1) 
AUCtau The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume -1)
Cmax The maximum (peak) observed plasma serum concentration after single dose administration (mass 
x volume -1)
Ctrough The minimum (peak) observed plasma serum concentration (mass x volume -1)
Tmax The time to reach maximum (peak) plasma, blood , serum, or other body fluid drug concentration 
after single dose administration (time)
T1/2 The elimination half -life associated with the terminal slope (lz) of a semi logarithmic concentration -
time curve (time). Use qualifier for other half -lives
12.5.3.1 Handl ing of missing values/censoring/discontinuations
Missing values for an y PK parameters or concentrations will not be imputed and will be treated 
as missing. Below the limit of quantitation (BLQ) values will be set to zero by the bioanal yst 
and will be displ ayed in the listings as zero and flagged. BLQ values will be treated as missing 
for the calculation of the geometric means and geometric CV%.
12.5.3.2 Population pharmacokinetic analy sis
If data permit, a mixed -effects model may be applied to the spartalizumab and/or capmatinib 
concentration -time data to generate post hocestimates of pharmacokinetic parameters using 
NONMEM to characterize spartalizumab and/or capmatinib exposure. If there are sufficient 
data for analysis, the details of the population pharmacokinet ic analyses will be provided in a 
separate reporting and analy sis plan, and the results may be reported in a separate population 
pharmacokinetic report. Data from this and other studies may  be pooled for anal ysis.

Novartis Confidential Page 133
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 134
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 135
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
12.7 Interim analy ses
Not Applicable.
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
No formal statistical power calculations to determine sample size were performed for this study .
In the randomized part approximately  90 subjects will be randomized in a 2:1 ratio in this study ; 
60 subjects in capmatinib and spartalizumab combination arm and 30 subjects in docetaxel arm. 
The primary endpoint of the study  will be overall survival. The sample size is based on 
observing a clinicall y relevant OS in capmatinib and spartalizumab combination arm compared 
to docetaxel arm.
The expected median OS for docetaxel as second -line chemotherapy  is ~8 months 
(Herbst et al 2016, Rittmey eret al2017 ). It is therefore reasonable to assume the median OS of 
~8 months for docetaxel in this study  and 33.3% reduction in hazard rate for overall survival in 
capmatinib plus spartalizumab arm compared to docetaxel arm, which corresponds to an 
increase in median OS by  4 months under the exponential assumption.
Therefore
The HR of OS for capmatinib and spartalizumab combination vs docetaxel i s ≤ 0.667
The upper limit of two sided 80% CI of HR of OS for capmatinib and spartalizumab 
combination vs docetaxel is < 1.0
are considered clinicall y relevant activity  in subjects in the capmatinib and spartalizumab 
combination arm.
Considering a 2:1 randomization, with approximately  60 OS events, the probability  of 
observing clinicall y relevant activity  is 66% when the true HR is 0.60 and the probability  of 
observing clinically  relevant activity  is 24% when the true HR is 0.80. The operating 
characteristi cs are presented in Table 12-2.
With 60 subjects in capmatinib and spartalizumab combination arm and 30 subjects 
in docetaxel 
arm, and assuming a median OS of 8 months in docetaxel arm and a HR of 0.66, 60 OS events 
will be observed in ~18 months with a recruitment rate of 15 subjects per month.

Novartis Confidential Page 136
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 12-2 Operating characteristics
True Median OS of docetaxel vs 
Median OS of capmatinib and 
sparta lizumab True HR Probability  of success (% )
6 vs 8 0.75 32.5
6 vs 10 0.60 65.9
6 vs 12 0.50 86.8
8 vs 8 1.0 5.8
8 vs 10 0.80 24.1
8 vs 12 0.66 50.0
8 vs 13 0.62 62.3
8 vs 14 0.57 72.5
12.8.2 Secondary  endpoint(s)
Not applicable.
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regu lations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the investigator is required to sign a protocol signature page confirming his/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found i n this protocol and to give access to all relevant data and records to Novartis 
monitors, auditors, Novartis Quality Assurance representatives, designated agents of Novartis, 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinic al site is 
requested by a regulatory authority , the investigator must inform Novartis immediately  that this 
request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit, 
LPLV) and finalization of the study  report, the results of this trial will be submitted for 
publication and posted in a publicly  accessi ble database of clinical trial results, such as the 
Novartis clinical trial results website and all required Health Authority  websites (e.g. 
Clinicaltrials.gov, EudraCT etc.).

Novartis Confidential Page 137
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings
13.4 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes.
14 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances, including 
incidental collection, is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemen ted.
14.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are require d for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action, and the IRB/IEC at the study  site should be informed according to 
local regulations.

Novartis Confidential Page 139
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Camidge DR, Bang YJ, Kwak EL, et al (2012) Activity  and safet y of crizotinib in patients 
with AL K-positive non- small -cell lung cancer: updated re sults from a phase 1 study . Lancet 
Oncol. p. 1011-9.
Camidge DR, Sequist LV, Jänne PA, et al (2018) Phase Ib Study  of High -dose Intermittent 
Afatinib in Patients With Advanced Solid Tumors. Clin L ung Cancer.
Cedrés S, Felip E, Cruz C, et al (2018) Activity of HSP90 I nhibiton in a Metastatic Lung 
Cancer Patient With a Germline BRCA1 Mutation. J. Natl. Cancer Inst..
Champiat S, L ambotte O, Barreau E, et al (2016) Management of immune checkpoint 
blockade d ysimmune toxicities: a collaborative position paper. An n. Oncol. p. 559 -74.
Christensen JG, Burrows J, Salgia R (2005) c- Met as a target for human cancer and 
characterization of inhibitors for therapeutic intervention. Cancer Lett. p. 1 -26.
Comprehensive molecular profiling of lung adenocarcinoma (2014). Natur e p. 543-50.
Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via 
the EM algorithm. Journal of the Roy al Statistical Society . Series B (Methodological) p. 1 -38.
Dent S, Zee B, Dancey  J, et al (2001) Application of a new multinomial phase II stopping rule 
using response and earl y progression. J. Clin. Oncol. p. 785-91.
Drilon A (2016) MET Exon 14 Alterations in L ung Cancer: Exon Skipping Extends Half -
Life. Clin. Cancer Res. p. 2832-4.
EMA Guidance (2012) Guideline on the evaluat ion of anticancer medicinal products in man.
Eccles BK, Geldart TR, Laurence VM, et al (2011) Experience of first - and subsequent- line 
systemic therapy  in the treatment of non- small cell lung cancer. Ther Adv Med Oncol p. 163 -
70.
Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid 
tumours: Revised RECI ST guideline (version 1.1). Eur. J. Cancer p. 228
-47.
Ellis S, Carroll KJ, Pemberton K (2008) Anal ysis of duration of response in oncology  trials. 
Contemp Clin Trials p. 456 -65.
Ettinger DS, Akerley  W, Bepler G, et al (2010) Non -small cell lung cancer. J Natl Compr 
Canc Netw p. 740-801.
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics.
Ferlay  J, Soerjomataram I, Dikshit R, et al (2015) Cancer incidence and mortality  worldwide: 
sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer p. E359 -86.
Frampton GM, Ali SM, Rosenzweig M, et al (2015) Activation of MET via diverse exon 14 
splicing alterations occurs in multip le tumor ty pes and confers clinical sensitivity  to MET 
inhibitors. Cancer Discov p. 850-9.
Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br. J. 
Haematol p. 29 -45

Novartis Confidential Page 141
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Liu H, Wu Q, Liu Y, et al (2015) Prognostic significance of β1,6 -N-
acetylglucosamin yltransferase V expression in patients with hepatocellular carcinoma. Jpn. J. 
Clin. Oncol. p. 844-53.
Liu X, Wang Q, Yang G, et al (2011) A novel kinase inhibitor, INCB28060, blocks c -MET-
dependent signaling, neoplastic activities, and cross- talk with EGFR a nd HER -3. Clin. Cancer 
Res. p. 7127-38.
Malvezzi M, Carioli G, Bertuccio P, et al (2017) European cancer mortality predictions for 
the y ear 2017, with focus on lung cancer. Ann. Oncol. p. 1117 -
1123.
Mendenhall MA, Goldman JW (2015) MET -Mutated NSCL C with M ajor Response to 
Crizotinib. J Thorac Oncol p. e33 -4.
Molnarfi N, Benkhoucha M, Funakoshi H, et al (2015) Hepatocy te growth factor: A regulator 
of inflammation and autoimmunity . Autoimmun Rev p. 293 -303.
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Control 
Clin Trials p. 11-8.
Murphy  ST, Alton G, Bailey  S, et al (2011) Discovery  of novel, potent, and selective 
inhibitors of 3- phosphoinositide -dependent kinase (PDK1). J. Med. Chem. p. 8490-500.
NCCN (2018) Clinical Practic e Guidelines in Oncology . Non- Small Cell Lung Cancer.
Neuenschwander B, Capkun -Niggli G, Branson M, et al (2010) Summarizing historical 
information on controls in clinical trials. Clin Trials p. 5-18.
Nguyen KS, Sanford RA, Huberman MS, et al (2012) Patter ns of care for non -small -cell lung 
cancer at an academic institution affiliated with a national cancer institute -designated cancer 
center. J Oncol Pract p. 57-62.
Novello S, Barlesi F, Califano R, et al (2016) Metastatic non- small -cell lung cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann. Oncol. p. v1-v27.
Paik PK, Drilon A, Fan PD, et al (2015) Response to MET inhibitors in patients with stage IV 
lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Ca ncer Discov p. 
842-9.
Park JA, Cheung NV (2017) L imitations and opportunities for immune checkpoint inhibitors 
in pediatric malignancies. Cancer Treat. Rev. p. 22
-33.
Rabin R, de Charro F (2001) EQ- 5D: a measure of health status from the EuroQol Group. 
Ann. Med. p. 337-43.
Reck M, Popat S, Reinmuth N, et al (2014) Metastatic non- small -cell lung cancer (NSCLC): 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann. Oncol. p. 
iii27-39.
Riley  JL, June CH, Blazar BR (2009) Human T regula tory cell as Therapeutic Agents: take a 
billion or so and call me in the morning. Immunit y p. 656 -65.

Novartis Confidential Page 143
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evalu ate the response 
to treatment in solid tumors. J. Natl. Cancer Inst. p. 205-16.
Waqar SN, Morgensztern D, Sehn J (2015) MET Mutation Associated with Responsiveness to 
Crizotinib. J Thorac Oncol p. e29 -31.
Weiss JM, Stinchcombe TE (2013) Second -Line Therapy for Advanced NSCL C. Oncologist 
p. 947-53.
Wolf J, Han J, Nishio M, et al (2017) GEOMETRY Mono
-1: Phase II, Multicenter Study  of 
MET I nhibitor Capmatinib (INC280) in EGFR Wt, MET- Dysregulated Advanced NSCLC p. 
poster.
Wu CFJ (1983) On the convergence prope rties of the EM algorithm p. 95 -103.
Zhou C, Wu YL, Chen G, et al (2011) Erlotinib versus chemotherapy  as first -line treatment 
for patients with advanced EGFR mutation- positive non- small -cell lung cancer (OPTIMAL, 
CTONG -0802): a multicentre, open -label, ra ndomised, phase 3 study . Lancet Oncol. p. 735 -
42.
de Marinis F, Grossi F (2008) Clinical evidence for second -and third -line treatment options 
in advanced non -small cell lung cancer. Oncologist p. 14-20.

Novartis Confidential Page 144
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16 Appendices
16.1 Appendix 1: Guidelines for Response, Duration of Overall 
Response,  TTF, TTP, Progression-Free Survival, and Overall 
Survival  (based on RECIST 1.1)
Document type: TA Specific Guideline
Document status: Version 3.2: February 11, 2016
Version 3.1: November 29, 2011
Version 3: October 19, 2009 Version 2: January 18, 2007 Version 
1: December 13, 2002
Release date: 11-Feb-2016
Authors (Version 3.2): Kalyanee Appanna, Bharani Dharan, Steven Green, Randi 
Isaacs, Susan Schnakenberg, Jessica Wang, Cristian Massacesi
Authors (Version 3.1): Kalyane e Appanna, Bee Chen, Bharani Dharan, Steven Green, 
Diana Porshneva, Kannan Subramanian, Michel Gauthier, Nilima 
Patel, Sandra Chica, Aruna Vattikola, Emmanuel Zuber
Authors (Version 3): Kalyanee Appanna, Steven Green, Samit Hirawat, David 
Lebwohl, Cristian Massacesi, Liza Morgan, Haren Rupani, Jeffrey  
Stuart, Aruna Vattikola, Gabriele von Ingersleben
Authors (Version 2): Renaud Capdeville, Bee Chen, Insa Gathmann, Steven Green, 
David Lebwohl, Michael Murawsk y, Lixia W ang, Emmanuel Zuber
Authors (V ersion 1): Insa Gathmann, W illiam  Mietlowski, Beate Kiese, Kathy Mellars, 
Renaud Capdeville, Margaret Dugan
16.1.1 Introduction
The purpose of this document is to provide the working definitions and rules necessary  for a 
consistent and efficient analy sis of efficacy  for oncology  studies in solid tumors. This document 
is based on the RECI ST criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009).
The efficacy  assessments described in Section 16.1.2 and the definition of best response in 
Section
16.1.3.1 are based on the RECI ST 1.1 criteria but also give more detailed instructions 
and rules for determination of best response. Section 16.1.3.2 is summarizing the “time to event” 
variables and rules which are mainl y derived from internal discussions and regulatory 
consultations, as the RECI ST criteria do not define these variables in detail. Section 16.1.4 of 
this guideline describes data handling and programming rules. This section is to be referred to 
in the SAP (Statistical Analy sis Plan) to provide f urther details needed for programming.
16.1.2 Efficacy  assessments
Tumor evaluations are made based on RECIST criteria (Therasse et al 2000), and revised 
RECI ST guidelines (version 1.1) ( Eisenhauer et
al2009 ).

Novartis Confidential Page 145
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.1.2.1 Definitions
16.1.2.1.1 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
tobe made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease -the presence of at least one measurable nodal or non -nodal lesion. If the 
measurable disease is restricted to a solitary  lesion, its neoplastic nature should be confirmed 
by cytology /histology .
For patients without measurable disease see Section 16.1.3.2.9.
Measurable lesions (both nodal and non -nodal)
Measurable non
-nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 1 0mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes ≥ 15 mm in short axis can be 
considered for selection as target lesions. Ly mph nodes measuring ≥ 10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.
Cystic lesions:
Lesion s that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no septations, 
and low CT density  [water -like] content) should not be considered as malignant lesi ons 
(neither measurable nor non -measurable) since they  are, b y definition, simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as measurable 
lesions, if they  meet the definition of measurability  described above. However, if 
noncy stic lesions are present in the same patient, these are preferred for selection as target 
lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI  or pathological ly mph nodes with ≥ 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly  
identified by  physical exam that is not measurable by  reproducible imaging techniques.
16.1.2.1.2 Eligibility based on measurable disease
If no measurable lesions are identified at baseline, the patient may  be allowed to enter the study 
in some situations. Guidance on how patients with just non -measurable disease at baseline will 

Novartis Confidential Page 146
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
be evaluated for response and also handled in the statistical analy ses is given in 
Section 16.1.3.2.8.
16.1.2.2 Methods of tumor measur ement -general guidelines
In this document, the term “contrast” refers to intravenous (i.v.) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm). All baseli ne 
evaluations should be performed as closely
 as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.
Imaging- based evaluation is preferred to evaluation by clinical examination when both 
methods have be en used to assess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced C T of chest, abdomen and pelvis should preferably be performed 
using a 5 mm slice thickness with a contiguous reconstruction algorithm. CT/MRI  scan 
slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. 
If, at baseline, a p atient is known to have a medical contraindication to CT contrast or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow -up: a non -contrast CT of chest (MRI  not recommended due to 
respiratory  artifacts) plus contrast -enhanced MRI of abdomen and pelvis.
A change in methodology  can be defined as either a change in contrast use (e.g. keeping 
the same technique, like CT, but switching from with to without contrast use or vice -versa, 
regardless of th e justification for the change) or a major change in technique (e.g. from CT 
to MRI , or vice -versa), or a change in an y other imaging modalit y. A change from 
conventional to spiral CT or vice versa will not constitute a major “change in method” for 
the pur poses of response assessment. A change in methodology  will result by  default in a 
UNK overall lesion response assessment as per Novartis calculated response. However, 
another response assessment than the Novartis calculated UNK response may be accepted 
from the investigator or the central blinded reviewer if a definitive response assessment 
can be justified, based on the available information.
FDG -PET: can complement CT scans in assessing progression (particularl y possible for 
‘new’ disease). New lesions on the basis of FDG -PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If new disease is indicated by a positive PET scan but is not confirmed by  CT (or some 
other conventional technique such as MRI) at the same assessment, then follow -up 
assessments by  CT will be needed to determine if there is trul y progression occurring at 
that site. I n all cases PD will be the date of confirmation of new disease by CT (or some 
other conventional technique such as MRI) rather than the date of the positive PET scan. 
If there is a positive PET scan without an y confirmed progression at that site by CT, then a 
PD cannot be assigned.

Novartis Confidential Page 147
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by aerated lung. However, CT is preferable.
Physical exams: Evaluation of lesions by  physical examination is accepted when lesions 
are superficial, with at least 10mm size, and can be assesse d using calipers.
Ultrasound: When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions, unless pre -specified by  the 
protocol. I t is, however, a possible alternative to clinical mea surements of superficial 
palpable l ymph nodes, subcutaneous lesions and thy roid nodules. US might also be useful 
to confirm the complete disappearance of superficial lesions usually  assessed by  clinical 
examination.
Endoscopy  and laparoscopy : The utilizati on of endoscopy and laparoscop y for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Theref ore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor m arkers: Tumor markers alone cannot be used to assess response. However, some 
disease specific and more validated tumor markers (e.g. CA- 125 for ovarian cancer, PSA 
for prostate cancer, alpha-FP, LDH and Beta-hCG for testicular cancer) can be integrated 
as non-target disease. If markers are initially  above the upper normal limit they  must 
normalize for a patient to be considered in complete clinical response when all lesions 
have disappeared.
Cytology and histology
: Cytology  and histology  can be used to diff erentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of an y effusion that appe ars or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable di sease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination: Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules a nd palpable l ymph nodes). For the case of skin lesions, 
documentation by  color photography , including a ruler to estimate the size of the lesion, is 
recommended.
If the protocol is considering specific sy mptoms as objective signs of clinical progression, e .g. 
bone pain or GI bleeding, then the criteria for clear worsening of these non-measurable ‘lesions’ 
indicative of PD should be clearl y specified in the protocol. In that case, the protocol should 
clearl y specify  that additional criteria are used to compl ement RECI ST criteria.

Novartis Confidential Page 148
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.1.2.3 Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non -target lesions:
Target lesions: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be s elected on the basis of their size (lesions with the longest diameter) and 
their suitability  for accurate repeated measurements (either by  imaging techniques or 
clinically ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  methods for which slice 
thickness is not applicable (e.g. clinical examination, photograph y) should be at least 10 
mm in longest diameter. See Section 16.1.2.1.1.
Nodal target : See 
Section 16.1.2.1.1.
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be ca
lculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by which to characterize the objective tumor response. Each 
target lesion identified at baseline must be followed at each subsequent evalu ation and 
documented on eCRF.
Non-target lesions : All other lesions are considered non- target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throug hout the study ; measurements of these lesions 
are not required. Multiple non -
target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
16.1.2.4 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study ). Ateach assessment response is evaluated first separately 
for the target (Table 16-1) and non - target lesions (Table 16-2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 16-3) as well as the presence or absence of new lesions.
If tumor markers are used as non -target lesions to evaluate response, please specify  criteria for 
CR, SD and PD in the protocol, e.g. CR='Normalization of tumor marker level', PD='Elevation 
of tumor markers to certain level', SD='Not qualify ing for CR or PD'. These criteria are 
indication and study  specific. In that case, the proto col should clearly specify  that additional 
criteria are used to complement RECI ST criteria.
16.1.2.4.1 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non-target 

Novartis Confidential Page 149
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
lesions as well as new lesions that are detected. At the assessment visit all of the separate lesion 
evaluation data are examined by the investigator in order to derive the overall visit respons e. 
Therefore all such data applicable to a particular visit should be associated with the same 
assessment number.
Non-nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as 0 mm.
Measurements of non-nodal target lesions that become 5 mm or less in longest diameter are 
likely  to be n on-reproducible. Therefore, it is recommended to report a default value of 5 mm, 
instead of the actual measurement. This 
default value is derived from the 5 mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measureme nt 
should be given for all lesions larger than 5 mm in longest diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated.
Nodal lesions
A nodal lesion < 10 mm in size by short axis is considered normal. Lym ph nodes are not 
expected to disappear completely , so a “non -zero size” will alway s persist.
Measurements of nodal target lesions that become 5 mm or less in short axis are likely  to be 
non-reproducible. Therefore, it is recommended to report a default value of 5 mm, instead of 
the actual measurement. This default value is derived from the 5 mm CT slice thickness 
(but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to < 10 mm in its short axis, it will be considered 
normal for response purpose determination. The lymph node measurements will continue to be 
recorded to allow the values to be included in the sum of diameters fortarget lesions, which 
may be required subsequently  for response determination.
16.1.2.4.2 Determination of target lesion response
Table 16-1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response 
(CR):Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.

Novartis Confidential Page 150
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Response Criteria Evaluation of target lesions
Progressive Disease 
(PD):At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as reference the smallest sum of diameter of all target lesions recorded at 
or after baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm 2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions 
which would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3
1. SOD for CR may not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non-nodal target lesions are still not present and all 
nodal lesions are <10 mm in size. In this case, the target lesion response is CR
3. In exceptional circumstances an UNK response due to change in method could be over -ruled by the 
investigator or central reviewer using expert judgment based on the available information (see Notes on target 
lesion response and methodology change in Section 16.1.2.2 ).
Notes on target lesion response
Reappearance of lesions: I f the lesion appears at the same anatomical location where a target 
lesion had previousl y dis appeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/ra diologist has to decide between the following 
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented in Table 16-1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diam
eters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at 
or after baseline with at least 5 mm increas e in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, please refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements: In cases where measurements are missing for one or more tar get 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100 mm at baseline and the sum of diameters for 3 of those lesions at a pos t-baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal lesion decrease to normal size: When nodal d isease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.

Novartis Confidential Page 151
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Lesions split: I n some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (l ong axis - non- nodal lesion, short axis -nodal lesions) 
of the two split lesions should be added together and the sum recorded in the diameter 
field on the case report form under the original lesion number. This value will be included 
in the sum of diameters when deriving target lesion response. The individual split lesions 
will not be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced: Conversel y, it is also possible that two or more lesions which were 
distin ctly separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such t hat they  
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the case report form, the diameter of the “merged lesion” 
should be recorded for the size of one of the original lesions while a size of “0 mm” 
should be entered for the remaining lesion numbers which have coalesced.
The measurements for nodal lesions , even if < 10 mm in size, will contribute to t he 
calculation of target lesion response in the usual way  with slight modifications.
Since lesions < 10 mm are considered normal, a CR for target lesion response should be 
assigned when all nodal target lesions shrink to < 10 mm and all non -nodal target le sions 
have disappeared.
Once a CR target lesion response has been assigned a CR will continue to be appropriate 
(in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion r esponse if 
either a non
-nodal target lesion “reappears” or if any  single nodal lesion is at least 10 mm 
and there is at least 20% increase in sum of the diameters of all nodal target lesions 
relative to nadir with at least 5 mm increase in the absolute sum of the diameters.
A change in method for the evaluation of one or more lesions will usually lead to an UNK 
target lesion response unless there is progression indicated b y the remaining lesions which 
have been evaluated b y the same method. In exceptional c ircumstances an investigator or 
central reviewer might over -rule this assignment to put a non -UNK response using expert 
judgment based on the available information. E.g. a change to a more sensitive method 
might indicate some tumor shrinkage of target lesi ons and definitel y rule out progression 
in which case the investigator might assign an SD target lesion response; however, this 
should be done with caution and conservatively  as the response categories have well 
defined criteria.
16.1.2.4.3 Determination of non-target lesion response
Table 16-2 Response criteria for non -target lesions
Response Criteria Evaluation of non -target lesions
Complete Response 
(CR):Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease 
(PD):Unequivocal progression of existing non -target lesions.1

Novartis Confidential Page 152
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Response Criteria Evaluation of non -target lesions
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK): Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than 
baseline2.
1. The assignment of PD solely based on change in non -target lesions in light of target lesion response of CR, 
PR or SD should be exceptional. In such circumstances, the opinion of the investigator or central reviewer does 
prevail.
2. It is recommended that the investigator and/or central reviewer should use expert judgment to assign a Non-
UNK response wherever possible (see notes section for more details)
Notes on non -target lesion response
The investigator and/or central reviewer can use expert judgment to assign a non -UNK 
response wherever possible, even where lesions have not been fully  assessed or a different 
method has been used. In many  of these situations it may  still be possible to identify  
equivocal progression (PD) or definitively  rule this out (non- CR/Non -PD) based on the 
available information. In the specific case where a m ore sensitive method has been used 
indicating the absence of any  non-target lesions, a CR response can also be assigned.
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non- target nodal lesions 
returned to normal size (i.e. < 10 mm). If an y of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. ≥ 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless there is unequivocal pr ogression of the non-target lesions (in which 
case response is PD) or it is not possible to determine whether there is unequivocal 
progression (in which case response is UNK).
Unequivocal progression: To achieve “unequivocal progression” on the basis of no n-target 
disease there must be an overall level of substantial worsening in non -target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has 
increased sufficientl y to merit discontinuation of therap y. A modest 
“increase” in the size 
of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable 
disease at baseline. If there is uneq uivocal progression of non- target lesion(s), then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 16.1.2.4.2 for assigning PD following a CR for 
the non- target lesion response in the presence of non- target lesions nodal lesions should be 
applied.
16.1.2.4.4 New lesions
The appearance of a new lesion is alway s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 

Novartis Confidential Page 153
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
there is definitely a new lesion, then progre ssion should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessment 
(see Section 16.1.2.5).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 
≥10 mm for the first time in the study  plus 5 
mm absolute increase. FDG -PET : can complement CT scans in assessing progression 
(partic ularly possible for ‘new’ disease). See Section 16.1.2.2.
16.1.2.5 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non-target lesion response and presence of new lesions as shown below in Table 16-3.
Table 16
-3 Overall lesion response at each assessment
Target lesions Non-target lesions New Lesions Overall lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 16.1.2.4
If there are no baseline scans available at all, then the overall lesion response at each assessment 
should be considered Unknown (UNK).
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the CR.
16.1.3 Efficacy  definitions
The following definitions primarily relate to patients who have measurable disease at baseline. 
Section 16.1.3.2.8 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to appl y the same concepts.
16.1.3.1 Best overall response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 

Novartis Confidential Page 154
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if any assessments occur after treatment wi thdrawal the protocol 
should specificall y describe if these will be included in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive analyses. As a default, any  assessments ta ken more than 30 day s after the last dose 
of study  treatment will not be included in the best overall response derivation. If any alternative 
cancer therapy  is taken while on study  any subsequent assessments would ordinarily  be 
excluded from the best overa ll response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requ ires confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by repeat assessments that should be performed not < 4 weeks after the 
criteria for response are first met.
Longer intervals may  also be appropriate. However, this mu st be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials intended to support accelerated approval, confirmation is needed
For all other trials, confirmation of r esponse may  be considered optional.
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 7 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression ≤ 12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than 6 weeks or early  progression within the first 12 weeks)
The time durations specified in the SD/PD/UNK definitions above are defaults based on a 6 
week tumor assessment frequency . However these may be modified for specific indications 
which are more or less aggressive. In addition, it is envisaged that the time duration may also 
take into account assessment windows. E.g. if the assessment occurs every 6 weeks with a time 
window of +/ -7 days, a BOR of SD would require a SD or better response longer than 5 weeks 
after randomization/start of treatment.

Novartis Confidential Page 155
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the st atus would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (≥ 30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not≥ 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR a ssignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD - PR -PR -PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (20 0 mm to 160 mm) at the following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note: these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided
from different sources:
Investigator overall lesion response
Novartis calculated overall lesion response (based on measurements from Investigator )
The primary  analysis of the best overall response will be based on the sequence of 
investigator//calculated (investigator) overall lesion responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is al so referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD. The objective of this endpoint is to summarize patients with signs of “activit y” 
defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.

Novartis Confidential Page 156
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Clinical benefit rate (CBR) is the proportion of patients with a best overall response of CR or 
PR , or an overall lesion response of SD or Non-CR/Non -PD which lasts for a minimum time 
duration (with a default of at least 24 weeks in breast cancer studies). This endpoint measures 
signs of activity  taking into account duration of disease stabilization.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations forwhich these will be calculated. The time point for 
EPR is study  specific. EPR is used for the multinomial designs of Dent etal2001 and counts 
all patients who at the specified assessment (in this example the assessme nt would be at 8 weeks 
± window) do not have an overall lesion response of SD, PR or CR. Patients with an unknown 
(UNK) assessment at that time point and no PD before, will not be counted as early progressors 
in the analysis but may be included in the deno minator of the EPR rate, depending on the 
analysis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included inthe denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations based on an ITT approach).
16.1.3.2 Time to event variables
16.1.3.2.1 Progression- free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression
-free survival is censored at the date of last adequate 
tumor assessment.
PFS rate at x weeks is an additional measure used to quantify PFS endpoint. It is recommended 
that a Kaplan- Meier estimate is used to assess this endpoint.
16.1.3.2.2 Overall survival
All patients should be followed until death or until patient has had adequate follow -up time as 
specified in the protocol whichever comes first. The follow -up data should contain the date the 
patient was last seen alive / last known date patient alive, the date of death and the reason of 
death (“Stud y indication” or “Other ”).
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death due to an y cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive.

Novartis Confidential Page 157
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.1.3.2.3 Time to progre ssion
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.
Time toprogression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor 
assessment.
16.1.3.2.4 PFS2
A recent EMA guidance (EMA Guidance 2012 )recommends a substitute end point 
intermediate to PFS and OS called PFS2, a surrogate for OS when OS cannot be measured 
reliably , which assesses the impact of the experimental therap y on next- line treatment. The main 
purpose of this endpoint is to assess long term maintenance strategies, particularly  of 
resensitizing agents and where it is necessary to examine the overall “field of influenc e”.
PFS2, which could be termed PFS deferred, PFS delay ed, tandem PFS, or PFS version 2.0, is 
the time from date of randomization/start of treatment to the date of event defined as the first 
documented progression on next
-line treatment or death from any cause. The censoring rules 
for this endpoint will incorporate the same principles as those considered for PFS in this 
document, and in addition may involve other considerations which will need to be detailed in 
the protocol.
Please note that data collection for the PFS2 is limited to the date of progression and not specific 
read of the tumor assessments.
It is strongl y recommended that the teams consult regulatory  agencies for scientific advice given 
the limited experience with the use of this endpoint in regulatory  setting in light of 
methodological issues with respect to censoring foreseen.
16.1.3.2.5 Time to treatment failure
This endpoint is often appropriate in studies of advanced disease where early discontinuation is 
typicall y related to intolerance of the study  drug. In some protocols, time to treatment failure 
may be considered as a sensitivity  analysis for time to progression. The list of discontinuation 
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the st udy or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.
16.1.3.2.6 Duration of response
The analy sis of the following variables should be performed with much caution when restricted 
to responders since treatment bias could have been introduced. There have been reports where 

Novartis Confidential Page 158
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
a treatment with a significantly  higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve 
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly  in good risk patients only. This is described in more detail by 
Morgan 1988.
It is recommended that an analysis of all patients (both 
responders and non-responders) be 
performe d whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by evaluating the results in the context of the observed response rates... If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques described in Ellis et
al2008. It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed res
ponse.
For summary  statistics on “responders” only the following definitions are appropriate. (Specifi c 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR) : For patients with a CR or PR (which may have to 
be confirmed) the start date is the date of first documented response (CR or PR) and the end 
date and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.
Duration of overall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
16.1.3.2.7 Time to respo nse
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study  and its importance. Where the response nee ds to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response inSection 16.1.3.2.6. It is recommended that 
an anal ysis of all patients (both responders and non -responders) be performed whether or not a 
“responders onl y” descriptive analysis 
is presented. Where an inferential statistical comparison 

Novartis Confidential Page 159
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
is required, then all patients should definitely  be included in the analysis to ensure the statistical 
test is valid. For anal ysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options:
at maximum follow -up (i.e. FPFV to L PLV used for the anal ysis) for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  mak es use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
atlast adequate tumor assessment date otherwise. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endpoint described for the time to overall response endpoint.
16.1.3.2.8 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion response is progressio n -the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.
In the calculation of the assessment date for time to event variables, any unscheduled 
assessment should be treated similarly  to other evaluation s.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates whic h are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was m ade before an event or a censoring reason 

Novartis Confidential Page 160
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of tr eatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window for the next 
tumor assessment as per protocol (see Section 16.1.3.2.8).
Example (if protocol defined 
schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive f rom the survival follow -up page is 
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact date.
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
16.1.3.2.9 Handling of patients with non -measurable disease only at baseline
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by design (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients 
with non-
measurable disease is derived slightly  differently  according to 
Table 16-4.
Table 16
-4 Overall lesion response at each assessm ent: patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 16.1.2.4 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 

Novartis Confidential Page 161
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
only non- measurable disease may  be highlighted in an appropriate fashi on e.g. in particular by 
display ing the specific numbers with the non- CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.
For ORR it is recommended that the main ITT analy sis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all other patients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non -measurable disease at baseline, with possible sensitivity analyses which 
exclud e these particular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non
-measurable 
disease.
16.1.3.2.10 Sensitivity analyses
This section outlines the possible event and censoring dates for progression, as well as addresses 
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignored if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary  analysis in detail with respect to the definition of event and censoring dates and also 
include a description of one or more sensitivity  analy ses to be performed.
Based on definitions outlined in Section 16.1.3.2.7 , and using the draft FDA guideline on 
endpoints 
(FDA Guidelines: 2005 Clinical Trial Endpoints fortheApproval ofCancer Drugs andBiolog
ics) as a reference, the following anal yses can be considered:
Table 16-5 Option s for event dates used in PFS, TTP, duration of response
SituationOptions for end -date (progression or censoring)1
(1) = default unless specified differently  in the 
protocol or RAP Outcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before 
next scheduled assessment(1) Date of progression 
(2) Date of next scheduled assessment2Progressed
Progressed
C
1Progression or death after 
exactly  one missing 
assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C
2Progression or death after 
two or more missing 
assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation 
due to ‘Disease progression’ 
without documented 
progression, i.e. clinical 
progression based on 
investigator claim(1) Ignore clinical progression and follow situations 
above
(2) Date of discontinuation (visit date at which clinical 
progression was determined)As per above 
situations
Progressed

Novartis Confidential Page 162
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
SituationOptions for end -date (progression or censoring)1
(1) = default unless specified differently  in the 
protocol or RAP Outcome
F New anticancer therapy 
given(1) Ignore the new anticancer therapy and follow 
situations above (ITT approach)
(2) Date of last adequate assessment prior to new 
anticancer therapy
(3) Date of secondary anti -cancer therapy
(4) Date of secondary anti -cancer therapyAs per above 
situations
Censored
Censored
Event
G Deaths due to reason other 
than deterioration of ‘Study 
indication’(1) Date of last adequate assessment Censored (only 
TTP and duration 
of response)
1. Definitions can be found in Section 16.1.3.2.7 .
2. After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in 
Section 16.1.3.2.7 .
3. The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS ev ent at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case of only  one missing 
assessment.
(C2) censoring at the date of the last ade quate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitiv ity analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression : By default, opti on (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) may 
be used as sensitivity  analy sis. If progression is claimed based on clinical deterioration inste ad 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1) (ITT) is the recommended approach; events 
documented after the initiation of new cancer therap y will be considered for the primary 
analysis i.e. progressions and deaths documented after the initiati on of new cancer therapy 
would be included as events. This will require continued follow -up for progression after the 
start of the new cancer therapy . In such cases, it is recommended that an additional sensitivity  
analysis be performed by censoring at las t adequate assessment prior to initiation of new cancer 
therap y.
Option (2), i.e. censoring at last adequate assessment may be used as a sensitivity  analy sis. If a 
high censoring rate due to start of new cancer therapy  is expected, a window of approximatel y 

Novartis Confidential Page 163
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
8 weeks performed after the start of new cancer therap y can be used to calculate the date of the 
event or censoring. This should be clearl y specified in the anal ysis plan.
In some specific settings, local treatments (e.g. radiation/surgery ) may not be considered as 
cancer therapies for assessment of event/censoring in PFS/TTP/DoR analysis. For example, 
palliative radiotherap y given in the trial for analgesic purposes or for lytic lesions at risk of 
fracture will not be considered as cancer therap y for the assessment of BOR and PFS analyses. 
The protocol should clearly  state the local treatments which are not considered as antineoplastic 
therapies in the PFS/TTP/DoR analy sis.
The protocol should state that tumor assessments will be performed every  x  w eeks until 
radiological progression irrespective of initiation of new antineoplastic therapy . It is strongl y 
recommended that a tumor assessment is performed before the patient is switched to a new 
cancer therap y.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -
up schedules for tumor assessments, e.g. by assigning the dates for censoring and 
events only  at scheduled visit dates. The latter could be han dled b y replacing in Table 16-5 the 
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investig ators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease 
area and have to be specified in the 
protocol or RAP documentation.
16.1.4 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
16.1.4.1 Study/project specific decisions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
16.1.4.2 End of treatment phase completion
Patients may voluntarily withdraw from the study  treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -

Novartis Confidential Page 164
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
up, the investigator or designee should show "due diligence" by documenting in the source 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 7 days of the last 
study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Progressive disease
Study  terminated by  the sponsor
Non-compliant with study  treatment
No longer requires treatment
Treatment duration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
Death is a reason which “ must ” lead to discontinuation of patient from trial.
16.1.4.3 End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment 
and post -treatment evaluations but prior to collecting survival follow-up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressive disease
Study  terminated by  the sponsor
16.1.4.4 Medical validation of programmed overall lesion response
In order to be as objective aspossible the RECI ST programmed calculated response assessment 
is very strict regarding measurement methods (i.e. any assessment with more or less sensitive 
method than the one used to assess the lesion at baseline is considered UNK) and not available 

Novartis Confidential Page 165
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
evaluations (i.e. if any target or non-target lesion was not evaluated the whole overall lesion 
response is UNK unless remaining lesions qualified for PD). This contrasts with the slightly  
more flexible guidance given to local investigators (and to the central reviewers) to use expert 
judgment in determining response in these type of situations, and therefore as a consequence 
discrepancies between the different sources of response assessment often arise. To ensure the 
quality  of response assessments from the local site and/or the central reviewer, the responses 
may be re -evaluated by clinicians (based on local investigator data recorded in eCRF or based 
on central reviewer data entered in the database) at Novartis or external experts. In addition, 
data review reports will be available to identify  assessments for which the investigators’ or 
central reader’s opinion does not match the programmed calculated response based on RECIST 
criteria. This may be queried for clarification. However, the investigator or central reader’s 
response assessment will never be overruled.
If Novartis elect to invalidate an overall lesion response as evaluated by the investigator or 
central reader upon internal or external review of the data, the calculated overall lesion response 
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the 
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
RECI ST criteria should be carefull y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
16.1.4.5 Programming rules
The following should be used for programming of efficacy  results:
16.1.4.5.1 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
16.1.4.5.2 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT sca n) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined inSection 16.1.3.2.8). If all measurement dates have 
no day  recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.

Novartis Confidential Page 166
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.1.4.5.3 Incomplete dates for last known date patient alive or de ath
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
16.1.4.5.4 Non-target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non
-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
16.1.4.5.5 Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
16.1.4.5.6 Censoring re ason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the f ollowing censoring reasons are possible:
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer avai lable*
Event documented after two or more missing tumor assessments (optional, see Table 16-5)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section 16.1.3.2.7. This reason is applicable when 
adequate evaluations are missing for a specified period 
prior to data cut-off (or prior to any 
other censoring reason) correspond ing to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progression after treatment completion or when onl y UNK assessments are 
available just prior to data cut -off.
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -

Novartis Confidential Page 167
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to cen sor in case of no baseline assessment.

Novartis Confidential Page 168
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 169
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 170
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 171
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 172
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 173
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 174
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 175
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 176
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 177
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 178
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 179
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 180
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 181
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201

Novartis Confidential Page 182
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.3 Append ix 3: Safety  follow -up diagram
Figure 16-1 Safety  follo w-up diagram for run -in and arm 1
conMeds: concomitant medications

Novartis Confidential Page 183
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.4 Appendix 4: Bay esian logistic regression model (BLRM)
This appendix provides details of the statistical model, the derivation of prior distributions from 
historical data, and the results of the Bayesian analy ses and respective dosing decisions for 
some hy pothetical data scenarios.
16.4.1 Statistical model
The statistical model comprises single -agent toxicity  parts, which allow the incorporation of 
single -agent toxicity  data, and an interaction part.
16.4.1.1 Single agent parts
LetπINC(dINC) be the risk of DLT for capmatinib given as a single agent at dose dINC; πPDR(dPDR) 
be the risk of DL T for spartalizumab given as a single agent at dose dPDR. Single agent toxicit y 
is modelled using logistic regression for the risk of DLT against log -dose:
Capmatinib: logit(πINC(dINC)) = log(αINC) + βINC log(dINC/ 400)
Spartalizu mab: logit(πPDR(dPDR)) = log(αPDR) + βPDRlog(dPDR/ 400)
where 400mg is used to scale the doses of both capmatinib and spartalizumab. Hence, αINCand
αPDR (>0) are the single -agent odds of a DLT at 400mg (BID, total daily  dose 800mg) and 
400mg (q4w), res pectively ; and βINCand βPDR(>0) are the increase in the log -odds of a DLT b y 
a unit increase in log- dose for capmatinib and spartalizumab respectively .
The statistical model comprises single -agent toxicity  parts, which allow the incorporation of 
single -agent toxicity  data, and an interaction part.
16.4.1.2 Interaction
Under no interaction, the risk of a DLT at dose dINCof capmatinib and dose dPDRof 
spartalizumab is:
π0comb(dINC, dPDR) = 1 -(1 - πINC(dINC)) (1 - πPDR (dPDR))
To allow for interaction between capmatinib and spartalizumab, an odds multiplier is introduced. 
The risk of DLT for combination dose (dINC, dPDR)is then given b y:
odds (πcomb(dINC, dPDR)) = exp (η x dINC/ 400 x dPDR/ 400) x odds (π 0comb(dINC, dPDR)),
where odds(π) = π / (1 -π); and ηis the log-odds ratio between the interaction and no interaction 
model at the reference doses. Here η = 0corresponds to no interaction, with η > 0 and η < 0
representing s ynergistic and antagonistic toxicity  respectivel y.
16.4.2 Prior specifications
The Bayesian approach requires the specification of prior distributions for all model parameters, 
which include the single agent parameters log(αINC), log(βINC)for capmatinib, log(αPDR), 
log(βPDR)for spartalizumab, and the interaction parameter η.A meta -analytic-predictive (MAP) 
approach was used to derive the prior distribution for the single -agent model parameters based 
upon available DLT data.

Novartis Confidential Page 184
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
16.4.2.1 Prior distribution for the logistic parameters
Description of the meta-analytic-predictive (MAP) approach
The aim of the MAP approach is to derive a prior distribution for the logistic parameters 
(log(α*),log(β*)) of the new trial using DLT data from historical studies.
Let rdsand ndsbe the number of patients with a DLT, and the total number of patients at dose d
in historical trial s(s= 1, ... , S). The corresponding probability of a DLT is πds. The model 
specifications for the derivation of the MAP prior are as follows:
rds | πds  Bin (πds, nds)
logit(πds) = log(αs) + βslog(d / d ref)
(log(αs), log(βs)) | μ, Ψ~ BVN (μ, Ψ), s = 1, ... , S
(log(α*), log(β*)) | μ, Ψ~ BVN (μ, Ψ)
where dref is the reference dose. The parameters μ = (μ1, μ2) and Ψ are the mean and between-
trial covariance matrix for the logistic parameters, the latter with standard deviations τ1, τ2, and 
correlation ρ. The parameters τ1 and τ2quantify the degree of between trial heterogeneity. The 
following priors will be used for these parameters:
!normal priors for μ1and μ2,
!log-normal priors for τ1and τ2, and
!a uniform prior for ρ.
The MAP prior for single-agent model parameters in the new trial, (log( α*), log(β*)), is the 
predictive distribution
(log(α*), log(β*)) | (rds, nds : s = 1, ... , S )
Since the predictive distribution is not available analytically, MCMC is used to simulate values 
from this distribution. This is implemented using JAGS version 3.4.0. The sample from this distribution is then approximated by a mixture of bivariate normal (BVN) distributions. BVN mixtures with increasing numbers of mixture components are fitted to the sample using the expectation-maximization (EM) algorithm ( Dempster et al 1977 , Wu CFJ 1983 ). The optimal 
number of components of the mixture is then identified using the Akaike information criterion (Akaike 1974 ).
Single agent capmatinib
For the MAP model for capmatinib, reference dose d
ref= 400 mg (BID) is used, and data from 
S = 2 historical studies are available.
Weakly informative normal priors are assumed for μ1and μ2, with means corresponding to an 
assumed 10% risk of DLT at the reference dose of 400 mg, and a doubling in dose leading to a doubling in the odds of the risk of a DLT, respectively. Priors for τ
1and τ2 are assigned such 
that (1) their medians correspond to moderate between trial heterogeneity, and (2) their uncertainty (95% prior interval) cover plausible between-trial standard deviations (Neuenschwander et al 2010 ).
The prior distributions for the model used for deriving the MAP priors are specified in 
Table 16-9 .
Novartis Confidential Page 185
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Table 16-9 Prior distributions for the parameters of the MA P model used to derive 
the prior for the single -agent capmatinib model parameters
Parameter Prior distribution
μ1 N(mean = logit(0.1), sd = 2)
μ2 N(mean = 0, sd=0.001)
τ1 log-normal(mean = 0.25, sd = log(2)/1.96)
τ2 log-normal(mean = 0.125, sd = log(2)/1.96)
ρ uniform(-1,1)
Historical data
The dose-DLT data of capmatinib single agent in tablet formulation and BID dosing schedule 
from the following clinical studies are considered as the relevant information (Table 16-10) and 
used to derive the prior distribution for the BL RM parameters (log(αINC), log (βINC)).
CINC280X2102: a Phase I study  on adult patients with MET dependent advanced solid 
tumors.
CINC280X1101: a Phase I study  of capmatinib in Japanese adult patients with advanced 
solid tumors.
The DLT observation window was 4 weeks in both trials. The 
AE records of the patients did 
not show any  events that had occurred during the 5th and 6th weeks post -baseline andmet the 
specified DLT criteria.
Table 16-10 Historical dose -DLT data from capmatinib single agent clinical studies
Dose in BID (mg) Number of evaluable patients Number of DLTs
CINC280X2102
400 4 0
CINC280X1101
200 3 0
400 10 1
Single agent spartalizumab
The prior distribution of spartalizumab single agent BLRM model parameters (log(αPDR), log 
(βPDR))is a mixture of two components: a MAP prior, and a robustification component, used to 
allow for a dose/toxicity  relationship for spartalizumab in combination that differs substantially 
from that in single agent. The components form a mixture prior with respective weights (0.95, 
0.05).
Component 1:
For the MAP model for sp artalizumab, reference dose dref= mg (q4w) is used, and data from S 
= 1 historical studies is available.
Weakly  informative normal priors are assumed for μ1and μ 2, with means corresponding to an 
assumed 10% risk of DLT at the reference dose of 400 mg, an d a doubling in dose leading to a 
doubling in the odds of the risk of a DLT, respectively . Priors for τ1and τ2are assigned such 
that (1) their medians correspond to moderate between trial heterogeneity , and (2) their 
uncertaint y (95% prior interval) cove r plausible between -trial standard deviations 
(Neuenschwander et al 2010 ).

Novartis Confidential Page 186
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
The prior distributions for the model used for deriving the MAP priors are specified in 
Table 16-11.
Table 16
-11 Prior distributions for the parameters of the MA P model used to derive 
the prior for the single -agent spartalizumab model parameters
Parameter Prior distribution
μ1 N(mean = logit(0.1), sd = 2)
μ2 N(mean = 0, sd=0.001)
τ1 log-normal(mean = 0.25, sd = log(2)/1.96)
τ2 log-normal(mean = 0.125, sd = log(2)/1.96)
ρ uniform(-1,1)
Historical data
The dose-DLT data of spartalizumab single agent from the following clinical study  are 
considered as the relevant information (Table 16-12) and used to derive the prior distribution 
for the BL RM parameters (log(αPDR), log (βPDR)).
CPDR001X2101: open label multicenter Phase I/II study  of the safet y and efficacy of 
spartalizumab administered to patients with advanced malignancies.
The DLT observation window in the Phase I dose escalation part of this trial was 4 weeks. The 
6-week AE records of thepatients did not show difference from the 4-week data in DLT 
observation. It is assumed that DLT rate is associated with total exposure of PDR00l within the 
observation window, and the average weight of a patient is 80 kg. Then each dose level in the 
historical data dqKw[mg/kg] (K = 2 or 4) can be converted to a flat dose level in a q4w dosing  
schedule, d q4w[mg], using the following:
dq4w[mg] = d qKw[mg/kg] * 80[kg] / K[week] *4[week].
Table 16-12 Historical dose -DLT data from spartalizumab single agent clinical 
studies
Dosing schedule Dose level (mg/kg)Converted to dose 
level in q4w (mg) Number of 
evaluable patients Number of DLTs
q2w 1 160 16 0
q2w 3 480 15 0
q2w 10 1600 8 0
q4w 3 240 6 0
q4w 5 400 10 0
Component 2:
To take into account the potential situation that spartalizumab in combination is substantially  
more toxic than when administered as single agent, and that the longer DLT period of 56 day s 
may increase the chance of experiencing toxicity , a second high -toxicity  prior component with 
vague bivariate normal distribution is added to improve the robustness of the final prior. The 
parameters of this weekly informative prior distribution are described below:
The mean ( log (α (c2)PDR), log (β (c2)PDR)) = (logit(0.33), 0), i.e. the median DLT rate at the 
reference dose (400 mg) was assumed to be 0.33 and doubling in dose was assumed to 
double odds of DLT.

Novartis Confidential Page 187
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
The standard deviations of log (α (c2)PDR)and log (β (c2)PDR) are set to 2 and 1, respectivel y.
The correlation between log (α (c2)PDR)and log (β (c2)PDR)is set to 0, assuming 
independence.
16.4.2.2 Prior distribution for the interaction parameter
Although no interaction is expected for the two agents, uncertaint y remains. Therefore, a normal 
prior for the log-odds multiplier ηcentered at 0 is used that allows for both synergistic and 
antagonistic toxicity . The following assumptions will be used for interaction parameter.
ηis normally  distributed, with mean 0, and s tandard deviation
At the run- in dose of 400mg (BID) capmatinib in combination with 400mg spartalizumab 
q4w, η distribution corresponds to a best guess of no interaction and a 97.5% probability  
of having more than 2 -fold increase in odds of DLT due to inter action compared to no 
interaction for capmatinib in combination with spartalizumab
Additional historical data for capmatinib and spartalizumab combination
The dose-DLT data for the combination from CINC280X2108 are considered as relevant 
information (Table 16-13) and will be incorporated into the prior model using discounted 
weighting.
CINC280X2108 : A phase Ib/II, open -label, multi
-center study  of capmatinib in combination 
with spartalizumab or spartalizumab single agent in a dvanced hepatocellular carcinoma
The DLT observation window was 6 weeks.
Data from CINC280X2108 will be incorporated into the prior model using discounted 
weighting, where weight is determined as:
weight = 1 / (1+2nτ2/ sd2), where nrefers to study  sample size and τ and sdcorrespond to the 
assumed mean and standard deviation for between -trial heterogeneit y. In this case, a moderate 
between -trial heterogeneity  is assumed (τ = 0.250, sd = 2).
Table 16-13 Historical dose -DLT data from capmatinib in combination with 
spartalizumab 300 mg Q3W
Capmatinib dose in BID 
(mg) Number of evaluable 
patients Number of DLTsWeight to be used in 
prior model
CINC280X2108 0.62
200 5 0
300 6 0
400 9 1
16.4.2.3 Summary  of prior distributions
The prior distributions of the model parameters are summarized inTable 16-14. The prior 
distribution of DL T rates are summarized in 
Table 16-15.
Table 16
-14 Prior distribution for the model parameters
Parameter mean Standard deviations correlation weight
Capmatinib single agent model

Novartis Confidential Page 188
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
Parameter mean Standard deviations correlation weight
(log(αNC), log(βINC)) ~ BVN
(MAP) (-2.848, 0) (1.012, 0) 0 1
Spartalizumab single agent model
(log(αPDR), log(βPDR)) ~ BVN mixture
Component 1 
(MAP)(-5.034,0) (1.199, 0.141) 0.003 0.95
Component 2 
(robustification)(-0.708, 0) (2, 1) 0 0.05
Interaction parameter
Normal
η 0 0.354 N/A N/A
Table 16-15 Summary  of prior distribution of DLT rates
Capmatinib
BID dose 
(mg)Prior probabilities that P(DLT) is in the 
interval :
Mean SDQuantiles
[0, 0.16) [0.16, 0.33) [0.33,1] 2.5% 50% 97.5%
In combination with spartalizumab 400 mg Q4W
capmatinib 
=4000.915 0.081 0.004 0.078 0.057 0.013 0.064 0.227
16.4.2.4 Hypothetical data scenarios
To illustrate the performance of the Bay esian model used to guide the run- in part, hy pothetical 
DLT scenarios are display ed. In each case, the possibility  of going to the randomized phase is 
shown. The safet y and tolerability  of the dose is determined usin g the model based assessment 
of the risk of DLT in future patients and the rules as described in Section 6.5.1 .
The dose may  be recommended to continue if probability of excessive toxicity (i.e. DLT rate ≥ 
33%) < 0.25, satisfy ing the EWOC criteria.
Table 16-16 Hypothetical DLT scenarios
ScenarioNumber of
Patients Number of DLTsPosterior probabilities
Median
P(DLT)P(excessive
toxicity )
1 10 5 0.224 0.159
2 10 6 0.227 0.318
3 12 6 0.251 0.222
4 12 7 0.298 0.388
5 15 7 0.259 0.233
6 15 8 0.304 0.395
If ≤ 5 DLT’s are observed in 10 evaluable patients in run-in, the probability  of excessive toxicity 
satisfies the EWOC criteria.
If ≥ 6 DLT’s are observed in 10 evaluable patients in run-in, the probability  of excessive toxicity 
do not satisfy  the EWOC criteria. In this case, it would be recommended to stop the study .
If ≤ 6 DLT’s are observed in 12 evaluable patients in run-in, the probability  of excessive toxicity 
satisfies the EWOC criteria.

Novartis Confidential Page 189
Oncology Clinical Trial Protocol (Version No. 00) Protocol No. CINC280D2201
If ≥ 7 DLT’s are observed in 12 evaluable patients in run-in, the probability  of excessive toxicity 
do not satisfy  the EWOC criteria. In this case, it would be recommended to stop the study .
If ≤ 7 DLT’s are observed in 15 evaluable patients in run-in, the probability  of excessive toxicity 
satisfies the EWOC criteria.
If ≥ 8 DLT’s are observed in 15 evaluable patients in run-in, the probability  of excessive toxicity 
do not satisfy  the EWOC criteria. In this case, it would be recommended to stop the study .
